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Abstract
The purinergic signalling system comprises extracellular nucleotides such as adenosine
triphosphate (ATP), which signals through the two P2 receptor subfamilies; P2X (P2X1-7)
and P2Y (P2Y1, 2, 4, 6, 11, 12, 13, and 14). Breakdown of ATP to adenosine diphosphate (ADP) and
adenosine monophosphate (AMP), by the ecto-nucleotidase ecto-nucleoside triphosphate
diphosphohydrolase-1 (CD39), and finally AMP to adenosine, by ecto-5’-nucleotidase
(CD73) allows activation of adenosine receptors (A1, A2A, A2B and A3). Purinergic signalling
is important in inflammation and immunity, and has been implicated in transplantation,
including hematopoietic stem cell transplantation (HSCT) and a major complication of
allogeneic HSCT; graft-versus-host disease (GVHD). In allogeneic mouse models of GVHD,
activation of P2X7, or blockade of CD73 or A2A, worsen disease, while A2A activation
reduces GVHD. Purinergic signalling is also implicated in skin disorders including psoriasis.
Prior to this thesis, the role of purinergic signalling in humanised models of GVHD and the
imiquimod (IMQ)-induced psoriasis-like inflammatory mouse model remained unexplored.
The overarching aim of this thesis was to establish a humanised non obese diabetic (NOD)severe combined immunodeficient (SCID)-IL-2 receptor γ common chain null (IL-2Rγnull)
(NSG) mouse model of GVHD in our laboratory and utilise this model to investigate the role
of purinergic signalling in this disease. Additionally, this thesis aimed to establish the IMQinduced psoriasis-like inflammatory mouse model in our laboratory and to investigate the role
of P2X7 in this model.
Chapter 2 details the establishment of the humanised NSG mouse model of GVHD, where
NSG mice injected with human (h) peripheral blood mononuclear cells (PBMCs),
subsequently develop GVHD. During this study, 10 mice developed clinical GVHD and three
mice developed subclinical GVHD only. A comparison of these mice highlighted that clinical
GVHD correlated with increased splenic hCD4+:hCD8+ T cell ratios, serum human interferon
ii

(IFN)-γ concentrations and intestinal interleukin (IL)-17 expression. Comparison of healthy
mice with those with subclinical or clinical GVHD allowed characterisation of histological
GVHD. This revealed leukocyte infiltration and histological damage in the liver, small
intestine and skin, target organs of GVHD.
Chapters 3 and 4 investigated the role of P2X7 in the humanised NSG mouse model of
GVHD. A short-term regime of P2X7 blockade using Brilliant Blue G (BBG) (Chapter 3) did
not impact survival, but reduced serum hIFN-γ concentrations and leukocyte infiltration and
damage to the liver, small intestine and skin. A long-term regime of BBG (Chapter 4) did not
impact serum hIFN-γ concentrations but reduced leukocyte infiltration and apoptosis to the
livers of humanised NSG mice. Therefore, activation of P2X7 is an important signalling
pathway involved in GVHD development in this model.
Chapters 5 and 6 investigated the role of the CD39/CD73/A2A signalling axis in the
humanised NSG mouse model of GVHD. CD39 and CD73 blockade using αβ-methyleneADP (APCP) (Chapter 5) worsened disease through increased weight loss, leukocyte
infiltration and damage to livers, and serum hIL-2 concentrations. However unlike allogeneic
mouse models, adenosine receptor blockade with the broad-spectrum antagonist caffeine had
no impact on disease. This suggests the accumulation of ATP rather than prevention of
adenosine production is promoting GVHD. Conversely, A2A activation using CGS 21680
(Chapter 6) had differing effects on disease development. CGS 21680 caused beneficial
effects through reduced leukocyte infiltration and damage in livers, and serum human tumour
necrosis factor alpha (hTNF-α) concentrations. CGS 21680 also caused detrimental effects
through reduced weight gain and regulatory T cell frequencies, and increased serum hIL-6
concentrations.

iii

Finally, Chapter 7 investigated the role of P2X7 in IMQ-induced psoriasis-like inflammation.
IMQ induced ATP release from keratinocytes in vitro and up-regulated P2X7 expression in
the skin of these mice. However, pharmacological blockade of P2X7 with the antagonists
BBG or A804598, or P2X7 deficiency, did not impact IMQ-induced psoriasis-like
inflammation.
In conclusion, this thesis demonstrated for the first time that purinergic signalling pathways,
predominantly the accumulation of ATP and subsequent activation of P2X7, is important in
disease development in the humanised NSG mouse model of GVHD. Additionally, P2X7 is
up-regulated in involved skin, but is not essential for the development of IMQ-induced
psoriasis-like inflammation.
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Chapter 1: Introduction
1.1.

Inflammatory Diseases

The immune system provides host defence against disease, protecting an organism from
infection and death. The immune system incorporates the innate immune system, responsible
for rapid non-specific responses, and the adaptive immune system, responsible for slower but
specific responses to pathogens. The immune system promotes inflammation to remove
pathogens (Janeway Jr and Medzhitov, 2002). The adaptive immune cells; B and T cells, are
important in developing memory to pathogens and clear them quickly after subsequent
infection (Flajnik and Kasahara, 2009). However, an imbalance in this process or abnormal
responses to normal healthy tissues can result in inflammatory diseases. In whole organ
transplantation, donor organs can be rejected due to the body recognising foreign tissue
(Starzl et al., 1993). After allogeneic hematopoietic stem cell transplantation (HSCT),
patients can develop graft-versus-host disease (GVHD). GVHD results from donor (graft) T
cells mounting a ‘normal’ immune response upon detection of ‘foreign’ antigens, resulting in
an immune response against an immunocompromised patient (host) (Billingham, 1965).
Alternatively, inflammatory diseases can result from an exaggerated autoimmune response
due to genetic or environmental factors, leading to damage to tissues such as the pancreas in
diabetes (Donath and Shoelson, 2011), or the skin in psoriasis (Chandra et al., 2015).

1.2.

HSCT

HSCT involves the transfer of immunocompetent cells into an immunocompromised patient,
and is a curative therapy for blood cancers including acute myeloid leukemia (Bortin and
Rimm, 1978) and acute lymphoblastic leukemia (Buckner et al., 1973). HSCT is also
considered a curative therapy for other haematological disorders such as aplastic anaemia
1

(which was the first recorded case of bone marrow transplantation (Osgood et al., 1939)),
sickle cell anaemia (Vermylen et al., 1988) and Wiskott-Aldrich syndrome (Ozsahin et al.,
2008). Currently there are >25,000 HSCTs performed annually worldwide (D'Souza and
Fretham, 2017).
HSCT can be performed in one of two ways. Autologous HSCT involves the in vivo
expansion of healthy cells, or the ex vivo expansion and transplantation of healthy host
hematopoietic cells into the host after chemo- and/or radio-therapy (McGuire, 1998), leading
to reconstitution of the host’s immune system. However, due to the nature of some
haematological malignancies, autologous HSCT is not possible, and instead these patients
receive

allogeneic

immunocompetent

HSCT.
cells

Allogeneic

(graft)

from

HSCT
a

healthy

involves

the

individual

transplantation
(donor),

to

of

another

immunocompromised recipient (host). Allogeneic HSCT reduces the risk of complications by
matching donors for histocompatibility, either through using related donors or genetic
screening (Sheldon and Poulton, 2006). In cancer patients, the aim of allogeneic HSCT is
two-fold; to reconstitute a functional immune system, and to benefit from the
graft-versus-tumour (GVT) effect, where donor cells recognise and destroy malignant host
cells (Weiden et al., 1979). Hereafter, HSCT will refer to allogeneic HSCT unless stated
otherwise.
The reconstitution of the immune system provides the patient with protection against
subsequent infection, while the recognition of ‘foreign’ host tissue forms the basis of the
GVT effect (Kolb, 2008). However, immunocompetent cells in the graft can also recognise
and mount an immune response against healthy ‘foreign’ host tissue resulting in GVHD. The
current, and only, treatment for GVHD is immunosuppression through the use of steroids
(Auletta and Cooke, 2009). However, immunosuppression to prevent GVHD can lead to
other problems associated with HSCT. Suppressing the patient’s immune system to a great
2

extent leaves the patient susceptible to subsequent infection or cancer relapse, due to
immunosuppression leading to a reduced GVT effect (Fefer, 2004).

1.3.

GVHD

GVHD remains a major problem following HSCT, with a morbidity rate of 50% and a
mortality rate of 15-30% (Jagasia et al., 2012, Storb et al., 2013). Early GVHD research led
Billingham (1965) to outline three criteria for GVHD to occur. Firstly, the graft must contain
immunocompetent cells. Secondly, the host must be immunologically disparate from the
donor. Finally, the host must be incapable of preventing the inflammatory response of
transplanted immunocompetent cells against the genetically disparate host.
Due to difficulties in finding genetically similar donors, in HSCT some patients receive
mismatched donor cells. In these cases, recognition of ‘foreign’ host tissues and development
of GVHD is due to mismatches of the major histocompatibility complexes (MHC). MHCs are
important cell surface receptors present on antigen presenting cells (APCs), where MHC
class I molecules (MHC-I) interact with CD8 and MHC class II molecules (MHC-II) interact
with CD4 on T cells (Mellman and Steinman, 2001). In humans, MHC is more commonly
referred to as human leukocyte antigen (HLA). In humans there are three major (HLA-A, -B,
and –C) and three minor (HLA-E, -F, and –G) classes of HLA on MHC-I, and three major
(HLA-DP, -DQ, and –DR) and two minor (HLA-DM, and -DO) classes of HLA on MHC-II
(Marsh et al., 2002). However, even in HLA-matched HSCT, GVHD can still develop due to
differences in minor histocompatibility antigens (miHAgs). There are a large number of
miHAgs (for a recent review see Dzierzak-Mietla et al. (2012)). Most miHAg are present on
the Y chromosome (chr) and as such sex-matching is also important in HSCT (Miklos et al.,
2005, Wang et al., 2018).
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As GVHD develops, it can manifest as one of two forms; acute or chronic. Originally acute
GVHD was classified as occurring within 100 days, and chronic as persisting beyond 100
days, post-transplantation (Martin et al., 1990, Sullivan et al., 1991). However, subsequent
research has demonstrated that acute and chronic GVHD have unique aetiologies, and acute
GVHD can emerge after 100 days post-transplantation (Ferrara et al., 2009). For a recent
review of chronic GVHD see Zeiser and Blazar (2017b). From this point onwards GVHD
will refer to acute GVHD.
GVHD can be characterised by a three step process (Ferrara et al., 1999) (Figure 1.1.). The
first stage occurs before the transplantation and is characterised by the inflammatory
environment caused by the underlying condition or the treatment regime. This step involves
release of pro-inflammatory cytokines including tumour necrosis factor (TNF)-α, interferon
(IFN)-γ, and interleukin (IL)-6 (Knulst et al., 1994), as well as other signalling molecules
including damage associated molecular patterns (DAMPs) from damaged and dying cells
(Wilhelm et al., 2010). The second stage involves antigen processing of MHC or miHAg
peptides by APCs, and subsequent presentation to T cells, leading to T cell activation. The
release of cytokines due to initial damage results in up-regulation of MHC molecule
expression, co-stimulatory molecules and adhesion molecules on APCs (Ferrara et al., 1999).
APCs interact with T cells through MHC and co-stimulatory molecules to identify “self”. In
the final stage, T cells migrate to target organs and release additional cytokines to mediate
inflammatory damage. In particular, CD4+ helper T (Th) cells can differentiate into different
subtypes and release cytokines, such as Th1 cells release of IFN-γ and IL-2, Th2 cells release
of IL-4 and IL-13 (Mosmann et al., 1986), or Th17 cells release of IL-17 (Harrington et al.,
2005) to promote GVHD. CD4+ T cells subsequently recruit CD8+ T cells, which can
produce cytokines as well as release perforin and granzyme to promote inflammation and
exacerbate GVHD (Graubert et al., 1997). The inflammation and damage caused by GVHD
4

affects one or more organs, with the most commonly affected organ being the skin, which is
involved in 81% of cases, followed by the small intestine (54%) and the liver (50%) (Martin
et al., 1990). GVHD is a debilitating disease that manifests according to the involved target
organs. Skin involvement can manifest as a painful and/or itchy rash that can cover a majority
of a patient’s body. When the liver is affected the patient will demonstrate jaundice (a
yellowing of the skin and eyes), while involvement of the gastrointestinal tract can lead to
abdominal pain, nausea and vomiting (Zeiser and Blazar, 2017a).

Figure 1.1. The three step process of GVHD. 1. The underlying condition or the treatment regime
involves release of pro inflammatory cytokines and DAMPs such as ATP, from damaged and dying
cells. 2. DC activation of T cells, leads to T cell differentiation. 3. CD4+ and CD8+ T cell activation
results in cytokine release, leading to a feed forward loop of inflammation. Abbreviations; ATP,
adenosine triphosphate, interferon, DC, dendritic cell, IFN, and interleukin , IL tumour necrosis
factor, MHC, major histocompatibility complex, TGF, tumour growth factor, TNF-α. Adapted from
(Ferrara et al., 1999).
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1.4.

Cell Types in GVHD

GVHD results in inflammatory damage to target organs, promoted through APC activation of
CD4+ T cells, CD4+ T cell proliferation and subsequent activation of CD8+ T cells, and
pro-inflammatory cytokine release. Conversely, regulatory T (Treg) cells and natural killer T
(NKT) cells have been shown to play an anti-inflammatory role, where higher numbers of
these cells inversely correlates with disease severity (Schneidawind et al., 2014). In fact, ex
vivo expansion of Treg cells is being investigated as a therapeutic strategy to prevent GVHD
in HSCT patients (Heinrichs et al., 2016). Additionally, natural killer (NK) cells play a
controversial role in GVHD development. Some studies have implicated NK cells in GVHD
development, while others have shown NK cells reduce GVHD severity (Simonetta et al.,
2017). The role of each different immune cell subset in the development of GVHD is
described further below and summarised in Figure 1.2.
1.4.1. APCs
An important part of immunity is the bridging of the innate and adaptive immune systems.
Originally, alloantigen expression on host epithelium was thought to be required for initiation
of GVHD, however this is not the case (Teshima et al., 2002). Instead, in the development of
GVHD, activation of the adaptive immune response is achieved through activation of T and
B cells by antigen presentation by APCs (Shlomchik et al., 1999). Notably,
non-hematopoietic APCs do have the ability to initiate GVHD (Koyama et al., 2011), and
although macrophages can act as professional APCs (Kambayashi and Laufer, 2014), in
HSCT dendritic cells (DCs) are the main APC responsible for initiating GVHD development
(Markey et al., 2009).

6

Figure 1.2. The role of different cell types in GVHD development. Activation of naïve T cells by
DCs results in T cell differentiation depending on i) the type of DC and the signals it provides, and ii)
the cytokines and other factors present. CD4+ T cells can differentiate to Th1 cells, which exacerbate
GVHD through pro-inflammatory cytokine release, Th2, Treg or iNKT cells which reduce GVHD
through anti-inflammatory cytokine release, or Th17 cells which exacerbate or reduce GVHD. CD8+
T cells can be activated by DC or CD4+ T cells and exacerbate GVHD through IFN-γ and/or
perforin/granzyme release. Finally, NK cells can exacerbate GVHD through pro-inflammatory
cytokine release, or reduce GVHD through reducing Th1 cell activation. Abbreviations: DC, dendritic
cell, FoxP3, forkhead box P3, IFN-γ, interferon gamma, IL, interleukin, iNKT, invariant natural killer
T cell, MHC, major histocompatibility complex, NK, natural killer cell, TCR, T cell receptor, TGF-β,
tumour growth factor beta, TNF-α, tumour necrosis factor alpha, Treg, regulatory T cell.
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1.4.1.1.

DCs

Since their initial discovery and classification as an essential mediator of immunity
(Banchereau and Steinman, 1998), DCs have been established as professional APCs (Caux et
al., 1996). Human DCs can often be identified as CD83 expressing cells (Zhou and Tedder,
1995). DCs express MHC-I and/or MHC-II, and present processed antigen to activate CD8+
and/or CD4+ T cells, respectively (Banchereau and Steinman, 1998). DCs can be separated
into two classes, DC1 cells which activate Th1 cells, and DC2 cells which activate Th2 cells
(Banchereau et al., 2000). In GVHD, DC1 cells are deemed pro-inflammatory as Th1 cells
mediate GVHD (Mowat, 1989, Garside et al., 1994, Via and Finkelman, 1993), while DC2
are anti-inflammatory as Th2 cells are shown to reduce the incidence and severity of GVHD
(Pan et al., 1995, Pan et al., 1999) (discussed in Section 1.4.2. below). DCs have been further
characterised and demonstrated to be heterogeneous mix of different subtypes (for a
comprehensive review see Mildner and Jung (2014)). DCs can be found in human (h)
peripheral blood mononuclear cells (PBMCs). Following HSCT DCs may be of host and/or
donor origin, with donor DCs eventually outnumbering host DCs (Auffermann-Gretzinger et
al., 2002). Early studies demonstrated that host DCs are sufficient to promote GVHD, even in
small numbers, in allogeneic mouse models (Zhang et al., 2002b, Duffner et al., 2004), yet
depletion of DCs does not prevent GVHD development (Li et al., 2012). Furthermore,
reduced DC numbers also correlates to increased prevalence of GVHD in humans (Reddy et
al., 2004). This is due to some DCs being tolerogenic, which can promote Treg cells and
reduce GVHD (Sela et al., 2011). Transplantation of ex vivo generated tolerogenic DCs can
prevent GVHD (Sato et al., 2003). As DCs play major roles in preventing GVHD,
manipulation of DCs to promote tolerance represents a potential immunotherapy in HSCT
patients.
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1.4.2. T Cells
T cells are an important adaptive immune cell subtype and depending on the subset, mediate
their effects through release of cytokines and/or perforin and granzymes. T cells are the main
immune cell type responsible for mediating the inflammatory damage of GVHD (Sprent et
al., 1975, Korngold and Sprent, 1978, Kernan et al., 1986). T cells can be classified by
expression of CD3, which along with the T cell receptor (TCR)-α and β chains constitute the
TCR complex in the majority of T cells (Yanagi et al., 1984, Hedrick et al., 1984) (with 0.5 –
14% expressing a γδ TCR instead of an αβ TCR (Groh et al., 1989)). T cells can be activated
by APCs which interact through engagement of the TCR on T cells with MHC molecules
present on APCs (Harding and Unanue, 1990). T cells also require co-stimulatory signalling
to be activated, which can be through CD28 on the T cell interacting with CD80 or CD86
present on the APC (Lafferty and Cunningham, 1975, June et al., 1987).
All T cells express a TCR, but T cell subsets can be further classified by expression of other
markers. Conventional T cells can be classified as CD4+ (helper) or CD8+ (cytotoxic) T cells.
Both CD4+ (Korngold and Sprent, 1982) and CD8+ (Korngold and Sprent, 1985) T cells play
a role in the development of GVHD. CD4+ T cells were originally divided into two main
subtypes, T helper 1 (Th1) and T helper 2 (Th2) cells depending on the cytokines they
produce after activation (Mosmann et al., 1986). Since then other CD4+ subtypes have been
identified including Th17, Treg, and NKT cells. More information about these cells and the
role of each subtype is discussed below.
1.4.2.1.

Th1 Cells

Th1 cells are a CD4+ T cell subset characterised by expression of the transcription factor Tbet
(Szabo et al., 2000) and release of IFN-γ and IL-2 (Mosmann et al., 1986) (Fig 1.2). The role
of Th1 cells in GVHD was first characterised by the CD4+ T cell production of IFN-γ
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(Mowat, 1989, Garside et al., 1994) and IL-2 (Via and Finkelman, 1993) early in GVHD
development. IFN-γ and IL-2 blockade confirmed the importance of these cytokines in
promoting GVHD (Mowat, 1989, Via and Finkelman, 1993). Th1 cells have also been shown
to induce IL-12 production from APCs, which feeds back to further induce Th1 proliferation,
and inhibit Th2 differentiation, which collectively exacerbates GVHD (Via et al., 1994).
Further, mice with a “quadruple” deficiency in Th2 cytokine production (i.e. mice genetically
deficient in IL-4, IL-5, IL-9, and IL-13), exhibit worsened GVHD due to greater Th1 cell
differentiation (Tawara et al., 2008). As well as releasing cytokines to promote damage, Th1
cells can damage target tissues through release of Fas ligand (Baker et al., 1996, Kataoka et
al., 2001). Additionally, Th1 cells also recruit CD8+ T cells to exert damage to target organs,
as discussed below (Section 1.3.2.6). In an allogeneic mouse model it was shown that Th1
cells preferentially cause GVHD in the liver and gastrointestinal tract (Yi et al., 2009), whilst
in a humanised mouse model of GVHD, human Th1 cells generated ex vivo have been shown
to drive GVHD development (Amarnath et al., 2010).
Due to the role of Th1 cells and their cytokine production, current treatments for GVHD
include the use of cyclosporine and tacrolimus, which target Th1 responses by reducing IL-2
production, and rapamycin, which reduces T cell sensitivity to IL-2 (Khanna, 2000, Antin et
al., 2003). However, the role of IFN-γ in GVHD remains controversial (Yang et al., 2005b),
as IFN-γ has also shown to have protective roles in GVHD in some models (Brok et al.,
1993). Therefore, IFN-γ blockade itself is not considered an efficacious therapy in HSCT
recipients.
1.4.2.2.

Th2 Cells

Th2 cells are a CD4+ T cell subset characterised by the expression of the transcription factor
Gata-3 (Zheng and Flavell, 1997), and release of the cytokines IL-4, IL-5 and IL-13
(Mosmann et al., 1986). Originally, DC2 cell activation of Th2 cells was shown to reduce the
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incidence and severity of GVHD (Pan et al., 1995, Pan et al., 1999). However, subsequent
studies demonstrated genetic deficiency (Murphy et al., 1998) or blockade (Ushiyama et al.,
1995) of IL-4 could prevent disease development in allogeneic mouse models of GVHD. Th2
cells have since been shown to exacerbate GVHD, and specifically exert inflammatory
damage to the liver and skin, while inflammatory damage to the intestines can be mediated by
either Th1 or Th2 cells (Nikolic et al., 2000).
1.4.2.3.

Th17 Cells

Th17 cells are a functionally distinct CD4+ T cell subset characterised by the expression of
the transcription factor RAR-related orphan receptor gamma (RORγt) (Ivanov et al., 2006)
and release of IL-17A and IL-17F (Harrington et al., 2005), and IL-22 (Chung et al., 2006)
(Fig 1.1). Th17 cells have been implicated in GVHD development, where they predominantly
exert pro-inflammatory effects; however some studies describe a beneficial effect, so the role
of Th17 cells in GVHD remains controversial.
Th17 cells were proposed to exacerbate GVHD, as transfer of IL-17 deficient CD4+ T cells
delayed, but did not prevent GVHD in an allogeneic mouse model of GVHD (Kappel et al.,
2009). Supporting this observed pro-inflammatory role, transplantation of in vitro
differentiated Th17 cells mediated GVHD in an allogeneic mouse model (Carlson et al.,
2009), with inflammatory damage most evident in the skin (Carlson et al., 2009, Hill et al.,
2010). Additionally, human Th17 cells exacerbate GVHD in a humanised mouse model due
to IL-17 and IFN-γ production (Delens et al., 2018). Blockade of the Janus-associated kinase
(JAK)2, signal transducer and activator of transcription (STAT)3 pathway prevents Th17
generation (Betts et al., 2014) and reduces GVHD severity in humanised mice (Betts et al.,
2015). Alternatively, Th17 cell-derived IL-22, exacerbates GVHD through a reduction in
Treg expansion in target organs and increased CD8+ cell infiltration (Couturier et al., 2013).
Genetic deficiency of IL-22 in donor T cells (Couturier et al., 2013), or pharmacological
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blockade with an anti-IL-22 antibody (Wu et al., 2018) attenuates GVHD through increased
Treg cells. As well as reducing Treg cell numbers, in both allogeneic mouse models of
GVHD and in HSCT patients Th17 cells exert their pro-inflammatory effects in co-operation
with Th1 cells (Carlson et al., 2009). In allogeneic mouse models of GVHD, specific
blockade of the transcription factors Tbet and RORγt (i.e. simultaneously blocking Th1 and
Th17 differentiation), but not blockade of RORγt alone, can prevent GVHD development (Yu
et al., 2011). Additionally, the use of an anti-IL-12/23p40 antibody can reduce disease
severity through decreased Th1 and Th17 cell numbers in target organs in an allogeneic
mouse model (Wu et al., 2015) and delay GVHD onset in HSCT patients (Pidala et al.,
2017).
The role of Th17 cells in promoting GVHD is confounded by some studies, which describe
positive benefits of IL-17 and/or Th17 cells. Absence of Th17 cells leads to increased GVHD
severity, due to augmented Th1 cell activation and differentiation (Yi et al., 2008).
Additionally, recipient IL-17A was recently shown to be important in preventing intestinal
GVHD (Varelias et al., 2017). Finally, IL-22 deficiency in recipients resulted in more severe
GVHD (Hanash et al., 2012). A recent study by Cai et al. (2018) demonstrated that Th17
cells increase Th1 cell responses, while IL-17 downregulates Th1 cell infiltration of target
organs in GVHD, demonstrating individual roles of Th17 cells and IL-17 in an allogeneic
mouse model of GVHD. Furthermore, IL-17 deficient donor T cells reduce GVHD, but IL-17
deficiency of all cells in the graft exacerbates GVHD, suggesting Th17 cells exacerbate
GVHD, but systemic IL-17 plays a protective role.
Therefore, the role of Th17 cells in allogeneic mouse models can be confounded by the role
of IL-17, which notably can also be produced by γδ T cells (Sutton et al., 2009), NKT cells
(Rachitskaya et al., 2008), as well as mast cells and neutrophils (Lin et al., 2011). Thus, the
role of Th17 cells and IL-17 requires further elucidation in HSCT patients.
12

1.4.2.4.

Treg Cells

Treg cells are characterised by the expression of the transcription factor Forkhead box protein
3 (FoxP3) (Hori et al., 2003). However, FoxP3 can be expressed by subsets of CD4+ T cells
other than Treg cells (Morgan et al., 2005). Thus, Treg cells can alternatively be identified by
high expression of CD25 and low expression of CD127 (Fazekas de St Groth et al., 2011).
Treg cells differ from other CD4+ T cells subsets as they predominantly suppress immune
responses (Itoh et al., 1999). This suppression is mediated by release of IL-10 and tumour
growth factor (TGF)-β (Groux et al., 1997), and/or direct interaction with conventional T
cells (Thornton and Shevach, 1998). Treg cells may also exert anti-inflammatory effects
through perforin or granzyme release to cause apoptosis of inflammatory T cell subsets
(Gondek et al., 2005). However, Treg cells can also exert anti-inflammatory effects by
production of adenosine (Deaglio et al., 2007), which can subsequently activate adenosine
receptors to promote the release of anti-inflammatory cytokines (Haskó et al., 2008).
Treg cells play important roles in preventing development of GVHD. In allogeneic mouse
models, transplantation of donor Treg cells can limit the development of GVHD (Hoffmann
et al., 2002) through suppression of alloreactive T cells (Edinger et al., 2003). Moreover,
transplantation of ex vivo expanded Treg cells can reduce GVHD development in humanised
mouse models (Cao et al., 2009, Hannon et al., 2014). In patients, FoxP3 expression on
circulating PBMCs inversely correlates with GVHD severity in HSCT patients (Miura et al.,
2004), and higher numbers of donor Treg cells present in peripheral blood grafts prior to
transplantation reduces the risk of GVHD development in patients (Rezvani et al., 2006).
Supporting this, GVHD severity inversely correlates with numbers of Treg cells in the
intestine (Rieger et al., 2006) and skin (Fondi et al., 2009) of patients with GVHD.
Collectively, these findings have led to the potential use of expanded Treg cells as a
preventative therapy for GVHD in HSCT patients (Heinrichs et al., 2016). Unfortunately, the
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potential of Treg cell transplantation as a therapy to prevent GVHD is limited by the
propensity of Tregs to revert to a pro-inflammatory phenotype in inflammatory environments
(Kim et al., 2009, Hanidziar and Koulmanda, 2010).
1.4.2.5.

Natural Killer T Cells

NKT cells are a subtype of T cell which were originally characterised by the expression of
NK (CD161) and T cell (αβ-TCR) markers (Makino et al., 1995). Further research has led to
the characterisation of NKT cells to be any CD1d-restricted T cell, recognising the
non-classical MHC CD1d (Bendelac et al., 1995). NKT cells can be one of three subtypes;
Type 1, Type 2, and NKT-like cells (Godfrey et al., 2004). Few studies have investigated the
latter two subtypes in GVHD. Donor Type 2 cells (CD1d-restricted cells not expressing the
invariant TCR) suppress GVHD development (Kim et al., 2007). Conversely activation of
NKT-like cells in in vitro cultures suggests they may worsen GVHD (Wang et al., 2008), but
this has not been further investigated. However, type 1 NKT, or invariant NKT (iNKT), cells
are the most commonly studied CD1d-restriced subset and the role of iNKT cells in GVHD
has been elucidated. iNKT cells express an invariant TCR (Vα14-Jα18 in mice, and Vα24Jα18 in humans) (Porcelli et al., 1993), and can be further subdivided based on the cytokine
production of iNKT1, iNKT2 and iNKT17 cells reflecting Th1, Th2 and Th17 cells,
respectively (Chang et al., 2012, Lee et al., 2013). Furthermore, there is recent evidence of
another two iNKT cell subsets; a “follicular helper” T cell like-NK cell (iNKTFH) and an
IL-10 secreting iNKT cell (iNKT10) (Chang et al., 2012, Lynch et al., 2012, Lynch et al.,
2015). However, neither of these cells have been fully characterised, nor has their role in
GVHD been investigated.
In general, NKT cells play a role in GVHD, mostly by suppressing GVHD development. In
earlier studies, peripheral NKT cells (identified by expression of CD161 and αβ-TCR) were
shown to have a suppressive role in mouse models of HSCT (Zeng et al., 1999, Lan et al.,
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2001). Mice lacking iNKT1 cells due to a genetic deficiency of the TCR subunit Jα18
demonstrated more severe GVHD (Haraguchi et al., 2005). Co-transplantation of in vitro
induced (Kuwatani et al., 2006) or ex vivo expanded donor (Haraguchi et al., 2005, Yang et
al., 2010) or third-party (Schneidawind et al., 2014) iNKT1 cells can suppress disease in
allogeneic mouse models of GVHD. The suppressive ability of iNKT cells is through
promoting Th2 responses (Hashimoto et al., 2005, Margalit et al., 2005) or up-regulation of
Treg cell responses (Pillai et al., 2009, Vela-Ojeda et al., 2010, Schneidawind et al., 2015). In
patients, lower numbers of peripheral blood iNKT cells also correlate with worsened GVHD
(Crough et al., 2004, Haraguchi et al., 2004).
1.4.2.6.

CD8+ (Cytotoxic) T Cells

CD8+ T cells are characterised by expression of the CD8 molecule, which specifically binds
to MHC-I molecules on APCs. Similar to CD4+ T cells, CD8+ T cells can produce cytokines,
predominantly IFN-γ, to exert pro-inflammatory effects (Szabo et al., 2002). CD8+ T cells are
also known as cytotoxic T cells due to their ability to exert pro-inflammatory effects through
the release of perforin and granzymes (Pearce et al., 2003).
In GVHD, CD8+ T cells play important roles in causing or exacerbating the inflammatory
damage. Whilst, CD4+ T cells initiate disease, GVHD is exacerbated by CD8+ T cell
expansion (Rus et al., 1995). This was supported by demonstrating transplantation of MHC-I
deficient donor cells led to reduced GVHD severity in allogeneic (Matte et al., 2004) and
humanised (King et al., 2009) mouse models. Infiltration of CD8+ T cells into the portal areas
of the liver (Murai et al., 1999) and into Peyer’s patches in the intestines (Murai et al., 2003)
promotes GVHD in these respective organs. Furthermore, CD44lo CD62Lhi CD8+ T cells, a
self-renewing CD8+ T cell subset emerging early in GVHD pathogenesis, generates and
sustains memory and effector CD8+ T cells to further promote GVHD (Zhang et al., 2005).
Whilst CD8+ T cells are known to exert inflammatory damage in GVHD through perforin and
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granzyme release, CD8+ T cells also produce IFN-γ to promote inflammation in GVHD (Rus
et al., 1995). Alternatively, a role for an IL-17-producing CD8+ T cell subset (Tc17) in
GVHD has also been identified. Similar to Th17 cells, Tc17 cells exert pro-inflammatory
effects through production of IL-17 to promote GVHD in an allogeneic mouse model of
GVHD (Gartlan et al., 2015).
1.4.3. Natural Killer Cells
NK cells lack CD3 expression, but express CD56 (Lanier et al., 1989). Similar to CD8+ T
cells, NK cells can exert their effects through production of cytokines or release of perforin
and granzyme (Smyth et al., 2005). Alternatively, NK cells can exert their effects through
antibody-dependent cell-mediated cytotoxicity (Katz et al., 1987).
NK cells are another important cell type implicated in GVHD development, but whether
these cells play a detrimental or beneficial role is still controversial. Early studies using cell
activity assays and immunophenotyping demonstrated donor NK cells were present in GVHD
target organs in allogeneic mouse models, suggesting NK cells exacerbate GVHD (Guillen et
al., 1986, Ferrara et al., 1989). In allogeneic mouse models of GVHD, transfer of cells with a
genetic mutation leading to NK cell deficiency failed to cause GVHD, supporting the idea
that NK cells exacerbate GVHD (Ghayur et al., 1987). In a humanised SCID mouse model,
transfer of activated NK cells, which produce IFN-γ and TNF-α, exacerbated GVHD (Xun et
al., 1993). In patients, higher numbers of NK cells are found in the liver (Dilly and Sloane,
1985), intestines (Roy et al., 1993) and skin (Acevedo et al., 1991) and NK cells correlate
with GVHD severity (Dokhelar et al., 1981).
Subsequent research has also identified a beneficial role of NK cells in GVHD. In allogeneic
mouse models of GVHD, transfer of NK cells alone does not induce GVHD, whilst cotransfer with splenocytes prevents GVHD (Murphy et al., 1992). NK cells prevent GVHD
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development by inhibiting T cell proliferation and depleting APCs (Ruggeri et al., 2002). In
patients, higher numbers of alloreactive NK cells inversely correlates with GVHD
development (Ruggeri et al., 2007, Tanaka et al., 2012a, Kim et al., 2016b).

1.5.

Models of GVHD

Seminal studies of GVHD were conducted in canines. Inflammatory damage to the GVHD
target organs; liver, gastrointestinal tract and skin, demonstrated damage was greater in dogs
transplanted with tissue that was genetically mismatched for dog leukocyte antigens (Storb et
al., 1974, Kolb et al., 1979), which is equivalent to HLA mismatch in humans. Canines also
offered useful models for the development of immunosuppression, which was the first
therapy for GVHD (Kolb et al., 1973). Although canines offer a good model of GVHD
(Markey et al., 2014), the majority of current studies are conducted using mice. Mice afford
useful models to study human disease as, like dogs, they are genetically similar to humans,
but are much easier and cheaper to maintain, have shorter breeding times and allow the use of
transgenic variants and well-established inbred strains. Both allogeneic and humanised mouse
models of GVHD have been established and will be discussed below.
1.5.1. Allogeneic Mouse Models of GVHD
Similar to humans, GVHD in allogeneic mouse models can emerge due to differences in
either MHC or miHAgs, depending on the donor and recipient strains. In mice, MHC
antigens are known as H2, with each mouse strain exhibiting a unique haplotype, denoted by
a subscript letter. Complete MHC-mismatch models of allogeneic GVHD involve the transfer
of bone marrow from one strain of mouse to another with a completely different MHC
haplotype (denoted by H2x where x is the haplotype).
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The most common complete MHC-mismatch model of allogeneic GVHD involves the
transfer of bone marrow and splenocytes from C57BL/6 mice to BALB/c mice (H2b to H2d)
(van Leeuwen et al., 2002). Other complete mismatch models include the transfer of bone
marrow and splenocytes from C3H/HeJ to C57BL/6 mice (H2k to H2b) (Blazar et al., 1991),
and C57BL/6 to B10.BR mice (H2b to H2k) (Vallera et al., 1981). These complete MHCmismatch models were used to elucidate that T cells were the major immune cell that drives
GVHD inflammation (Sprent et al., 1975, Korngold and Sprent, 1978), and are useful models
to study HLA-mismatch transplants in HSCT patients, such as in the cases of unrelated
donors.
Other allogeneic mouse models of GVHD include haploidentical models, which involve
transplantation where one H2 allele is identical, but the other differs. Some examples of these
models include the C57BL/6 to B6C3F1 (H2b to H2k/b) (Kanamaru et al., 1984), and the
C57BL/6 to B6D2F1 (H2b to H2b/d) (Pickel and Hoffmann, 1977), and are relevant to
transplants in HSCT patients when there is a partial HLA-mismatch. Finally, there are
allogeneic mouse models of GVHD where the H2 is a complete match, but GVHD arises due
to miHAgs. Some examples of these models include the B10.D2 to BALB/c mice (H2d to
H2d) (Korngold and Sprent, 1987) and C57BL/6 to BALB.b (H2b to H2b) mice (Berger et al.,
1994). These models are useful to elucidate miHAgs involved in GVHD, and reflect the
development of GVHD in HSCT patients who receive an HLA-matched transplant.
Allogeneic mouse models of GVHD have been instrumental in elucidating GVHD
pathophysiological mechanisms and derivation of early therapies for GVHD. Therapeutic
targets investigated in these models aim to target a specific part of the three-step progression
of GVHD. This includes altering the conditioning regime by way of non-myeloablative, or
reduced intensity, conditioning to reduce inflammatory cytokines and damage (Aoudjhane et
al., 2005). Alternatively therapies target the characteristic pro-inflammatory cytokine storm
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such as TNF-α blockade (Hill et al., 1999), or more recently hIL-6 blockade (Tawara et al.,
2011). Other therapies aim to prevent the activation and proliferation of T cells, such as the
use of post-transplant cyclophosphamide to deplete proliferating cells (Ganguly et al., 2014),
and the development of cellular therapies such as transfer of Treg cells to suppress activated
cells (Hoffmann et al., 2002, Edinger et al., 2003), which have since been translated to the
clinic (Couriel et al., 2009, Kanakry et al., 2014, Di Ianni et al., 2011).
Allogeneic mouse models of GVHD are not without disadvantages. Besides the large
differences in immune systems between mice and humans (Mestas and Hughes, 2004,
Schroeder and DiPersio, 2011), mice used in allogeneic models of GVHD have low genetic
diversity due to inbreeding, and therefore donors have very specific genetic disparities to
recipients. Furthermore, mice are usually housed under pathogen-free conditions, unlike
HSCT patients (Zeiser and Blazar, 2016). Finally, allogeneic mouse models transfer bone
marrow cells supplemented with splenocytes as a source of T cells, whilst in humans grafts
often contain peripheral T cells, which will differ in function to those found in the spleen
(Zeiser and Blazar, 2016). Therefore, to address these disadvantages and better study human
immune responses in vivo, numerous humanised mouse models have been developed.
1.5.2. Humanised Mouse Models of GVHD
Humanised mouse models of GVHD utilise mice with genetic abnormalities or deficiencies
to allow engraftment of human cells, which subsequently mediate GVHD in these animals.
Each model utilises a unique strain of mouse that receives a transfer of human cells, most
commonly hPBMCs. The CB17-SCID (scid/scid) mouse possesses the severe combined
immunodeficiency (SCID) mutation on the protein kinase, DNA-activated, catalytic
polypeptide (Prkdcscid) which prevents V(D)J recombination leading to impaired B and T cell
development (Bosma et al., 1983). This model allows engraftment of human cells, however
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after hPBMC injection engraftment of human cells in these mice is low due to spontaneous
development of functional murine B and T cells, and constitutive NK cell activity (Greiner et
al., 1998). Additionally, the lack of diverse human T cell development in these mice limits
the use of this model for investigating potential therapies (Garcia et al., 1997). Subsequently,
breeding of CB17-SCID mice with NOD mice allowed the development of the NOD/SCID
mouse strain (Shultz et al., 1995), with improved human cell engraftment due to NOD mice
possessing a polymorphism in the Sirpa gene, which promotes “phagocytic tolerance” (i.e.
reduces macrophage clearance) of human leukocytes (Yamauchi et al., 2013). However,
human cell engraftment is still low in these mice, due to NK cells, whilst the lifespan of these
mice is limited due to lymphoma development (Shultz et al., 1995). Subsequently, the NODSCID-IL-2 receptor γ common chain null (IL-2Rγnull) (NSG) mouse which lacks IL-2Rγ and
subsequently lacks functional T, B and NK cells, allowing greater human cell engraftment
was developed (Ito et al., 2002, Shultz et al., 2005).
1.5.3. The Humanised NSG Mouse Model of GVHD
Injection of NSG mice with hPBMCs can establish a humanised NSG mouse model of
GVHD (King et al., 2009) (Figure 1.3). There are variations of this model, which differ by
the number and source of hPBMCs injected and the route of injection (Hogenes et al., 2014,
De La Rochere et al., 2018). Whilst these various models exist, the humanised NSG mouse
model, established by injection of hPBMCs provides a robust model of GVHD (Ali et al.,
2012). Accordingly, from this point forward the humanised NSG mouse model will refer to
NSG mice injected with hPBMCs (Figure 1.3).
Within three to eight weeks following injection of hPBMCs, NSG mice develop phenotypical
signs of GVHD. These signs include weight loss, hunching, reduced activity, fur ruffling and
skin denudation, as first described by Cooke et al. (1996) in allogeneic mouse models.
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Figure 1.3. The humanised NSG mouse model of GVHD. Immunodeficient NSG mice are injected with

freshly isolated hPBMCs and subsequently develop GVHD. GVHD can be assessed by clinical
scoring as indicated. Abbreviations: GVHD, graft-versus-host disease, h, human, NSG, non-obese
diabetic-severe combined immunodeficient-interleukin-2 receptor γ common chain null, PBMC,
peripheral blood mononuclear cell.

King et al. (2008) demonstrated that NSG mice rapidly engraft hPBMCs within a matter of
weeks following injection with 5 x 106 hPBMCs/mouse, although 100% engraftment is
typically observed with injection of ≥10 x 106 hPBMCs/mouse. Indeed, 10 x 106
hPBMCs/mouse is sufficient for 100% engraftment, with no significantly greater engraftment
after injection of 20 x 106 or 50 x 106 hPBMCs/mouse (King et al., 2008).
The main GVHD target organs in humans; the liver, gut and skin, are similarly affected in
humanised NSG mice, and leukocyte infiltration and inflammation reflects GVHD
development as in HSCT patients. The liver demonstrates leukocyte infiltration, concentrated
around portal triads (King et al., 2009), with both portal triads and parenchymal tissue
damaged (King et al., 2009, Ehx et al., 2017). The gut also demonstrates leukocyte
infiltration (King et al., 2009, Nakauchi et al., 2015) as well as apoptosis (Nakauchi et al.,
2015). Finally, the skin demonstrates leukocyte infiltration within the dermis and epidermis
(King et al., 2009). The original study by King et al. (2009) demonstrated that infiltrating
leukocytes are of human origin, staining for hCD45+. King et al. (2009) also demonstrated
that the majority of engrafted human leukocytes are T cells, and immunohistochemical
analysis of organs using a hCD3 antibody demonstrated human T cells are the main
infiltrating leukocyte in the liver (Ehx et al., 2017), and gut (Nakauchi et al., 2015).
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Immunohistochemical staining of skin has shown hCD45 cells infiltration (King et al., 2009)
but the identity of these human leukocytes is unknown. However, target organ specificity of
effector memory T cells that express tissue-specific homing receptors, such as cutaneous
lymphocyte antigen have been shown to home to the skin in this model (Ali et al., 2012).
King et al. (2009) demonstrated that hCD8+ T cells drive GVHD development, as deletion of
MHC-I molecules significantly delayed disease, compared to MHC-I deficiency suggesting
CD8+ T cells are important for promoting more rapid GVHD. However, deletion of MHC-II
also delays GVHD (King et al., 2009). Moreover, a subsequent study by Covassin et al.
(2011) demonstrated CD4+ T cells are sufficient to mediate disease as injection of CD4+ T
cells alone induces GVHD in humanised NSG mice. Activation of human T cells relies on
co-stimulatory signals (Lafferty and Cunningham, 1975), and human CD28 can recognise
murine B7.2 to act as a co-stimulatory signal (Freeman et al., 1993), which is required for T
cell activation in humanised NSG mice (Søndergaard et al., 2013). However, whether murine
MHC is responsible for antigen presentation to human T cells, or whether murine MHC is the
antigen itself remains to be elucidated. Additionally, human Treg cell numbers inversely
correlate to GVHD severity and can prolong survival in humanised NSG mice (Bruck et al.,
2013, Achita et al., 2018). This parallels the higher numbers of donor Treg cells correlating
to reduced risk of GVHD development in HSCT patients (Rezvani et al., 2006). However,
stable long-term engraftment of Treg cells in humanised NSG mice requires expression of
human IL-2 (Abraham et al., 2012).
Human T cells migrate to target organs and produce cytokines to exert inflammatory damage,
with cytokines implicated in GVHD in HSCT patients also implicated in humanised NSG
mouse models. Serum hTNF-α concentrations are increased as soon as 24 hours post-hPBMC
injection and pharmacological blockade of TNF-α can prevent GVHD development in
humanised NSG mice (King et al., 2009). Similarly, serum human IL-6 is also increased with
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GVHD development in humanised mice (Amarnath et al., 2010), and blockade can reduce
disease severity (Gu et al., 2016a). Humanised NSG mice demonstrate increased levels of
hIL-2 and hIFN-γ (Abraham et al., 2017), and while blockade of these cytokines has not been
investigated, successful treatments that reduce and/or prevent GVHD have correlated with
reduced serum hIFN-γ (Amarnath et al., 2011, Gregoire-Gauthier et al., 2012) or hIL-2
(Abraham et al., 2012, Gregoire-Gauthier et al., 2012). Furthermore, whilst hIL-17 blockade
has not been investigated, reduced serum hIL-17 correlates with successful treatments that
reduce and/or prevent GVHD (Gregoire-Gauthier et al., 2012). In contrast, IL-10, which
correlates to reduced disease severity in humans (Holler et al., 2000), has been shown to
exacerbate GVHD in humanised NSG mice, but can act synergistically with hIL-2 to delay
disease (Abraham et al., 2015).
The humanised NSG mouse model of GVHD can be utilised as a preclinical mouse model of
GVHD, and therapies that have shown promise in both this model and clinical trials in HSCT
patients are discussed briefly below and summarised in Table 1.1. Therapies may aim to
prevent inflammation by targeting cytokines or T cells. TNF-α blockade using the humanised
monoclonal antibody (mAb) Etanercept delayed GVHD onset, but did not prevent disease
development in humanised NSG mice (King et al., 2009) or humans (Choi et al., 2012b,
Gatza et al., 2014). Furthermore, although TNF-α is an important pro-inflammatory cytokine
in the innate immune system (Serbina et al., 2003), TNF-α blockade may leave HSCT
recipients more susceptible to infection (Choi et al., 2012b).
Other therapies aim to reduce GVHD by preventing T cells activation, proliferation or
migration to target organs. The use of post-transplant cyclophosphamide depletes alloreactive
T cells, and reduces GVHD severity in humanised NSG mouse models (Kanakry et al.,
2013a). This therapy is currently being investigated in HSCT patients, but can cause
infection-independent fever (O’Donnell et al., 2015). Alternatively, injection of
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immunosuppressive cell types such as Treg cells at the time of hPBMC-injection reduces
GVHD in humanised NSG mice (Hannon et al., 2014, Achita et al., 2018) and is being
investigated as a potential therapy in HSCT patients. However, Treg cells revert to a
pro-inflammatory phenotype in inflammatory environments (Kim et al., 2009, Hanidziar and
Koulmanda, 2010), which may limit their use as a therapy for GVHD in HSCT patients. The
addition of mesenchymal stem cells, as a suppressive cell type, reduces inflammatory damage
of GVHD in humanised NSG mice (Bruck et al., 2013, Huang et al., 2017), but fails to
reduce GVHD in HSCT patients (Galipeau, 2013). Finally, CCR5 blockade prevents T cells
tracking to target organs in humanised NSG mice (Burger et al., 2017a), but may be limited
in humans as CCR5 antagonists can cause hepatotoxicity (Kim et al., 2016a). Therefore,
whilst therapies for GVHD are currently being tested in the clinic, these therapies each have
limitations, and there is a need for alternative strategies and targets.
The purinergic signalling system plays a role in immunity and has been implicated in
numerous inflammatory disorders (see Section 1.10.). Whilst purinergic signalling has been
implicated in allogeneic mouse models of GVHD (see Section 1.10.1.), the role of purinergic
signalling has not been investigated in humanised mouse models of GVHD and is limited in
humans. Due to the importance of purinergic signalling in immunity and inflammation, this
signalling system has also been implicated in other inflammatory diseases such as psoriasis.
Therefore a brief overview of psoriasis will be presented.
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Table 1.1. Therapeutic strategies investigated in the humanised NSG mouse model of GVHD
currently in clinical trials. Abbreviations; CCR5, C-C chemokine receptor, IL, interleukin, JAK,
Janus associated kinase, mAb, monoclonal antibody, NSG, non-obese diabetic-severe combined
immunodeficient-interleukin-2 receptor γ common chain null, Treg, regulatory T cell

Therapeutic
strategy in
humanised
NSG model

Reference(s)

TNF-α blockade
(Etanercept
anti-TNF-α)

(King et al., 2009)

Therapeutic
strategy in clinical
trial(s)

Current
status of
clinical
trial(s)*

Reference(s)

(Choi et al., 2012b,
Gatza et al., 2014)

Etanercept (anti TNF-α)

Completed

Infliximab (anti TNF-α)

Completed
Recruiting,
Suspended,
Unknown
Recruiting

(Trzonkowski et al.,
2009, Brunstein et al.,
2011)

(O’Donnell et al.,
2015)

Regulatory T cell
co-transplantation

(Hannon et al.,
2014, Achita et al.,
2018)

Donor Treg cell
infusion

Post-transplant
cyclophosphamide

(Kanakry et al.,
2013a)

Post-transplant
cyclophosphamide

Active,
Completed,
Recruiting

CCR5 blockade

(Burger et al.,
2017b)

PRO 140 (anti-CCR5
mAb)

Recruiting

Ex vivo expansion

Mesenchymal
stem cells

(Bruck et al., 2013,
Huang et al., 2017)

Ex vivo expansion

Active,
Recruiting,
Suspended,
Unknown

IL-6 blockade
(Tocilizumab
(anti-IL-6R))

(Gu et al., 2016b)

Tocilizumab
(anti-IL-6R)

Recruiting,
Terminated,
Withdrawn

JAK1/2 blockade

(Betts et al., 2017,
Betts et al., 2018)

Multiple mAb;
Baricitinib (JAK1/2)
Itacitinib (JAK1)
Ruxolitinib (JAK1/2)

(Galipeau, 2013)

Results not published

Recruiting
Recruiting
Recruiting

*According to clinicaltrials.gov (last accessed 16/11/2018)
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1.6.

Psoriasis

Psoriasis affects 1-3% of the general population of Western countries (Lebwohl et al., 2014),
and is estimated to cost the United States of America healthcare system alone $112 billion
per year (Brezinski et al., 2015). Psoriasis is an autoimmune disease of the skin, which
manifests as red or pink areas of skin covered in white plaque-like lesions of dry flaky skin,
present on areas of the body including the scalp, elbows, knees and lower back (Schön and
Boehncke, 2005). Whilst the cause of psoriasis is still unknown, the plaque-like lesions form
due to an autoimmune response leading to inflammation mediated by T cell activation by
APCs, leading to hyper-proliferation of keratinocytes (Schön et al., 2006) and recruitment of
neutrophils (Schön et al., 2017).
The typical plaque-like lesions as described above are indicative of psoriasis vulgaris, which
is the predominant form of psoriasis constituting ~90% of all cases (Griffiths and Barker,
2007). Less common is pustular psoriasis, where plaques also swell with pus, as opposed to
the dry flaky skin of psoriasis vulgaris (Schön and Boehncke, 2005, Nestle et al., 2009b), or
guttate psoriasis, which emerges after an infection such as tonsillitis and resolves within a
few months of onset (Griffiths and Barker, 2007). However, a third of guttate psoriasis
patients subsequently develop psoriasis vulgaris (Martin et al., 1996). If any of these forms
are allowed to progress, they can form psoriasis erythroderma, which covers the entire body
(Nestle et al., 2009b).
The exact cause of psoriasis is still unknown, but genetic susceptibility is implicated in
psoriasis development (Liang et al., 2017). A susceptibility locus, termed PSORS1 is in the
MHC region on chr 6 (6p21) (Balendran et al., 1999) and is associated with up to 50% of
psoriasis cases (Asumalahti et al., 2002). Within this gene, the MHC-I molecule HLA-C, and
the specific allele HLA-Cw*0602 have been implicated as causative factors, with patients
26

homozygous for this allele at a greater risk of developing psoriasis (Gudjonsson et al., 2003).
However there are also a number of other susceptibility loci including PSORS2 (chr 17q)
(Tomfohrde et al., 1994), PSORS3 (chr 4p) (Matthews et al., 1996), PSORS4 (chr 4q) (de Cid
et al., 2009), PSORS5 (chr 3q) (Vasilopoulos et al., 2008), PSORS6 (chr 19p) (Lee et al.,
2000), PSORS7 (chr 1p) (Veal et al., 2001), PSORS8 (chr 16q) (Nair et al., 1997), PSORS9
(chr 4q) (Zhang et al., 2002a) and PSORS10 (chr 18p) (Asumalahti et al., 2003).

1.7.

Cell Types in Psoriasis

The characteristic plaque-like lesions of psoriasis emerge due to the pro-inflammatory
environment mediated by different T cell subsets, predominantly Th1, Th17, and CD8+ T
cells. Activation of T cells by APCs causes hyper-proliferation of keratinocytes and
recruitment of neutrophils to further promote inflammation.
The CD4+ subsets Th1 and Th17, and CD8+ T cells are all important mediators of psoriasis.
The majority of T cells in the serum and psoriatic lesions are Th1 and CD8+ T cells, and the
high levels of TNF-α and IFN-γ in psoriatic lesions and serum of psoriasis patients suggests
psoriasis is a Th1 and CD8+ T cell mediated disease (Schlaak et al., 1994, Austin et al.,
1999). IFN-γ is an important pro-inflammatory cytokine in psoriasis (Wei et al., 1999, Haider
et al., 2008) which can cause hyperproliferation of keratinocytes (Bata-Csorgo et al., 1995).
Further, IFN-γ production by Th1 cells can lead to a feedback loop to activate APCs and
promote Th17 development (Kryczek et al., 2008). After the discovery and characterisation
of Th17 cells (Harrington et al., 2005), these cells were implicated in the pathogenesis of
psoriasis due to their activation by the pro-inflammatory cytokine IL-23 (Piskin et al., 2006).
IL-23 is upregulated in psoriatic lesions (Piskin et al., 2006) and is essential for activation of
Th17 cells (McGeachy et al., 2009), which release IL-17 to promote inflammation in this
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disease (Tonel et al., 2010, Rizzo et al., 2011, Guenova et al., 2015). IL-17, as well as TNFα, IL-21 and IL-22, produced by Th17 cells are present in psoriatic lesions and in higher
levels in serum from psoriasis patients compared to healthy controls (Boniface et al., 2007,
Lowes et al., 2008, Caruso et al., 2009). These cytokines induce proliferation of, and
antimicrobial peptide release from, keratinocytes (Ivanov et al., 2006, Shi et al., 2011).
T cells require antigen presentation by APCs for their activation and therefore APCs play an
important role in psoriasis. The classical APCs of the skin are Langerhans cells (LCs)
(Streilein and Bergstresser, 1984), which can present antigen to T cells (Romani et al., 1989),
but their role in psoriasis remains unknown (Perera et al., 2012). LC numbers are lower in
skin from psoriasis patients (Haftek et al., 1983), and their migration is hindered in psoriatic
skin compared to healthy skin (Cumberbatch et al., 2006). Furthermore, a seminal paper from
(Mizumoto et al., 2002), demonstrates CD39 is the predominant ecto-nucleotidase present on
LCs and is essential for degradation of ATP, a danger signal implicated in skin inflammation
(Killeen et al., 2013). This suggests LCs play a preventative role in psoriasis, consistent with
the tolerogenic nature of these cells (Kitashima et al., 2018).
Plasmacytoid and myeloid DCs are other APCs in the skin and play a major role in psoriasis
pathogenesis. Plasmacytoid DCs are normally absent from the skin of healthy people, but are
present in both lesional and healthy skin of psoriasis patients (Nestle et al., 2005). These cells
can become activated by antimicrobial peptides such as LL-37 (Lande et al., 2007) to
infiltrate the skin and release IFN-α (Wollenberg et al., 2002, Nestle et al., 2005). This in
turn promotes further release of LL-37 as well as additional antimicrobial peptides; S100
proteins and defensins from keratinocytes (Bando et al., 2007) to promote psoriasis, whilst
Plasmacytoid DC production of IFN-α, along with IL-6 and TNF-α can activate myeloid DC
(Nestle et al., 2005). Furthermore, LL-37 binds to RNA released by dying cells to activate
myeloid DCs (Ganguly et al., 2009), which promote inflammation by release of IL-23 (Tonel
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et al., 2010), which promotes Th17 cell responses. Macrophages also play a role in psoriasis,
and are found in increased numbers in psoriatic skin of patients (van den Oord and de WolfPeeters, 1994). These cells are essential for development of psoriasis-like inflammation in
mouse models through production of TNF-α (Wang et al., 2006) and IFN-γ (Stratis et al.,
2006).
T cell activation by APCs and cytokine production from both of these cell types causes
keratinocyte proliferation which results in the characteristic psoriatic lesions. Keratinocytes
constitute up to 90% of the cells of the skin (Nestle et al., 2009a) and are an innate immune
cell type involved in psoriasis pathogenesis (Barker et al., 1991). Hyperproliferation of
immature keratinocytes results in these cells migrating from the basal layer into the cornified
layer in a matter of 1-3 days rather than the usual 28-30 days (Schön and Boehncke, 2005),
which results in the thickening of the epidermis (acanthosis) characteristic of psoriatic
lesions. As mentioned above, keratinocytes promote inflammation and psoriasis through the
release of LL-37, defensins and S100 proteins (Bando et al., 2007), and release of these
antimicrobial peptides, as well as chemo-attractants such as IL-8 recruits neutrophils (BruchGerharz et al., 1996), which release cytokines resulting in a feed-forward loop of
inflammation (Terui et al., 2000). Neutrophils are found in large numbers in psoriatic skin
and there is renewed interest in their role in psoriasis (Schön et al., 2017). Finally,
keratinocytes can also release chemo-attractants such as CCL27 (Homey et al., 2002) and
IL-8 to recruit T cells into the skin (Homey et al., 2002, Albanesi et al., 2001), as well as
produce IL-23 (Piskin et al., 2006), further promoting the feed-forward loop of inflammation.
Although psoriasis is not directly lethal, the disease can greatly reduce the quality of life of
an individual, and increase their chance of cardiovascular disease (Neimann et al., 2006),
arthritis (Tey et al., 2010), and some cancers (Pouplard et al., 2013). There is currently no
cure for psoriasis, and current treatments range from topical treatments to phototherapy, but
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satisfaction with these treatments is low (Korman et al., 2015, Schaarschmidt et al., 2015).
New therapies for psoriasis aim to suppress the immune response through inhibition of proinflammatory cytokines such as TNF-α, IL-12/23 (Rustin, 2012) and IL-17A (Hueber et al.,
2010). However, these drugs have off-target effects, and targeting cell receptors represents a
better therapy. To achieve this pre-clinical mouse models are required.

1.8.

Models of Psoriasis

Psoriasis is a uniquely human disease (Gudjonsson et al., 2007), and due to the complex
nature of psoriasis studies are often limited to in vitro experiments or inferred from other
murine models of skin diseases such as croton oil-induced irritant contact dermatitis (ICD)
(Mizumoto et al., 2002) or hapten- or DNFB-induced contact hypersensitivity (CHS) models
of atopic dermatitis (AD) (Röse et al., 2012, Gaspari et al., 2016). However, neither ICD nor
CHS encapsulate the multifaceted innate and adaptive immune responses of psoriasis, and
subsequent models that better reflects psoriasis have been developed. Moreover, current
murine models of psoriasis only recapitulate some, but not every aspect of human psoriasis,
with each model offering unique advantages and disadvantages. Mouse models of psoriasis
can be characterised as belonging to one of four categories; spontaneous, transgenic,
xenogeneic, or inducible, as outlined below.
Spontaneous mouse models demonstrate skin pathologies that resemble psoriasis in some
ways, but lack some distinct features. The flaky skin (Ttc7fsn/Ttc7fsn) mouse model
demonstrates neutrophil infiltration into involved skin (Sundberg, 1994). Whilst the chronic
proliferative dermatitis mutation (cpdm/cpdm) (HogenEsch et al., 1993) and the homozygous
asebia (Scd1ab/ Scd1ab) (Gates and Karasek, 1965) mouse models demonstrate macrophage
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and mast cell infiltration. The latter model also demonstrates epidermal thickening but each
of these models lack other features of psoriasis, and thus have fallen out of use.
Transgenic mouse models involve the genetic over-expression or knock-out of specific genes
to imitate psoriasis. A transgenic mouse model causing a mutation in Stat3 in basal
keratinocytes causes spontaneous psoriatic-like skin lesions, which demonstrates keratinocyte
hyperproliferation, and infiltration of neutrophils and T cells (Sano et al., 2005). A transgenic
mouse model in which expression of IL-20 is targeted to basal keratinocytes results in altered
keratinocyte differentiation through Stat3 signalling (Blumberg et al., 2001). Alternatively,
deletion of a gene, such as in the Ilrn-/- mouse results in epidermal thickening and formation
of psoriatic plaques, with characteristic neutrophil and T cell infiltration (Shepherd et al.,
2004). These models are still being used, but not as often as xenogeneic or inducible models
which offer more advantages.
Xenogeneic mouse models involve the transplantation of human psoriatic lesions onto one of
three immunodeficient strains. Athymic “nude mice”, which lack functional T cells (Krueger
et al., 1981), maintain skin for months (Fraki et al., 1982). SCID mice, which lack functional
T and B cells, maintain skin grafts but engrafted leukocytes quickly become anergic
(Meyerrose et al., 2003). Finally, AGR129 mice, which lack functional T and B cells and
have immature NK cells, develop psoriatic lesions spontaneously when engrafted with
psoriatic skin due to activation and proliferation of T cells within the graft (Boyman et al.,
2004). However, these models are technically difficult and therefore require extensive
expertise, involve transplantation of human psoriatic tissue which is hard to obtain, require
concurrent transfer of human leukocytes and have low success rates (Mizutani et al., 2003,
Hawkes et al., 2018). As a result of the above limitations and difficulties, most in vivo
psoriasis models use inducible mouse models.
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Inducible mouse models involve the injection or application of cells or molecules to promote
inflammation and psoriasis development. A T cell-inducible model involves the
reconstitution of SCID mice with naïve CD4+ T cells, which subsequently develop psoriatic
lesions with epidermal thickening due to keratinocyte hyperproliferation, and infiltration of
immune cells (Schön et al., 1997). Alternatively, injection of cytokines such as IL-23
promotes keratinocyte hyperproliferation resulting in epidermal thickening and infiltration of
immune cells (Chan et al., 2006, Zheng et al., 2007). However, an emerging model is
imiquimod (IMQ)-induced psoriasis-like inflammation in mice.
1.8.1. The IMQ-Induced Psoriasis-Like Inflammation Mouse Model
The IMQ-induced psoriasis-like inflammation mouse model is established by application of
the Toll-like receptor (TLR)7/8 agonist IMQ onto mouse skin, as outlined in the landmark
study by van der Fits et al. (2009). IMQ is a commercially available topical treatment for
genital warts (Beutner et al., 1998) and basal cell carcinoma (Beutner et al., 1999), but
treatment leads to the development of psoriatic-like lesions on healthy skin after IMQ
application (Wu et al., 2004). In humans IMQ induces hyperproliferation of keratinocytes
(Ha et al., 2014), pDC infiltration and IL-23 production, which promotes activation and
proliferation of Th17 cells (Garzorz-Stark et al., 2018) promoting psoriatic-like lesions.
The original study by van der Fits et al. (2009) demonstrates that application of IMQ to the
ears or shaved backs of mice, induces redness, scaling and thickening of skin resulting in
lesions, with this skin thickening being due to altered differentiation and the
hyperproliferation of keratinocytes, similar to that observed in humans. Furthermore, this
study demonstrated the immune infiltrates consisted of neutrophils, T cells and professional
APCs, also characteristic of psoriatic lesions in humans. Further studies have validated the
ability of IMQ to mimic the characteristics and mechanisms of human psoriasis. As
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mentioned above (Section 1.6.), IL-23-induced Th17 activation and proliferation has been
shown to be important in human psoriasis, and IMQ induces psoriasis-like inflammation in
mice via the same mechanism (Yoshiki et al., 2014). Furthermore, the presence of cellular
infiltrates including T cells, and APCs including pDCs and LCs have been confirmed in
IMQ-induced psoriasis-like lesions (Yoshiki et al., 2014, Ha et al., 2014, Vinter et al., 2015,
Garzorz-Stark et al., 2018), while eosinophils promote neutrophil infiltration to further
promote inflammation in IMQ-induced lesions (Kim et al., 2018a).
The IMQ-induced psoriasis-like inflammation model offers advantages over other models of
psoriasis. Unlike spontaneous or transgenic models, the IMQ-induced psoriasis-like
inflammation model better recapitulates human psoriasis in vivo, and is easy to establish.
Additionally, compared to other inducible models, the IMQ-induced psoriasis-like
inflammation model does not require expensive reagents (such as recombinant cytokines),
and instead can be established relatively cheaply due to commercially available IMQ in the
forms of topical cream, such as AldaraTM (iNova Pharmaceuticals, Chatswood, Australia).
Finally, mice are not subjected to invasive procedures such as injections, with cream applied
topically with minimal animal handling. The IMQ-induced psoriasis-like inflammation model
is currently the most commonly used mouse model of psoriasis, with over 200 published
studies noted up to 2016 (Hawkes et al., 2017), and an additional 200 studies published in
2017 and 2018 (https://www.scopus.com, last accessed 24/10/2018).

1.9.

Purinergic Signalling

As outlined above, therapies for both GVHD and psoriasis are limited in humans,
highlighting the need to investigate alternative pathways for these inflammatory disorders.
Purinergic signalling plays an important role in numerous inflammatory disorders, and may
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play a role in these diseases. The concept of purinergic signalling was first coined, when the
purine-based nucleotide adenosine triphosphate (ATP) was suggested to be an important cotransmitter in the nervous system (Burnstock, 1972). Purinergic signalling is a network
involving extracellular nucleotides and nucleosides, plasma membrane receptors and ectoenzymes (Volonté and D’Ambrosi, 2008) (Figure 1.4). Adenine-based nucleotides and
nucleosides, and their respective receptors and ecto-enzymes, are the most widely studied
purinergic signalling molecules.

Figure 1.4. The purinergic signalling pathway. ATP is released from damaged or dying cells, or by
exocytosis or channels (such as connexion-43 or pannexin-1). Extracellular ATP can activate P2X
receptors, including P2X7. ATP is broken down to ADP and AMP by CD39, and AMP is broken
down to adenosine by CD73. Adenosine can activate adenosine receptors, including A2A. Finally
adenosine is removed by conversion to inosine by adenosine deaminase (not shown). Abbreviations;
ADP, adenosine diphosphate, AMP, adenosine monophosphate, ATP, adenosine triphosphate. Figure
partly adapted from Junger (2011).

ATP when found extracellularly can act as a DAMP and activate P2 receptors to cause
numerous downstream pro-inflammatory effects (Di Virgilio and Vuerich, 2015). ATP can be
released into the extracellular space by damaged and/or dying cells via channels such as
connexin-43 (Csóka et al., 2015, Qin et al., 2016, Wang et al., 2017) and pannexin-1 (Yang
et al., 2015, Lohman et al., 2015, Zhang et al., 2017, Parzych et al., 2017, Saez et al., 2017)
or by exocytosis (Sakaki et al., 2013, Ren et al., 2014, Zhang et al., 2017, Kato et al., 2017).
This ATP is commonly degraded to adenosine diphosphate (ADP) and adenosine
monophosphate (AMP) by the cell surface ecto-nucleotidase ecto-nucleoside triphosphate
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diphosphohydrolase-1 (CD39), and AMP is subsequently degraded to adenosine by ecto-5’nucleotidase (CD73) (Zimmermann, 2000). Adenosine can then activate purinergic P1
(adenosine) receptors, which commonly results in anti-inflammatory effects (Antonioli et al.,
2013) (Figure 1.4). Purinergic pathway is involved in numerous systems, including the
central nervous, cardiovascular, reproductive and immune systems (Burnstock, 2017).
1.9.1. P2 Receptors
1.9.1.1.

P2Y Receptors

P2Y receptors are a collection of eight G protein-coupled receptors (GPCRs) (P2Y1, 2, 4, 6, 11,
12, 13, and 14).

P2Y receptor stimulation involves the opening or closing of voltage-gated K+

(Hille, 1994), Na2+ (Cantrell and Catterall, 2001) or Ca2+ (Dolphin, 2003) channels and
second messenger cascades to exert their effect (Soltoff et al., 1998, Huwiler et al., 2000).
P2Y receptors are present on numerous neurological and immune cells (Burnstock and
Knight, 2004, Abbracchio et al., 2006). P2Y receptors will not be discussed further, except
for a small section on P2Y2 in GVHD below (Section 1.10.1.1.). For a comprehensive review
on P2Y receptors consult Abbrachio et al. (2006).
1.9.1.2.

P2X Receptors

P2X receptors are a family of seven ligand gated ion channels (P2X1-7) which, upon
stimulation by ATP, allow the flux of cations including Na+, K+ and Ca2+ (Khakh et al.,
2001). P2X receptors are important in immunity, are present on a number of immune cells
and result in numerous downstream signalling effects. For a comprehensive review on P2X
receptors see Burnstock and Boeynaems, (2014). In the P2X family of receptors, P2X4
demonstrates the shortest amino acid sequence and P2X7 the longest (Valera et al., 1994).
Although both subtypes are important in inflammation and immunity, P2X7 is the most
widely studied in this field (Adinolfi et al., 2017).
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1.9.1.3.

P2X7

P2X7 is encoded by the P2RX7 gene (Rassendren et al., 1997) located on chr 12 (12q24) in
humans (Buell et al., 1998). The P2RX7 gene is highly polymorphic and contains a number
of single nucleotide polymorphisms (SNP) (Sluyter, 2017). P2X7 was originally classified as
the “P2Z” receptor, however following the cloning of this receptor was renamed P2X7,
becoming the seventh member of the P2X receptor family (P2X1-7) (Surprenant et al., 1996).
Each full-length P2X7 subunit has a total molecular weight of 68 kDa (Nicke, 2008) or 75-82
kDa after N-glycosylation (Young et al., 2007, Adinolfi et al., 2010). The original
computational structure of P2X7 (Jiang et al., 2013) was based on the crystal structure of the
zebrafish P2X4 receptor (Kawate et al., 2009), while the structure of the first native (panda)
P2X7 receptor has since been characterised (Karasawa and Kawate, 2016). Overall,
recombinant P2X7 has been characterised in 12 different species (seven mammalian and five
non-mammalian) (Sluyter, 2017). Each P2X7 subunit is comprised of two transmembrane
domains, with the three ATP binding sites present on the extracellular loop, while the
carboxyl and amino termini are found intracellularly (Jiang et al., 2013, Karasawa and
Kawate, 2016). The structure of the P2X7 receptor is analogous to a “dolphin” with the head,
and three fins (dorsal fin, and left and right flippers) representing structurally distinct sections
of β-sheets connected to the “body” constituting the extracellular domain, and the “tail”
representing the transmembrane proteins anchoring P2X7 to the plasma membrane
(Karasawa et al., 2017). P2X7 is expressed on many immune cell types including DCs (Saez
et al., 2017), macrophages (De Torre-Minguela et al., 2016), T cells (Sluyter and Wiley,
2014), B cells (Pupovac et al., 2015), NK cells (Gu et al., 2000), neutrophils (Karmakar et
al., 2016) and basophils (Tsai et al., 2015) but absent on eosinophils (Mohanty et al., 2001).
Expression on mast cells is tissue-dependent (Kurashima et al., 2012).
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Due to the expression of P2X7 on a wide range of immune cell subsets, P2X7 plays both a
role in innate and adaptive immune responses. In the innate immune system, P2X7 activation
is important against bacterial infections, including Mycobacterium, Plasmodium spp. (Salles
et al., 2017) and Leishmania (Thorstenberg et al., 2018). However, P2X7 is also important in
adaptive immunity. ATP activation of P2X7 can inhibit generation and function of Treg cells
(Schenk et al., 2011), and induce apoptosis of Treg and NKT cells (Rissiek et al., 2014).
Conversely, P2X7 activation promotes immune homeostasis in follicular Th cells in Peyer’s
patches (Proietti et al., 2014) and P2X7 is important for survival of memory CD8+ T cells
(Savio et al., 2018).
P2X7 exerts its effects through a variety of downstream effects including reactive oxygen
species formation (Bartlett et al., 2013, Moreira-Souza et al., 2017), shedding of surface
molecules such as CD23 (Pupovac et al., 2015), CD62L (Gu et al., 1998, Sluyter and Wiley,
2002) and TNF-α (Barberà-Cremades et al., 2017), and up-regulation of CD80 and CD86
(Wilhelm et al., 2010, Lioi et al., 2015). P2X7 activation also causes NLRP3 inflammasome
activation and release of IL-1β and IL-18 (Buell et al., 1998, Piccini et al., 2008), IL-2 (Yip
et al., 2009), IL-6 (Solini et al., 1999, Caporali et al., 2008), IL-17 (Ghiringhelli et al., 2009),
IL-18 (Piccini et al., 2008), and prostaglandin E2 (Barbera-̀Cremades et al., 2012). P2X7
activation can also promote cell death, through apoptosis (Zheng et al., 1991), necrosis
(Dagvadorj et al., 2015), or pyroptosis (Vanderpuye-Orgle et al., 2015). The polymorphic
nature of P2RX7 also impacts the downstream effects of P2X7. For example loss-of-function
SNPs such as G496A impair ATP-induced IL-1β and IL-18 release from monocytes (Sluyter
et al., 2004b, Sluyter et al., 2004a). In contrast, gain-of-function SNPs such as A348T,
increase ATP-induced IL-1β release from monocytes (Stokes et al., 2010). P2RX7 SNPs also
play a role in some diseases where P2X7 is implicated as discussed below (Section 1.8.1.).
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Similar to other P2X receptors, P2X7 is a trimeric channel stimulated by binding of ATP to
its extracellular domain to promote subunit rearrangement and opening of a cation channel
(Di Virgilio et al., 2018). However, P2X7 is less sensitive to ATP compared to other P2X
receptors, requiring >100 μM for activation (Khakh and North, 2006) and therefore can
detect large concentrations of extracellular ATP released during cellular stress and damage.
Activation of P2X7 results in rapid influx of Na+ and Ca2+ and efflux of K+ (Surprenant et al.,
1996, Rassendren et al., 1997, Egan and Khakh, 2004). However, pro-longed activation of
P2X7 also causes the formation of a pore, which can be observed by measuring the uptake of
dyes such as 6-carboxyfluorescein (6-FAM), lucifer yellow, fura-2 (Steinberg et al., 1987),
ethidium2+ (Wiley et al., 1993) and YO-PRO-12+ (Surprenant et al., 1996), but not dyes >900
kDa (Steinberg et al., 1987, Surprenant et al., 1996). P2X7 is believed to be the pore forming
molecule (Di Virgilio et al., 2018), however other molecules such as pannexin-1 may also be
involved (Pelegrin and Surprenant, 2006) but their relative contribution remains to be
resolved.
Despite past and current debates of P2X7 pore formation, ATP-induced dye uptake remains
an efficient way to measure P2X7 activity in vitro (Jursik et al., 2007, Korpi-Steiner et al.,
2008). ATP is the physiological agonist of P2X7, with a half maximal excitatory
concentration (EC50) of 80-100 μM at human P2X7 (Wiley et al., 2011). However, the ATP
analogue, 2',3'-(4-benzoyl)-benzoyl-adenosine triphosphate (BzATP) is a more potent agonist
with an EC50 of 7-20 μM at human P2X7 (Carroll et al., 2009, Wiley et al., 2011). Notably,
P2X7 can also be activated by antimicrobial peptides such as LL-37, which directly activates
P2X7 to cause Ca2+ influx, pore formation, and cell proliferation in vitro in transfected
HEK-293 cells (Tomasinsig et al., 2008).
A number of P2X7 antagonists are commercially available (Bartlett et al., 2014), including
Brilliant Blue G (BBG), a non-toxic analogue of the US food and drug administration (FDA)
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approved food dye Brilliant Blue FCF (Apolloni and Volonte, 2013), as well as the
nucleoside reverse transcriptase inhibitor stavudine (Fowler et al., 2014). The antagonists
most relevant to this thesis and the half maximal inhibitory concentrations (IC50) of each are
summarised in Table 1.2.

Table 1.2. P2X7 antagonists, and the IC50 exhibited at human P2X7. Abbreviations: IC50, half

maximal inhibitory concentration, N.D., not determined.
Antagonist

IC50 (nM)

Reference

Brilliant Blue G (BBG)

300

(Jiang et al., 2000)

Pyridoxalphosphate-6-azophenyl2',4'-disulfonic acid (PPADS)

1200

(Donnelly-Roberts et al., 2009a)

KN-62

12.7

(Gargett and Wiley, 1997)

Stavudine

N.D.

(Fowler et al., 2014)

A804598

11

(Donnelly-Roberts et al., 2009b)

1.9.2. Ecto-nucleotidases
Whilst ATP plays a role in the activation of P2 receptors including P2X7 activation in
inflammation
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Ecto-nucleotidases are a family of cell surface enzymes that hydrolyse nucleotides and are an
important part of the purinergic signalling system throughout the body. They consist mainly
of four families; the ecto-nucleoside triphosphate di-phosphohydrolases (E-NTPDases); ectonucleotide pyrophosphatase/phosphodiesterases (E-NPPs); alkaline phosphatases (APPs); and
ecto-5’-nucleotidases (Zimmermann, 2000). As noted above, the ecto-nucleotidases, CD39
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and CD73 mediate the stepwise conversion of ATP to adenosine. Together these ectoenzymes play major roles in inflammation and immunity as outlined below.
1.9.2.1.

CD39

CD39 is encoded by the ENTPD1 gene located on human chr 10 (10q24.1) (Maliszewski et
al., 1994). CD39 is composed of two transmembrane domains, with the carboxyl and amino
domains found intracellularly, and a large hydrophobic domain found extracellularly (Heine
et al., 2001). CD39 has a molecular mass of 70-100 kDa, depending on the extent of
glycosylation (Kaczmarek et al., 1996). Originally thought to be a marker of B cell activation
(Ling et al., 1989), CD39 has since been found to be present on T cells (Kansas et al., 1991),
monocytes, DCs (Koziak et al., 1999) and NK cells (Kansas et al., 1991). CD39 is
responsible for Ca2+- and Mg2+-dependent degradation of extracellular ATP to ADP and
subsequently to AMP (Heine et al., 2001). The crystal structure of CD39 was partially
resolved after over expression in Chinese hamster ovary cells (Zhong et al., 2008), however
the full structure has since been characterised from a bacterium (Legionella pneumophilia)
(Zebisch et al., 2012, Zebisch et al., 2013). The full structure of CD39 revealed that both
ATP and ADP are hydrolysed at the same site, and this can be done sequentially,
demonstrating the efficient removal of ATP by CD39 (Zebisch et al., 2012, Zebisch et al.,
2013). Notably, effects of CD39 can be mimicked in part by the use of the ATPDase apyrase
(Handa and Guidotti, 1996).
Antagonists of CD39 include nucleotide-based compounds modelled from the structure of
ATP, including ARL67156, which is a weak inhibitor of human CD39 with an IC50 of 24 μM
(Crack et al., 1994) and 8-BuS-ATP with an IC50 of 5 ± 3 μM (Lecka et al., 2013).
Non-nucleotide-based inhibitors of human CD39 such as PSB-069, with an IC50 of 1.6 μM
(Longhi et al., 2017) and suramin, with an IC50 of 0.3 mM (Leal et al., 2005) are non-specific
(Baqi, 2015). Other non-nucleotide inhibitors belonging to the polyoxometalate (POM) group
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of compounds are relatively specific to CD39 (Muller et al., 2006). However, at least one of
these compounds (POM-1), which is commonly used as a specific CD39 antagonist, blocks
murine P2X7 (Pimenta-Dos-Reis et al., 2017). Thus, further investigation of the specificity of
these compounds is warranted.
1.9.2.2.

CD73

CD73 is encoded by the NT5E gene located on human chr 6 (6q14.3) (Boyle et al., 1988).
CD73 is a 71 kDa (Misumi et al., 1990) glycosylphosphatidylinositol-linked protein
(Zimmermann, 1992). CD73 is present on DCs (Berchtold et al., 1999) and T cells (Thomson
et al., 1990), but CD73 is absent on NK cells (Dalh Christensen and Andersen, 1992) and
monocytes (Clifford et al., 1997). CD73 is responsible for the degradation of AMP to
adenosine (Pearson et al., 1980), which is achieved by exposure of the active site when CD73
changes from the closed to open state, due to the large flexibility of CD73 homodimers
(Knapp et al., 2012).
Reactive blue 2 is an antagonist of human CD73, with a Ki of 20 μM (IC50 not determined)
(Baqi et al., 2010), but is non-specific exerting antagonistic properties at numerous human P2
receptors (Baqi, 2015). The specific antagonist αβ-methylene-ADP (APCP), can keep CD73
in the closed state (Knapp et al., 2012) and demonstrates an IC50 of 3.6-5.6 μM at human
CD73 (Crane et al., 2007, McManus et al., 2018). However, APCP is not specific to CD73 as
it has since been shown to also inhibit CD39 (Covarrubias et al., 2016).
1.9.3. P1 Receptors
Adenosine receptors, also known as P1 receptors, consist of four subtypes of GPCRs (A1,
A2A, A2B and A3) which, as the name suggests, are all activated by extracellular adenosine.
Under physiological conditions, activation of A2 receptors generally results in release of
cytokines that promote an anti-inflammatory effect, while A1 and A2 can have either pro- or
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anti-inflammatory effects. The expression of different subtypes of adenosine receptors varies
between cell types (Haskó et al., 2008). A2A and A2B bind the G-protein Gs, which stimulates
adenylyl cyclase to produce cAMP. Conversely, A1 and A3 bind Gi/o to inhibit adenylyl
cyclase (Fredholm et al., 2011a). A2A and A2B share 59% sequence homology (Lucattelli et
al., 2011), but A2A is better characterised than A2B and more commonly is the target of
therapies for diseases, such as Parkinson’s and Huntington’s disease, currently in human
trials (Borea et al., 2018). All four adenosine receptor subtypes are discussed below.
1.9.3.1.

A1

A1 is encoded by the ADORA1 gene located on human chr 1 (1q32.1) (Townsend-Nicholson
et al., 1995). Similar to all adenosine receptors, A1 consists of seven transmembrane proteins
(Cheng et al., 2017). A1 can be expressed as homodimers (Ciruela et al., 1995, Namba et al.,
2010), however A1 has also been shown to form heterodimers with β-adrenergic receptors
(Komatsu et al., 2012, Chandrasekera et al., 2013), and dopamine receptors (Gines et al.,
2000). Furthermore, A1 can also form heterodimers with other purinergic receptors including
A2A (Ciruela et al., 2006) and P2Y1 (Yoshioka et al., 2001, Yoshioka et al., 2002).
A1 predominantly plays a role in the nervous system (Chen et al., 2013), but is found on
immune cells including DCs (Panther et al., 2001, Schnurr et al., 2004), monocytes and
macrophages (Eppell et al., 1989, Thiele et al., 2004), T and B cells (Takahashi et al., 2007),
NK cells (Priebe et al., 1990), as well as neutrophils (Cronstein et al., 1990) and eosinophils
(Kohno et al., 1996). In innate immunity, A1 activation on neutrophils promotes a proinflammatory response, promoting chemotaxis of neutrophils and their adhesion to
endothelial cells (Cronstein et al., 1990, Cronstein et al., 1992). Furthermore, A1 activation
and promotes superoxide release from neutrophils (Cronstein et al., 1990) and eosinophils
(Ezeamuzie and Philips, 1999). In adaptive immunity, A1 activation results in chemotaxis of
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DCs and stimulation of T cells (Panther et al., 2001), T and B cell proliferation (Takahashi et
al., 2007) and NK cell activation (Priebe et al., 1990).
Adenosine is the physiological agonist of A1, however a number of selective agonists and
antagonists exist. The agonist N6-cyclopentyladenosine (CPA) demonstrates a Ki of 2.25 ±
0.18 nM (Cappellacci et al., 2008), 2-chloro-N6-cyclopentyladenosine (CCPA) demonstrates
a Ki of 0.8 ± 0.06 nM (Cappellacci et al., 2008) and N6-cyclohexyladenosine demonstrates a
Ki of 7.7 ± 2.2 nM (Kollias-Baker et al., 1997). Conversely, caffeine is commonly used as a
general adenosine receptor antagonist, due to its low cost and wide availability (Sattin and
Rall, 1970). However, the specific A1 antagonist DPCPX exhibits a Ki of 3.9 nM, but no IC50
has been published (Klotz, 2000).
1.9.3.2.

A2A

A2A is encoded by the ADORA2A gene located on human chr 22 (22q11.23) (MacCollin et
al., 1994). The crystal structure demonstrates A2A consists of seven transmembrane proteins,
and exhibits a unique binding site consisting of four disulphide bonds in the extracellular
domain (Jaakola et al., 2008, Lebon et al., 2011b, Weinert et al., 2017), but unlike the other
three adenosine receptors, A2A is the only adenosine receptor lacking a site for palmitoylation
at the carboxyl terminus (Linden, 2001).
A2A is constitutively expressed as homodimers (Canals et al., 2004), but can interact with
other proteins at the cell surface, forming heterodimers with cannabinoid receptors (Carriba
et al., 2007, Navarro et al., 2008) and dopamine receptors (Hillion et al., 2002). Association
of A2A and dopamine receptors can also lead to the formation of heterotrimers with metabolic
glutamate type 5 receptors (Cabello et al., 2009). Furthermore, a seminal paper by Moriyama
and Sitkovsky (2010), demonstrated that A2A is required for transport of A2B to the cell
surface, as the majority of A2B is degraded by the proteasome in A2A KO cells.
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Similar to A1, A2A plays a role in the nervous system, and therefore is found in the striatum
and other brain regions (Rosin et al., 1998, Lopes et al., 2002, Rebola et al., 2005). However,
due to the anti-inflammatory role in immunity, A2A is present on numerous immune subtypes
including granulocytes (Sullivan and Linden, 1998), APCs including DCs (Panther et al.,
2001), monocytes and macrophages (Eppell et al., 1989, Thiele et al., 2004), T and B cells
(Huang et al., 1997), NK cells (Priebe et al., 1990) and mast cells (Ryzhov et al., 2008). A2A
plays a role in both adaptive and innate immunity. Activation of A2A on neutrophils inhibits
their adhesion to endothelial cells (Eltzschig et al., 2004), reduces reactive oxygen species
production (Cronstein et al., 1990), and downregulates L-selectin and β2-integrin (Thiel et al.,
1996). A2A activation prevents phagocytosis in monocytes (Salmon et al., 1993) and
macrophages (Eppell et al., 1989). Upon activation DCs up-regulate A2A expression (Panther
et al., 2001, Fossetta et al., 2003) and concomitantly decrease production of proinflammatory IL-12, and increase production of anti-inflammatory IL-10 (Banchereau and
Steinman, 1998, Panther et al., 2001, Panther et al., 2003). A2A activation on T cells inhibits
IFN-γ, TNF-α and IL-4 production (Lappas et al., 2005, Odashima et al., 2005). Furthermore,
A2A activation inhibits T cell activation, leading to reduced inflammatory activity (Lappas et
al., 2005) and proliferation (Takahashi et al., 2007), while A2A activation on NK cells inhibits
their activity (Priebe et al., 1990).
The determination of the crystal structure of A2A in complex with the antagonist ZM241385
identified the ability of this antagonist to keep the receptor in an inactive state, potentially due
to the interaction with a tryptophan residue important for its activation (Jaakola et al., 2008).
Further characterisation of A2A in complex with the antagonist ZM241385 also identified an
allosteric pocket (Sun et al., 2017), whilst A2A in complex with other antagonists (xanthines)
(Cheng et al., 2017) may allow development of alternative agonists and antagonists.
Characterisation of the structure with an engineered G protein demonstrates how A2A is
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activated, and A2A is used as an example to allow elucidation of information about other
GPCRs (Carpenter et al., 2016). A2A activation on immune cells stimulates adenylyl cyclase
to promote cyclic AMP (cAMP) production, exerting an anti-inflammatory effect by
preventing T cell activation (Huang et al., 1997) and reducing pro-inflammatory cytokine
release (Ohta and Sitkovsky, 2001).
Adenosine is the physiological agonist of A2A, however a number of potent A2A agonists have
been developed. CGS-21680 demonstrates a Ki of 27 nM (Klotz et al., 1998) and an EC50 of
24-33 nM at human A2A (Himer et al., 2010). Similarly, ATL-146e demonstrates a Ki value
of 11 nM (but no EC50 determined) at human A2A (Lebon et al., 2011a), but is not
commercially available due to its current use in clinical trials as a therapy for heart conditions
(Gao and Jacobson, 2011). Specific antagonists of A2A include ZM241385 (but no IC50
determined for human A2A) and SCH-58261, which demonstrates an IC50 of 15 ± 3 nM at
human A2A (Varani et al., 1996).
1.9.3.3.

A2B

A2B is encoded by the ADORA2B gene located on human chr 17 (17p12) (Jacobson et al.,
1995). Similar to other adenosine receptors A2B consists of seven transmembrane proteins,
but also possesses a unique binding site for hypoxia-inducible factor, important for cellular
responses during hypoxia and inflammation (Kong et al., 2006, Gessi et al., 2010).
Furthermore, A2B is unique from other adenosine receptors requiring higher (micromolar)
concentrations for activation (Fredholm et al., 2011b). A2B can be expressed as homodimers
(Moriyama and Sitkovsky, 2010), but as mentioned above (section 1.9.5.) A2B can also form
heterodimers with A2A (Moriyama and Sitkovsky, 2010), as well as with other molecules
including adenosine deaminase (Herrera et al., 2001, Pacheco et al., 2005), SNARE proteins
(Wang et al., 2004) and netrin-1 (Corset et al., 2000).
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A2B is found on immune cells including monocytes and macrophages (Eppell et al., 1989,
Thiele et al., 2004), T and B cells (Gessi et al., 2005), neutrophils (Eckle et al., 2008) and
mast cells (Feoktistov and Biaggioni, 1995). A2B was originally thought to be absent on DCs
(Panther et al., 2001), but has since been shown to be expressed (Addi et al., 2008, Novitskiy
et al., 2008) on these cells. Expression of A2B on neutrophils is controversial. Using Western
blotting, one study showed A2B is not present on neutrophils (Fortin et al., 2006), while
others have demonstrated the presence of functional A2B on these cells (Wakai et al., 2001,
Thiel and Chouker, 1995). A2B plays roles in both innate and adaptive immunity. Activation
of A2B on neutrophils inhibits their migration and adhesion to endothelial cells (Wakai et al.,
2001) and prevents TNF-α production (Thiel and Chouker, 1995), whilst A2B activation on
monocytes promotes production of the anti-inflammatory cytokine IL-10 (Nemeth et al.,
2005). In adaptive immunity, A2B activation on T cells reduces IL-2 production (Mirabet et
al., 1999).
Similar to the other adenosine receptors, adenosine is the physiological antagonist of A2B,
however unlike the other receptors, no specific agonists for A2B exist (Fredholm et al.,
2011b). Nevertheless, MRS1754 is a specific A2B antagonist, which exhibits a Ki value of
403 ± 194 nM but no published IC50 value (Kim et al., 2000).
1.9.3.4.

A3

A3 is encoded by the ADORA3 gene located on human chr 1 (1p13.2) (Monitto et al., 1995).
Similar to all adenosine receptors, A3 consists of seven transmembrane proteins, and is
rapidly desensitised upon activation (Palmer and Stiles, 2000). A3 is expressed as a
homodimer and has been shown to form heterodimers (May et al., 2011), but the specific
binding partners have not been identified.
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A3 is expressed on immune cells including DCs (Fossetta et al., 2003, Panther et al., 2001),
monocytes and macrophages (Eppell et al., 1989, Thiele et al., 2004), T and B cells (Gessi et
al., 2004), neutrophils (Bouma et al., 1997, Walker et al., 1997b), eosinophils (Walker et al.,
1997a) and mast cells (Salvatore et al., 2000, Zhong et al., 2003). A3 is important in both
innate and adaptive immunity. A3 activation on neutrophils results in their migration in
response to chemoattractant release by microbes (Chen et al., 2006), whilst activation on
monocytes reduces IL-12 production (la Sala et al., 2005). In adaptive immunity, A3
activation on lymphocytes promotes their proliferation (Takahashi et al., 2007).
Adenosine is the physiological agonist of A3, whilst a selective agonist Cl-IB-MECA
demonstrates a Ki of 3.16 ± 0.007 nM at human A3 (Xia et al., 2018). Specific A3 antagonists
are derived from non-purine based classes, including flavonoids and dihydropyridines
(Jacobson et al., 1997). Two examples include MRS-1292 with a Ki of 29 nM (Gao et al.,
2002) and an IC50 of 41 ± 11 nM (Yang et al., 2005a), and MRS-3558 with a Ki of 0.3 nM
(Joshi and Jacobson, 2005) and an IC50 of 0.4 nM (Zhang et al., 2010).

1.10. Purinergic Signalling in Inflammatory Disorders
Extracellular ATP exerts pro-inflammatory effects in numerous diseases and ATP activation
of P2X7 is implicated in a number of these diseases (Adinolfi et al., 2017). Breakdown of
ATP to adenosine by CD39 and CD73 on numerous cell types typically results in beneficial
anti-inflammatory effects (Bours et al., 2006) and is important in reducing inflammation in
numerous inflammatory diseases (Antonioli et al., 2013). CD39 is important for adenosine
generation and Treg cell-mediated immune suppression (Deaglio et al., 2007). The
immunosuppressive function of Treg cells may in fact rely on the conversion of ATP to
adenosine (Deaglio et al., 2007, Ernst et al., 2010).
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In tissue transplantation, genetic differences in tissues or cells transplanted from one
individual to another is inevitable, and as mentioned above these differences can result in
immune responses and inflammation, potentially in the form of GVHD. Due to the
importance of purinergic signalling in immunity and inflammation, it is therefore likely
purinergic signalling plays a role in transplantation and GVHD. Alternatively, the skin is
highly immunogenic and in the case of skin diseases such as psoriasis, where chronic
inflammation is a characteristic of pathogenesis, it is likely purinergic signalling also plays a
role. The roles of purinergic signalling in transplantation and GVHD, as well as skin biology
and psoriasis are summarised below.
1.10.1. Purinergic Signalling in Transplantation
Purinergic signalling has been implicated in transplantation, predominantly studied in the
context of whole organ transplantation. Increased ATP concentrations and activation of the
P2X7 receptor can increase the risk of whole-organ rejection in heart (Vergani et al., 2013b),
lung (Liu et al., 2014), islet (Vergani et al., 2013a), and liver and skin (Amores-Iniesta et al.,
2017) transplants. Similarly, genetic deficiency of CD39 or CD73 causes increased ischemia
in heart (Enjyoji et al., 1999, Dwyer et al., 2004, Eckle et al., 2007), liver (Yoshida et al.,
2015) and renal (Lu et al., 2008) transplants, however genetic deficiency of CD73 was found
to be protective in one study of renal transplantation (Rajakumar et al., 2010). Conversely,
increased CD39 and CD73 expression, correlates to reduced ischemia in heart (Dwyer et al.,
2004), renal (Grenz et al., 2007b, Grenz et al., 2007a, Crikis et al., 2010) and liver (Yoshida
et al., 2013) transplantation. The degradation of ATP to adenosine by CD39 and CD73 is
important as activation of A2A by adenosine reduces damage and rejection of lung (Sharma et
al., 2009, Gazoni et al., 2010), islet (Chhabra et al., 2010), renal (Lee and Emala, 2001,
Crikis et al., 2010), and skin (Sevigny et al., 2007) transplants.
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Whilst purinergic signalling plays a role in whole organ transplantation, it is also implicated
in HSCT. A study by (Lee et al., 2007) demonstrated that P2RX7 genotypes influence overall
survival in HSCT patients. HSCT recipients demonstrated significantly reduced survival
when their P2RX7 genotype, or the P2RX7 genotype of the donor, was homozygous for the
SNP encoding the mutation E496A compared to donors wild-type or heterozygous for this
allele. However, this finding was not replicated in a larger study (Karaesmen et al., 2017). A
recent abstract by Koldej et al. (2018) demonstrates that homozygosity for gain-of-function
P2RX7 SNPs (T375S, G150R, Q460R and A348T) leads to a reduced relapse-free survival
and overall survival in HSCT patients, however this data is yet to be published in full.
Moreover, both pharmacological and genetic evidence, mainly in allogeneic mouse models,
suggests a role for purinergic signalling in GVHD, as discussed below.
1.10.1.1.

P2Y2 in GVHD

P2Y2 has been implicated in GVHD, but findings are limited and will only be discussed
briefly. P2Y2 is present on neutrophils (Zhang et al., 1996), eosinophils (Mohanty et al.,
2001), mast cells (Gao et al., 2013), monocytes (Aga et al., 2002), macrophages (CoutinhoSilva et al., 2005), DCs (Berchtold et al., 1999), as well as T and B cells (Koshiba et al.,
1997, Trabanelli et al., 2012). Notably, P2Y2 deficient mice demonstrate reduced mortality,
serum IL-6, and histological damage in an allogeneic mouse model of GVHD (Klambt et al.,
2015). Specific genetic deletion of P2Y2 in hematopoietic tissues and more specifically on
inflammatory myeloid cells reduces GVHD severity (Klambt et al., 2015), while a lack of
P2Y2 in Treg cells worsens GVHD (Dürr et al., 2012). Collectively, this suggests both proand anti-inflammatory roles of P2Y2 in GVHD potentially limiting its therapeutic potential.
1.10.1.2.

P2X7 in GVHD

Evidence for the role of P2X7 in GVHD comes indirectly from studies of downstream effects
of P2X7 activation, as well as studies of pharmacological blockade and/or genetic deficiency
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of P2X7 in allogeneic mouse models of GVHD. In allogeneic mouse models of GVHD,
indirect evidence of the role of P2X7 in GVHD is supported by genetic deletion or
pharmacological blockade of IL-1 (the super family of cytokines, including IL-1β), with the
recombinant IL-1 receptor antagonist “anakinra” (10 mg/kg injected i.p. on days -1, 0, 1, 2, 4,
6, and 8) or a neutralising anti–IL-1β antibody (10 mg/kg injected i.p. on day -1), which
delayed GVHD and significantly increased survival (Jankovic et al., 2013). Additionally,
genetic deletion of the NLRP3 inflammasome in the host, but not the donor, also reduced
GVHD-associated weight loss, histological damage and mortality (Jankovic et al., 2013).
Furthermore, micro-RNA (miR)-155, which regulates inflammasome activation and IL-1β
production, as well as IL-6 and TNF-α production (Ceppi et al., 2009), is upregulated in
activated T cells in mice with acute GVHD (Ranganathan et al., 2012). Genetic deletion of
miR-155 results in reduced damage to target organs and an increased survival due to a
reduced number of activated T cells (Ranganathan et al., 2012) as well as reduced DC
migration, inflammasome activation and IL-1β production (Chen et al., 2015).
The role of P2X7 activation by ATP in promoting GVHD pathogenesis has been
demonstrated by pharmacological blockade and genetic deletion of P2X7 in allogeneic mouse
models of GVHD. First, ATP was shown to be released at the sites of tissue damage in
HSCT, where activation of P2X7 causes upregulation of the co-stimulatory molecules, CD80
and CD86 on DCs to promote T cell responses (Wilhelm et al., 2010). Second, apoptosis and
inflammation of target organs, as well as serum IFN-γ, was reduced in the presence of either
apyrase (4U injected i.p. days 0–2 and 6–8), or PPADS (10 μmol injected i.p. daily, days
0-10) or KN-62 (1 μmol injected i.p. daily, days 0-10). Finally, genetic deletion of P2X7 in
the host, but not the donor cells, reduces serum concentrations of the pro-inflammatory
cytokines IFN-γ, TNF-α, and IL-6, and prolonged survival (Wilhelm et al., 2010). Fowler et
al. (2014) validated these results by demonstrating that injection of stavudine (25 mg/kg,
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twice daily days 0-10) reduces weight loss and serum IFN-γ, TNF-α, and IL-6 concentrations,
and prolonged survival. Finally, P2X7 blockade using BBG (50 mg/kg or 75 mg/kg, injected
i.p. twice weekly for up to four weeks) reduces liver damage, as well as hepatic expression of
P2X7, and the pro-inflammatory cytokines IL-1β and IL-18 (Zhong et al., 2016).
Clinical studies in humans also support a potential role for P2X7 in GVHD. In HSCT, the
presence of loss-of-function SNPs, E496A or I568N in the recipient reduced the incidence of
GVHD (Koldej et al., 2018), however this data is yet to be published in full. Furthermore,
P2X7 is increased on circulating PBMCs and higher numbers of P2X7 expressing cells are
found in the colons of HSCT patients with GVHD (Wilhelm et al., 2010). The role of P2X7
in this disease has not been examined in a humanised mice mouse model of GVHD and is
limited in humans.
1.10.1.3.

CD39 and CD73 in GVHD

ATP is released at the sites of damage in HSCT recipients to promote inflammation but its
degradation by apyrase can prevent GVHD (Wilhelm et al., 2010). Moreover, CD39 and
CD73 have been shown to be important in preventing GVHD, in both in vitro and in vivo
allogeneic mouse models of GVHD.
In mixed lymphocyte reactions (MLRs), mesenchymal stem cells express increased CD39
and T cells express increased CD73, to increase adenosine concentrations and reduce
activation of conventional T cells (Saldanha-Araujo et al., 2011). Additionally, in co-cultures
of Treg and conventional T cells, up-regulation of CD39 and conversion of ATP to adenosine
by Treg cells reduces T cell stimulation and inflammation through a reduction in NOTCH1
signalling (Del Papa et al., 2017). Pharmacological blockade of CD73 in allogeneic MLRs
using the antagonist APCP (100 μM) reduces suppression of T cell proliferation by Treg cells
and increases IFN-γ concentrations (Wang et al., 2013). Similarly, an anti-human CD73 mAb
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(clone 2C5) increases TNF-α, IL-1β and IFN-γ concentrations in allogeneic MLRs (Young et
al., 2016).
Studies have also implicated roles for CD39 and CD73 in allogeneic mouse models of
GVHD. Inhibition of aurora kinase A and JAK2 with the dual antagonist AJI-214, increases
CD39 expression on the cell surface of Treg cells to promote degradation of extracellular
ATP and reduce GVHD (Betts et al., 2017). Furthermore, injection of another dual aurora
kinase A/JAK2 antagonist AJI-100 (50 mg/kg, injected i.p. daily, days 0-14) suppressed
expansion of activated human CD4+ T cells, Th17 cells, CD8+ T cells, and improved survival
in the humanised NSG mouse model of GVHD (Betts et al., 2017). This effect was shown to
be mediated through human CD39hi cells (Gu et al., 2016b). In an allogeneic mouse model of
GVHD, Tsukamoto et al. (2012) demonstrated that pharmacological blockade of CD73 using
APCP (50 mg/kg, injected i.p. daily, days 0-6), increases disease-related mortality. Similarly,
Wang et al. (2013) demonstrated APCP injection (20 mg/kg injected i.v. twice weekly) also
increases GVHD mortality, and increases splenic CD4+ and CD8+ T cell numbers and serum
IFN-γ and IL-6 concentrations. Although both these studies used APCP as a CD73 inhibitor,
this compound also blocks CD39 (Covarrubias et al., 2016), so a role for CD39 in this
process cannot be excluded. However, genetic deficiency of CD73 also increases histological
damage of target organs, splenic CD4+ and CD8+ T cell numbers and serum IFN-γ and IL-6
concentrations and worsens mortality in allogeneic mouse models of GVHD (Tsukamoto et
al., 2012, Wang et al., 2013).
In human allogeneic MLRs, human gingiva-derived mesenchymal stem cells fail to reduce T
cell suppression in the presence of APCP (200-500 μM) or POM-1(100 μM) (Huang et al.,
2017). Whilst, transfer of human gingiva-derived mesenchymal stem cells into humanised
NOD/SCID mice reduced histological damage, IL-4, IL-17, IFN-γ, IL-2 and TNF-α
production by T cells, and mortality, mediated through adenosine production. Notably, these
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effects are lost if these cells were incubated with POM-1 (100 μM) prior to transplantation
(Huang et al., 2017).
In conclusion, whilst CD39 and CD73 have been shown to be important in reducing disease
severity in allogeneic mouse models, the role of these ecto-enzymes in disease development
in a humanised NSG mouse model of GVHD has not been investigated and studies in humans
are limited.
1.10.1.4.

A2A in GVHD

The role of A2A has also been implicated in GVHD in allogeneic mouse models of this
disease. The non-selective adenosine receptor antagonist caffeine (10 mg/kg injected i.p. day
0-6, and 3-5 times a week onwards) worsens mortality (Tsukamoto et al., 2012). Moreover,
activation of A2A was identified as the adenosine receptor subtype responsible for exerting
anti-inflammatory effects in allogeneic mouse models of GVHD, as blockade with the A2A
antagonist SCH58261, but not the A2B antagonist MRS1754 (both 2 mg/kg, injected i.p. daily
day -2-12) increased serum TNF-α, IFN-γ and IL-6, and CD4+ and CD8+ T cell numbers, and
worsened mortality (Wang et al., 2013). Additionally, genetic deficiency of A2A increased
CD4+ and CD8+ T cell numbers (Tsukamoto et al., 2012, Wang et al., 2013), but the effect on
mortality was not reported in either study.
Supporting the role of A2A in GVHD, Lappas et al. (2010) demonstrated that treatment with
the A2A receptor agonist ATL-146e increased serum IL-10, and reduced serum IFN-γ and
IL-6. Furthermore, ATL-146e reduced activated splenic CD4+ and CD8+ T cell numbers,
decreased T cell infiltration into target organs and reduced weight loss and mortality in an
allogeneic mouse model of GVHD. ATL-146e, as well as the other agonists ATL-370 and
ATL-1223, also increased donor derived Treg cells in both the skin and colon in this same
model (Han et al., 2013). Finally, Amarnath et al. (2015) demonstrated that bone derived
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mesenchymal stromal cells reduced IFN-γ- and TNF-α-producing leukocytes, and reversed
disease. This beneficial effect is abrogated by the A2A antagonist ZM241385 (1.5 mg/kg
injected i.p. daily days 20-35), which prevented T cell suppression, worsened disease and
reduced survival in a humanised mouse model of GVHD (Amarnath et al., 2015).
1.10.1.5.

Summary

Combined, the above shows that purinergic signalling plays an important role in disease
development in allogeneic mouse models of GVHD. Extracellular ATP, released at sites of
damage during transplantation can activate P2X7 to promote T cell activation, proinflammatory cytokine release and damage to target organs, leading to further ATP release
and a feedforward loop of inflammation promoting GVHD. Degradation of extracellular ATP
to adenosine by the ecto-enzymes CD39 and CD73, can then promote A2A activation and
reduce GVHD (Figure 1.5.). However, the role of this signalling system in humanised mouse
models of GVHD remains unknown. Whether ATP release activates P2X7 to promote
GVHD, and whether degradation of ATP to adenosine by CD39 and CD73 and activation of
adenosine receptors reduces GVHD remains to be fully elucidated in humanised mouse
models.
1.10.2. Purinergic Signalling in Skin Biology and Disease
There is a well-established role for purinergic signalling in the skin. The roles of P2 and
adenosine receptors, as well as ecto-enzymes on skin cells and in a number of skin diseases,
is comprehensively reviewed by Burnstock et al. (2012). The role of P2X7 in skin biology
and psoriasis is discussed below.
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Figure 1.5. Purinergic signalling in allogeneic mouse models of GVHD. ATP is released during
the initial stages of inflammatory damage of GVHD, ATP is released. ATP activates P2X7 on APCs,
such as DCs, which leads to upregulation of the costimulatory molecules CD80 and CD86, which
leads to increased Th1 activation and IFN-γ release. This IFN-γ release up-regulates P2X7 expression
on APCs and propagates further tissue damage, resulting in further ATP release and a feed-forward
loop of inflammation. However, degradation of ATP to ADP and AMP by CD39, and subsequently to
adenosine by CD73, can activate A2A receptors on Treg cells (and mesenchymal stem cells; not
shown) to reduce GVHD. Abbreviations; ADP, adenosine diphosphate, AMP, adenosine
monophosphate, APC, antigen presenting cell, ATP, adenosine triphosphate, DC, dendritic cell,
IFN-γ, interferon gamma.

1.10.2.1. P2X7 in Skin Biology
P2X7 is present on a number of skin cell types including keratinocytes, as well as skin
resident DCs including LCs (Georgiou et al., 2005, Tran et al., 2010). Fluorescence based
immunostaining of normal skin found P2X7 to be present solely in the stratum corneum of
normal skin (Greig et al., 2003), but epidermal P2X7 was not detected by chromogen-based
immunohistochemistry (Pastore et al., 2007). P2X7 has been implicated in a number of skin
disorders, including AD and ICD. P2X7 is up-regulated in the epidermal basal layer of
inflamed skin of AD patients compared to normal human skin (Pastore et al., 2007) and in
55

murine CHS, a model of AD (Weintraub et al., 2015). Moreover, both pharmacological
blockade and genetic deficiency of P2X7 impairs CHS responses in mice due to the absence
of P2X7-mediated IL-1β release from DCs (Weber et al., 2010). Similarly, both
pharmacological blockade and genetic deficiency of P2X7 impair oedema, IL-1β production
and neutrophil infiltration in a murine model of croton oil-induced ICD (Da Silva et al.,
2013). Additionally, P2X7 on mast cells is involved in retinoid-induced ICD, mediated by
aberrant release of ATP within the skin and increased P2X7 expression on skin mast cells
(Kurashima et al., 2014). Thus, P2X7 activation is important in promoting AD and ICD but
its potential role in psoriasis remains largely unknown but as discussed below a role for P2X7
in this inflammatory disease is emerging.
1.10.2.2. P2X7 in Psoriasis
Although the role of P2X7 has not been investigated in animal models of psoriasis, in vitro
studies directly, and in vivo studies indirectly, support a role for P2X7 in psoriasis
pathogenesis. As mentioned above (Section 1.6) antimicrobial release is implicated in
psoriasis pathogenesis. LL-37 induces ATP release, caspase-1 activation and IL-1β release
from LPS-primed monocytes, which was inhibited in vitro by addition of oxidised ATP
(oATP) (100 μM) or KN-62 (0.1 μM) (Elssner et al., 2004). LL-37 activation of P2X7 also
inhibits skin fibroblast migration, an effect inhibited by addition of BBG (10 μM) (Kumagai
et al., 2013).
Alternatively, β-defensins and S100A proteins can cause ATP release, which activates P2X7
via an autocrine mechanism (Lioi et al., 2015, Wanke et al., 2016, Kim et al., 2018b). Human
β-defensin-3 also causes up-regulation of CD86 expression on monocytes, which can be
prevented by KN-62 (2 μM) (Lioi et al., 2015). Additionally, both human β-defensin-2 and -3
induce TNF-α and CXCL8 release from LPS-activated human monocytic THP-1 cells, which
can be abrogated by oATP (350 μM) or A438079 (10 μM) (Wanke et al., 2016). Finally,
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activation of P2X7, and subsequently the inflammasome, by S100A12 (the S100 protein most
associated with psoriasis activity (Wilsmann-Theis et al., 2015)) can be inhibited by suramin
(0.1 μM) or A804598 (1 μM) (Kim et al., 2018b).
ATP promotes proliferation of the human HaCaT keratinocyte cell line (Burrell et al., 2008),
suggesting a role for P2X7 in the characteristic hyperproliferation in psoriasis. However, this
proliferation relied on co-stimulation with parathyroid hormone related protein, which is not
associated with psoriasis activity (Sánchez Regaña et al., 2005). Alternatively, IFN-γ, which
is important in promoting psoriasis (Bowcock et al., 2001, Haider et al., 2008), can
upregulate the expression of P2X7 in primary keratinocytes (Pastore et al., 2007).
Furthermore, BzATP injection into normal human skin explants induces increased release of
IL-1β, IL-6 and TNF-α, which is abrogated by KN-62 (1 μM) (Killeen et al., 2013). P2X7
activation by BzATP also induces the functional maturation, including the up-regulation of
CD86 expression, on cutaneous DCs to promote Th17 responses (Killeen et al., 2013).
Finally, P2X7 mRNA is up-regulated in non-lesional skin of psoriasis patients compared to
healthy controls (Killeen et al., 2013). Combined, the findings above suggest P2X7 activation
on DCs by ATP or antimicrobial peptides can promote inflammation through proinflammatory cytokine release and/or T cell activation. Furthermore, P2X7 activation on
neutrophils or macrophages may also promote pro-inflammatory cytokine release (BarberàCremades et al., 2012, Karmakar et al., 2016). These cytokines may up-regulate P2X7
expression in the epidermis, leading to a feed-forward loop of inflammation (Figure 1.6).

1.11. Summary
GVHD remains a major complication following HSCT and current therapies involve general
immunosuppression leaving patients susceptible to infection or relapse (Auletta and Cooke,
2009). With >25,000 HSCTs performed annually worldwide (D'Souza and Fretham, 2017),
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and the incidence of GVHD approximately 50% (Jagasia et al., 2012), there is a dire need for
novel therapeutics. The presence of purinergic signalling molecules on immune cells and the
role of purinergic signalling in immunity is well established and represents a potential
therapeutic target. In relation to GVHD, P2X7 activation drives disease progression, while
the structure of the CD39/CD73/A2A pathway limits this progression. However, the majority
of this data is based on allogeneic mouse models, and the role of purinergic signalling in
pre-clinical humanised mouse models is completely lacking and is limited in humans with
GVHD. Investigation of the role of purinergic signalling in pre-clinical humanised mouse
models will provide insight into the role of this signalling system, and possibly identify
therapies in a pre-clinical mouse model of GVHD.

Initiation of psoriasis could cause the release of
DAMPS such as ATP, or antimicrobial peptides such as LL-37. This could act in a paracrine
manner and activate, and up-regulate P2X7 in the skin, or alternatively activate P2X7 on a
number of cell types. Activation of P2X7 on neutrophils, macrophages and DCs may result in
IL-1β release which can exacerbate psoriasis. LL-37 also inhibits neutrophil and macrophage
cell death (not depicted). Alternatively, ATP or LL-37 activation of P2X7 on DCs may result
in IL-23 release leading to Th17 activation, proliferation and migration into the skin, where
Th17 cells exacerbate psoriasis through IL-17 release. Alternatively, IL-2 release by T cells
in psoriasis can also cause Th17 cell differentiation and inflammation, or Th1 cell
differentiation which, along with macrophages, promotes inflammation through IFN-γ
Figure 1.6. The potential role of P2X7 in psoriasis.
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release. IFN-γ has also previously been shown to up-regulate P2X7 expression.
Abbreviations: ATP, adenosine triphosphate, DAMP, danger associated molecular pattern,
DC, dendritic cell, IFN-γ, interferon gamma, IL, interleukin, IMQ, imiquimod.

Psoriasis affects 1-3% of the general population of Western countries (Lebwohl et al., 2014)
and remains a significant financial burden. The role of purinergic signalling in skin biology
and disease is well characterised, but the role of P2X7 in psoriasis is limited to in vitro
studies and immunohistodensity studies of patient samples. The IMQ-induced psoriasis-like
inflammation mouse model represents a simple and efficient model to study psoriasis
pathogenesis and utilising this model may provide insights into the role of P2X7 in psoriasis.
Furthermore, the skin is a target organ of GVHD, and thus investigation of the role of
purinergic signalling in psoriasis may help elucidate the role of this pathway in other
inflammatory skin disorders including cutaneous GVHD.

1.12. Aims
1.12.1. General Aim
This thesis aims to elucidate the role of purinergic signalling, focussing on the roles of P2X7,
CD39, CD73, and A2A in a humanised mouse model of GVHD, and the role of P2X7 in IMQinduced psoriasis-like inflammation in mice.
1.12.2. Specific Aims
The specific aims of this PhD thesis are;
i.

To investigate the role of P2X7 in GVHD in a humanised NSG mouse model using a
short-term (Chapter 3) and long-term (Chapter 4) regime with the P2X7 antagonist
BBG.
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ii.

To investigate the role of the CD39 and CD73 pathway in GVHD in a humanised
NSG mouse model using the CD39/CD73 antagonist APCP (Chapter 5).

iii.

To investigate the role of A2A in GVHD in a humanised NSG mouse model using the
general adenosine receptor antagonist caffeine (Chapter 5), and the A2A agonist
CGS21680 (Chapter 6).

iv.

To investigate the role of P2X7 in an IMQ-induced psoriasis-like disease model using
the P2X7 antagonists BBG and A804598 and P2X7 knock-out mice (Chapter 7).
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2.2.

Abstract

Graft-versus-host disease (GVHD) is a frequent complication following allogeneic
hematopoietic stem cell transplantation (HSCT) with current therapies limited to general
immunosuppression. Humanised mouse models of GVHD are emerging as valuable
intermediaries to allow translation of findings from allogeneic mouse models to humans to
prevent and treat this disease, but such models require further characterisation. In this study,
humanised mice were generated by injecting immunodeficient non-obese diabetic severe
combined immunodeficiency interleukin-2 receptor γ common chain null (NSG) mice with
human peripheral blood mononuclear cells (hPBMCs). Clinical GVHD development was
assessed using established scoring criteria (weight loss, posture, activity, fur texture and skin
integrity). Differences between humanised NSG mice that developed clinical or subclinical
GVHD were then compared. Both groups of mice demonstrated similar frequencies of human
leukocyte engraftment. In contrast, mice that developed clinical GVHD demonstrated
increased histological damage compared to mice with subclinical GVHD. Furthermore, mice
with clinical GVHD exhibited increases in the splenic human CD4+:CD8+ T cell ratio, serum
human interferon (IFN)-γ and intestinal human interleukin (IL)-17 expression compared to
mice with subclinical GVHD. These cellular and molecular changes could be used as
potential markers of disease progression in this preclinical model. This study also provides
further insights into GVHD development which may be relevant to human HSCT recipients.

2.3.
•

Highlights

GVHD development in humanised mice is variable with the majority developing clinical
disease but a small proportion with subclinical disease.

•

Mice with clinical GVHD demonstrate increased splenic human CD4+:CD8+ T cell ratios
compared to mice with subclinical GVHD.
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•

Mice with clinical GVHD exhibit increased serum human interferon (IFN)-γ and
intestinal human interleukin (IL)-17 expression compared to mice with subclinical
GVHD.

2.4.

Introduction

Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative therapy for
haematological malignancies and other blood disorders. However, graft-versus-host disease
(GVHD) occurs in approximately half of the HSCTs conducted annually (Pavletic and
Fowler, 2012) and leads to a mortality rate of approximately 20% in these patients (Markey et
al., 2014). GVHD emerges when effector donor T cells mount an immune response against
host tissues (Billingham, 1965). GVHD is characterised by three stages. The first stage is
release of danger signals from cells damaged by the underlying disease and/or conditioning
regimes, followed by CD4+ T cell activation by antigen presenting cells resulting in cytokine
release, and finally CD4+ and CD8+ T cell-mediated inflammatory damage (Ferrara et al.,
1999, Ferrara et al., 2009). This damage can be propagated by the “cytokine storm” in the
latter stage, wherein Th1 and Th17 cells release pro-inflammatory cytokines such as
interferon (IFN)-γ (Ferrara et al., 1999, Ferrara et al., 2009) and interleukin (IL)-17 (Yi et al.,
2009, Gartlan et al., 2015), respectively, perpetuating a feed forward loop of inflammation.
Conversely, regulatory T (Treg) cells can modulate effector T cells to reduce T cell-mediated
inflammatory damage in GVHD (Edinger et al., 2003). Current therapies for GVHD are
limited, with the standard therapy being general immunosuppression achieved through
steroids, leaving patients susceptible to subsequent infections and/or disease relapse (Auletta
and Cooke, 2009). Therefore, greater understanding of the mechanisms important in GVHD
and elucidation of new therapies is essential to improve outcomes in HSCT patients and
prevent GVHD.
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Current studies into potential therapeutics for GVHD are investigated in allogeneic mouse
models before translation to the clinic. However, potentially due to large species differences
between humans and mice, therapies that delay or prevent GVHD in allogeneic mouse
models often do not translate to the clinic. To address this, previous studies have developed a
range of preclinical “humanised” mouse models (Shultz et al., 2007). The most commonly
used of these models is the humanised immunodeficient non-obese diabetic severe combined
immunodeficiency interleukin-2 receptor γ common chain null (NSG) mouse, developed by
Shultz et al. (2005) wherein mice readily engraft human peripheral blood mononuclear cells
(hPBMCs) due to three defects. First, the Scid mutation prevents V(D)J recombination to
impair B and T cell development (Bosma et al., 1983). Second, deletion of the Il2rg gene
results in absence of natural killer (NK) cells. Third, a polymorphism in the Sirpa gene,
present due to backcrossing onto a NOD background, promotes phagocytic tolerance of
xenogeneic leukocytes (Yamauchi et al., 2013). Human T cells recognise major
histocompatibility complex (MHC) I and II of NSG mice to cause GVHD in this humanised
mouse model (King et al., 2009), demonstrating that human T cell responses can be
investigated in vivo to better understand this disease in a preclinical setting.
The humanised NSG model of GVHD is emerging as a valuable intermediate to allow
translation of findings identified in allogeneic mouse models to human clinical trials. For
example, based on an earlier study in an allogeneic mouse model of GVHD (Hill et al.,
1999), King et al. (2009) demonstrated tumour necrosis factor (TNF)-α blockade could
reduce GVHD severity in this humanised mouse model, and Etanercept, an anti-TNF-α
monoclonal antibody (mAb) has subsequently shown efficacy in clinical trials (Busca et al.,
2007). More recently, Burger et al. (Burger et al.) demonstrated an anti-CCR5 mAb (PRO
140) could reduce GVHD in humanised NSG mice, with this mAb now being investigated in
clinical trials (Green and Dhody). Notably, the discovery of Treg cells, and their therapeutic
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potential in GVHD has progressed from allogeneic mouse models (Edinger et al., 2003), to
humanised NSG models (Abraham et al., 2012, Hannon et al., 2014), and finally to clinical
trials (Heinrichs et al., 2016). Therefore, the humanised NSG model offers a valid preclinical
model to test therapies for translation to the clinic. Although this mouse model has offered
numerous advancements, the characterization of GVHD in these mice has not been
adequately described.

2.5.

Objective

The current study aimed to investigate the characteristics of GVHD that were observed in
humanised NSG mice injected with human PBMCs that developed clinical disease compared
to those mice that displayed subclinical GVHD. This study demonstrated that all humanised
NSG mice had similar engraftment of human leukocytes, which were predominantly T cells.
In contrast, humanised NSG mice with clinical GVHD demonstrated greater splenic
CD4+:CD8+ T cells ratios, serum human IFN-γ concentrations and intestinal human IL-17
expression than humanised mice with subclinical GVHD. These cellular and molecular
changes could potentially be used as biomarkers of disease progression in this preclinical
model and provide insights into GVHD development which may be applicable to human
HSCT recipients.

2.6.

Materials and Methods

2.6.1. Antibodies for Flow Cytometry
Fluorescein isothiocyanate (FITC)-conjugated mouse anti-hCD4 (clone: RPA-T4), and
mouse anti-hCD45 (clone: HI30); R-phycoerythrin (PE)-conjugated mouse anti-hCD3 (clone:
UCHT1) and

mouse anti-hCD8 (clone:

RPA-T8); peridinin chlorophyll protein

(PerCP)-Cy5.5 conjugated mouse anti-hCD4 (clone: L200) and rat anti-mCD45 (clone: 3066

F11); and allophycocyanin (APCy)-conjugated mouse anti-hCD3 (clone: UCHT1) and mouse
anti-hCD19 (clone: HIB19) mAb were obtained from BD (San Jose, CA, USA).
2.6.2. Mice
All mouse experiments were conducted in accordance with approval by the Animal Ethics
Committee, University of Wollongong (Wollongong, Australia). Female NSG mice,
originally obtained from The Jackson Laboratory (Bar Harbor, ME, USA), were bred at the
Westmead Animal Research Facility (Westmead, Australia) or Australian BioResources
(Moss Vale, Australia). NSG mice, obtained at 6-10 weeks of age, were housed in filter top
cages in Tecniplast (Buggugiate, Italy) isolation cabinets, and provided with autoclaved food
and water, ad libitum. Mice were allowed to acclimatise for one week prior to injection.
2.6.3. Isolation of Human PBMCs
All experiments with human blood were conducted in accordance with approval by the
Human Ethics Committee, University of Wollongong. Peripheral blood was collected by
venepuncture into VACUETTE® lithium heparin tubes (Greiner Bio-One; Frickenhausen,
Germany). Whole blood, diluted with an equal volume of sterile phosphate buffered saline
(PBS) (Thermo Fisher Scientific, Waltham, USA), was underlaid with Ficoll-Paque PLUS
(GE Healthcare; Uppsala, Sweden) and centrifuged (560 x g for 30 min). hPBMCs were
collected and washed with PBS (430 x g for 5 min) and resuspended in PBS.
2.6.4. Humanised NSG Mouse Model of GVHD
NSG mice were injected intra-peritoneally (i.p) with 10 x 106 hPBMCs in 100 μL sterile PBS
(hPBMC group) or with 100 μL sterile PBS alone (control group) (day 0). Mice were
checked for engraftment of hPBMCs at 3 weeks post-injection by immunophenotyping tail
blood. Mice were monitored up to week 8 for signs of GVHD using a scoring system
(Chapter 3) giving a total clinical score out of 10 (Table 1). Mice were euthanised at 8 weeks
post-injection, or earlier if exhibiting a clinical score of ≥ 8 or a weight loss of ≥ 10%,
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according to the approved animal ethics protocol. Mice are assigned a score out of 2 for each of
the criterion outlined to give a total score of 10 (as previously described (Chapter 3)). Humanised
mice with clinical score < 3 were defined as subclinical GVHD, and mice with a clinical score ≥ 3
were defined as clinical GVHD.

Table 2.1. Scoring system for clinical GVHD.
GRADE
0
1
a
< 5%
5% to 10%
Weight loss
Normal
Hunching noted only at rest
Posture
Normal
Mild to moderately decreased
Activity
Normal
Mild to moderate ruffling
Fur texture
Scaling of paws/tail
Skin Integrity Normal
a
Percent of starting weight (day 0)

2
> 10%
Severe hunching
Stationary unless stimulated
Severe ruffling
Obvious areas of involved skin

2.6.5. Immunophenotyping by Flow Cytometry
Tail blood (20-30 μL) was collected into 200 μL of citrate solution (Sigma-Aldrich), diluted
with PBS and centrifuged (500 x g for 5 min). Spleens from euthanised mice were
mechanically dissociated, filtered through 70 μm nylon filters (Falcon Biosciences, New
York, NY, USA) and centrifuged (300 x g for 5 min). Blood and spleen cells were incubated
with ammonium chloride potassium (ACK) lysis buffer (150 mM NH4Cl, 1 mM KHCO3, 0.1
mM Na2CO3, pH 7.3) for 5 min and washed in PBS (300 x g for 5 min). Cells were then
washed in PBS containing 2% foetal bovine serum (300 x g for 3 min), and incubated for 30
min with fluorochrome-conjugated mAb, including respective isotype controls. Cells were
washed with PBS (300 x g for 3 min) and data was collected using a BD LSRII Flow
Cytometer (using band pass filters 515/20 for FITC, 575/26 for PE, 675/40 for PerCP-Cy5.5,
and 660/20 for APCy). The relative percentages of cells were analysed using FlowJo software
v8.7.1 (TreeStar Inc., Ashland, OR, USA).
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2.6.6. Histological Analysis
Tissues from euthanised mice were incubated overnight in neutral buffered (10%) formalin
(Sigma-Aldrich). Fixed tissues were removed, coated in paraffin, sectioned (5 μm) and
stained with haematoxylin and eosin (POCD; Artarmon, Australia). Histological changes
were assessed using a Leica (Wetzlar, Germany) DMRB microscope and Leica Application
Software version 4.3.
2.6.7. RNA Isolation and cDNA Synthesis
Tissues from euthanised mice or freshly isolated hPBMCs were stored in RNAlater (SigmaAldrich) at -20°C. RNA was isolated using TRIzol reagent (Thermo Fisher Scientific) as per
the manufacturer’s instructions. Isolated RNA was immediately converted to complementary
DNA (cDNA), using the qScript cDNA Synthesis Kit (Quanta Biosciences, Beverly, MA,
USA) as per the manufacturer’s instructions, and RNA stored at -80°C. cDNA was checked
by PCR amplification of the house keeping gene glyceraldehyde 3-phosphate dehydrogenase
(Invitrogen, Carlsbad, CA, USA) for 35 cycles (95°C for 1 min, 55°C for 1 min, and 72°C for
1 min) and a holding temperature of 4°C. Purity and size of amplicons were confirmed by 2%
agarose gel electrophoresis.
2.6.8. Quantitative Real-Time PCR
Quantitative real-time PCR (qPCR) reactions of cDNA samples were using TaqMan
Universal Master Mix II (Thermo Fisher Scientific) according to the manufacturer’s
instructions, with VIC-labelled human hypoxanthine phosphoribosyl transferase 1
(Hs99999909_m1) and FAM-labelled hIFN-γ (Hs00989291_m1), hIL-17 (Hs00936345_m1)
and hFoxP3 (Hs01085834_m1) primers (Thermo Fisher Scientific). qPCR cycles consisted of
two initial steps of 50°C for 2 min, and 95°C for 10 min and 40 cycles of 95°C for 15 s, and
60°C for 1 min. Reactions were conducted in triplicate using a Roche Diagnostics
(Indianapolis, IN, USA) LightCycler 480, and analysis was conducted using LightCycler480
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software v1.5.1. Human gene expression is shown relative to expression in cDNA from
freshly isolated donor hPBMCs.
2.6.9. ELISA
Blood, collected via cardiac puncture from euthanised mice, was incubated for 1 h at RT and
centrifuged (1,700 x g for 10 min). Supernatants were re-centrifuged (1,700 x g for 10 min)
and sera stored at -80°C. Serum cytokine concentrations were measured using a hIFN-γ
Ready-Set-Go! ELISA Kit (eBioscience, San Diego, CA, USA) as per the manufacturer’s
instructions. Absorbances (450 and 570 nm) were measured using a SpectraMax Plus 384
(Molecular Devices, Sunnyvale, CA, USA).
2.6.10. Statistical Analysis
Data is given as mean ± standard error of the mean (SEM). Statistical differences were
calculated using Student’s t-test for single comparisons or one-way analysis of variance
(ANOVA) with Tukey’s post-hoc test for multiple comparisons. Weight and clinical score
were analysed using a repeated measures two-way ANOVA with Tukey’s post-hoc test for
multiple comparisons. Median survival times (MST) were compared using the log-rank
(Mantel-Cox) test. Proportions of mice sacrificed prior to week 8 (mortality rates) were
compared using Fisher’s Exact test. All statistical analyses and graphs were generated using
GraphPad Prism 5 for PC (GraphPad Software, La Jolla, CA, USA). P < 0.05 was considered
significant for all tests.

2.7.

Results

2.7.1. Clinical GVHD Development Varies in Humanised NSG Mice
NSG mice, injected i.p. with either saline (control) or hPBMCs, were monitored for physical
manifestations of GVHD over 8 weeks. After 4 weeks, humanised NSG mice with GVHD
started to exhibit clinical signs of disease (Figure 2.1.A.). By end-point it became apparent
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that hPBMC-injected mice segregated into one of two groups based on clinical score (Table
2.1.); one group with scores ≥ 3 (clinical GVHD) and another group with scores < 3
(subclinical GVHD) (Figure1A). Mice with clinical scores ≥ 3 exhibited weight loss, reduced
activity, postural changes (hunching) and fur ruffling, with skin involvement in some mice,
whilst mice with clinical scores < 3 was solely attributed to fur ruffling and/or postural
changes (data not shown). The mean clinical score over the course of the experiment in
humanised mice with clinical GVHD was greater than both control mice and mice with
subclinical GVHD (P < 0.0001 and P = 0.0010, respectively) (Figure 2.1.B.). Weight loss
alone is indicative of GVHD development (Cooke et al., 1996). Notably, control mice and
humanised mice with subclinical GVHD continued to gain weight over the entire 8 weeks,
however, humanised mice with clinical GVHD started to lose weight after 4 weeks
(Figure1B). Although this difference was obvious after 4 weeks, the weight loss was not
statistically significant between groups (P = 0.2871). Humanised mice with clinical GVHD
had a MST of 50 days, which was significantly worse than control mice (P < 0.0001) and
humanised mice with subclinical GVHD (P < 0.0001) where all mice survived for 8 weeks
(Figure1C). Humanised mice with clinical GVHD exhibited an 80% mortality rate over 8
weeks, which was significantly greater than control mice (P < 0.0001) or humanised mice
with subclinical GVHD (P = 0.0350) (Figure 2.1.C.).
2.7.2. Increased Histological Damage and Leukocyte Infiltration is Associated
with Clinical GVHD
GVHD targets the liver, gastro-intestinal tract and skin in humanised NSG mice (King et al.,
2009), similar to humans (Ferrara et al., 2009). To compare control NSG mice and
humanised NSG mice with clinical or subclinical GVHD, histological analyses of target
tissues were conducted, as well as spleens to examine evidence of engraftment. As expected,
control mice demonstrated normal architecture and minimal
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Figure 2.1. Clinical GVHD development varies in humanised mice. (a–c) NSG mice were injected
i.p. with PBS (control) (n = 6) or 10 x 106 hPBMCs in PBS (n = 13) and monitored for GVHD over 8
weeks. NSG mice were monitored for (A) clinical score, (B) weight loss and (C) survival. Humanised
mice with subclinical GVHD (n = 3) were defined as having a clinical score < 3 and mice with
clinical GVHD (n = 10) were defined as having a clinical score ≥ 3. Data represents (a, b) group
means ± SEM, or (c) percent survival; *** P < 0.0001 compared to control mice, †† P < 0.01 and ††† P
< 0.0001 compared to mice with subclinical GVHD.

presence of leukocytes in spleens, livers, small intestines and skin (Figure2). Both humanised
NSG mice with subclinical or clinical GVHD demonstrated leukocyte infiltration in spleens
(Figure 2.2.), consistent with engraftment of hPBMCs. However, mice with subclinical
GVHD demonstrated leukocyte infiltration and minor apoptosis in the liver, whilst mice with
clinical GVHD demonstrated greater leukocyte infiltration and greater apoptosis compared to
both control mice and humanised mice with subclinical GVHD (Figure 2.2.). Humanised
mice with subclinical GVHD demonstrated leukocyte infiltration and minor damage to
enterocytes and occasional crypt epithelial cell apoptosis in the small intestine (Figure 2.2.).
Humanised mice with clinical GVHD demonstrated increased leukocyte infiltration and
structural damage including rounding of villi, enterocyte loss and crypt epithelial cell
apoptosis in the small intestine compared to mice with subclinical GVHD (Figure 2.2.).
Humanised mice with subclinical GVHD demonstrated similar intact architecture and
leukocyte infiltration to control mice in the skin, except for separation at the dermal
subcutaneous boundary in the former group (Figure2.2.). The skin of humanised mice with
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clinical GVHD demonstrated leukocyte infiltration, epidermal thickening, basal epithelial cell
apoptosis and dermal-subcutaneous boundary separation (Figure 2.2.).

Figure 2.2. Increased histological damage and leukocyte infiltration is associated with clinical
GVHD. Tissue sections (spleen, liver, small intestine and skin) from control mice (left panels) or
hPBMC-injected mice with subclinical GVHD (middle panels) or clinical GVHD (right panels) at end
point were stained with haematoxylin and eosin, and images captured by microscopy. Each image is
representative of three mice per group; bar represents 100 μm.
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2.7.3. Similar Engraftment of hPBMCs in Mice with Subclinical and Clinical
GVHD
To confirm that NSG mice injected with hPBMCs engrafted human leukocytes, blood was
collected at 3 weeks post-injection and spleens were collected at end-point and analysed by
flow cytometry. Blood (Figure 2.3.A-D.) and spleens (Figure 2.3.E-J.) revealed both murine
(m) and human (h) CD45+ cells in hPBMC-injected mice (Figure 2.3A, E.). As expected,
control mice demonstrated mCD45+ but no hCD45+ cells in the blood and spleen (Figure
2.1.B, F).
The frequency of hCD45+ leukocytes were calculated as a percentage of total hCD45+ and
mCD45+ cells. In the blood, mean hCD45+ engraftment was similar between mice with
subclinical GVHD (15.1 ± 2.2 %, n = 3) and mice with clinical GVHD (15.3 ± 3.2, n = 10)
(P= 0.9737) (Figure 2.3.B.). hCD45+ cells in the blood of hPBMC-injected mice were then
analysed for the presence of hCD3+ (human T cells) and hCD19+ cells (human B cells)
(Figure3A). NSG mice injected with hPBMCs showed the majority of engrafted human
leukocytes were T cells. The mean percentage of T cells in blood did not differ between mice
with subclinical GVHD (99.1 ± 0.1%, n = 3) or clinical GVHD (98.1 ± 0.4%, n = 10) (P =
0.1500) (Figure 2.3.C.). The remaining cells in the blood were hCD3- and hCD19-, the
frequencies of which did not differ between mice with subclinical GVHD (0.8 ± 0.1%, n = 3)
or clinical GVHD (1.8 ± 0.4%, n = 10) (P = 0.1869) (Figure 2.3.D.).
Similar to blood, mean hCD45+ engraftment in spleens was similar between mice with
subclinical GVHD (90.9 ± 1.7%, n = 3) and clinical GVHD (87.7 ± 2.9%, n = 10,
respectively) (P = 0.5880) (Figure 2.3.F.). Moreover, NSG mice injected with hPBMCs
showed the majority of engrafted human leukocytes in spleens were T cells. The mean
percentage of T cells in spleens did not differ between mice with subclinical GVHD (97.8 ±
0.5%, n = 3) or clinical GVHD (98.4 ± 0.2%, n = 10) (P = 0.1942) (Figure 2.3.G.). The
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remaining cells in spleens were hCD3- and hCD19-, the frequencies of which did not differ
between mice with subclinical GVHD (2.2 ± 0.5%, n = 3) or clinical GVHD (1.6 ± 0.2%, n =
10) (P = 0.1942) (Figure 2.3.H.).
Further analysis of the splenic human T cells (hCD3+ hCD19- cells) (Figure 2.3.E.) revealed
that mice with clinical GVHD demonstrated significantly greater proportions of hCD4+ T cell
engraftment (85.1 ± 2.0%, n = 10) than mice with subclinical GVHD (45.5 ± 8.4%, n = 3) (P
< 0.0001) (Figure 2.3.I.). Conversely, mice with clinical GVHD demonstrated significantly
lower proportions of hCD8+ T cell engraftment (12.8 ± 1.7%, n = 10) than mice with
subclinical GVHD (50.9 ± 8.8%, n = 3) (P < 0.0001) (Figure 2.3.I.). Moreover, mice with
clinical but not subclinical GVHD demonstrated a significantly greater proportion of hCD4+
than hCD8+ T cells (P < 0.0001), resulting in higher splenic hCD4+:hCD8+ T cell ratios (8.5
± 1.7, n = 10) than mice with subclinical GVHD (1.0 ± 0.3, n = 3) (P = 0.0418) (Figure
2.3.J.).
2.7.4. Increased Serum Human IFN-γ is Associated with Clinical GVHD
IFN-γ has been implicated in GVHD pathogenesis (Ferrara, 2000) and correlates to worse
disease in mice with allogeneic GVHD (Burman et al., 2007). Therefore, to determine if
humanised NSG mice with GVHD demonstrate changes in hIFN-γ, mRNA expression and
serum concentrations of this cytokine were analysed by qPCR and ELISA, respectively.
There was a 3-fold increase in relative hIFN-γ expression in spleens from mice with clinical
GVHD (0.7 ± 0.2, n = 3) compared to mice with subclinical GVHD (0.2 ± 0.1, n = 3) (P =
0.0880) (Figure 2.4.A.). There was also a 1.5-fold increase in relative hIFN-γ expression in
livers from mice with clinical GVHD (0.9 ± 0.1, n = 3) compared to mice with subclinical
GVHD (0.6 ± 0.3, n = 3) (P = 0.2576) (Figure 2.4.B.). However, small intestines from
humanised mice with subclinical GVHD or clinical GVHD demonstrated similar relative
hIFN-γ expression (0.7 ± 0.3 vs 0.9 ± 0.1, n = 3) (P = 0.5907) (Figure 2.4.C.). Notably, mice
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with clinical GVHD demonstrated significantly increased serum human IFN-γ concentrations
(42.9 ± 2.7 ng/mL) compared to mice with subclinical GVHD (25.0 ± 5.5 ng/mL) (P =
0.0155) (Figure 2.4.D.).

Figure 2.3. Humanised mice with clinical GVHD exhibit increased human CD4+:CD8+ T cell
ratios. (a-d) Blood (3 weeks post-hPBMC injection) and (e-f) spleens (end-point) from mice were
analysed by flow cytometry. Representative gates and quadrant regions are shown (a, e). (b - f)
hCD45+ leukocytes (hCD45+ mCD45-) are expressed as a percentage of total leukocytes (hCD45+
mCD45- + hCD45- mCD45+). (c, g) hCD3+ hCD19- cells and (d, h) hCD3- hCD19- cells are expressed
as a percentage of hCD45+ leukocytes. hCD4+ and hCD8+ T cells are expressed as a percentage of
hCD3+ T cells and (j) used to determine hCD4+:hCD8+ T cell ratios. (b-d, f-j) Data represents group
means ± SEM; symbols represent individual mice; ** P < 0.005, *** P < 0.0001 compared to control
mice; † P < 0.05, ††† P < 0.0001 compared to corresponding cells in mice with subclinical GVHD; ###
P < 0.0001 compared to corresponding CD8+ T cells.
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Figure 2.4. Humanised mice with clinical GVHD demonstrate increased serum hIFN-γ
concentrations. The relative expression of hIFN-γ in (a) spleens, (b) livers and (c) small intestines
from mice with subclinical and clinical GVHD were examined by qPCR. Data represents group
means ± SEM (n = 3 per group); symbols represent individual mice. (d) Serum hIFN-γ concentrations
were analysed by ELISA. Data represents group means ± SEM (subclinical GVHD n = 3, clinical
GVHD n = 5); ** P < 0.005 compared to mice with subclinical GVHD.

2.7.5. Increased Intestinal hIL-17 is Associated with Clinical GVHD
IL-17 exacerbates GVHD in allogeneic mouse models of this disease (Carlson et al., 2009,
Kappel et al., 2009) and in HSCT patients (Dander et al., 2009). Whilst, FoxP3 Treg cells
exert anti-inflammatory effects in allogeneic (Edinger et al., 2003) and humanised mouse
models (Cao et al., 2009), as well as in humans (Trzonkowski et al., 2009) to prevent GVHD.
To further explore potential immunological differences between humanised NSG mice with
subclinical or clinical GVHD, relative mRNA expression of hIL-17 and hFoxP3 in the
spleen, liver and small intestine was assessed by qPCR. Relative splenic hIL-17 expression in
mice with clinical GVHD (0.5 ± 0.2, n = 3) was 40% lower compared to mice with
subclinical GVHD (1.3 ± 0.5, n = 3) (P = 0.2505) (Figure 2.5.A). However, hepatic hIL-17
expression was similar between mice with clinical GVHD (1.5 ± 0.9, n = 3) and subclinical
GVHD (1.2 ± 0.2, n = 3) (P = 0.7717) (Figure 2.5.B.). Notably, intestinal hIL-17 expression
was evident in mice with clinical GVHD (1.8 ± 0.4, n = 3) but was absent in mice with
subclinical GVHD (0.0 ± 0.0, n = 3) (Figure 2.5.C.). Relative splenic hFoxP3 expression was
77

similar in humanised mice with subclinical GVHD (1.2 ± 1, n = 3) or clinical GVHD (0.6 ±
0.2, n = 3) (P = 0.5669) (Figure 2.5.D.). Relative hepatic hFoxP3 expression was also similar
in humanised mice with subclinical GVHD (1.3 ± 0.5, n = 3) or clinical GVHD (0.6 ± 0.2 and
2.0 ± 0.8, n = 3) (P = 0.4838) (Figure 2.5.E.). However, there was a 17-fold but variable
increase in intestinal hFoxP3 expression in mice with clinical GVHD (0.5 ± 0.3, n = 3)
compared to mice with subclinical GVHD (0.03 ± 0.01, n = 3) (P = 0.2020) (Figure 2.5.F.).

Figure 2.5. Humanised mice with clinical GVHD demonstrate increased intestinal hIL-17.
The relative expression of (a-c) hIL-17 and (d-f) hFoxP3 in (a, d) spleens, (b, e) livers and (c, f) small
intestines from mice with subclinical and clinical GVHD were examined by qPCR. Data represents
group means ± SEM (n = 3 per group); symbols represent individual mice.
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2.8.

Discussion

Humanised NSG mouse models of GVHD are used as preclinical models to test potential
therapeutics (Shultz et al., 2007), however these models have not been fully characterised.
The current study compared humanised NSG mice with subclinical and clinical GVHD,
which paralleled the degree of histological disease. Notably, mice with clinical GVHD
exhibited greater splenic hCD4+:hCD8+ T cell ratios, serum hIFN-γ concentrations and
intestinal hIL-17 expression than mice with subclinical GVHD.
Humanised mice with a clinical score < 3 were defined as having subclinical GVHD, and
only showed signs of mild to moderate fur ruffling and/or hunching only at rest. These two
criteria compared to the other three criteria used are relatively subjective (Naserian et al.,
2018), and thus may be attributed to events such as being recently awoken rather than GVHD
per se. Analysis of liver, small intestine and skin revealed that all humanised NSG mice had
histological evidence of GVHD (leukocyte infiltration, apoptosis and/or tissue damage).
Although the leukocyte infiltrates in these tissues were not assessed, previous studies have
confirmed infiltrates comprise hCD45+ leukocytes (King et al., 2009) predominantly hCD3+
T cells (Vlad et al., 2009, Ehx et al., 2017). Of note, histological evidence of GVHD was
more apparent in humanised mice with clinical GVHD compared to those with subclinical
GVHD. The reduced histological GVHD in mice with subclinical GVHD is similar to that
observed in the livers (Vlad et al., 2009, Abraham et al., 2015, Ehx et al., 2017, Burlion et
al., 2017) and small intestine (Vlad et al., 2009, Nakauchi et al., 2015) of humanised mice
following various treatments to prevent GVHD. To this end, the current study provided the
opportunity to examine differences in humanised mice with subclinical versus clinical
GVHD, and to determine factors that correspond with clinical GVHD development.
However, it should be noted that this study, like many others (Vlad et al., 2009, Amarnath et
al., 2011, Gregoire-Gauthier et al., 2012, Nakauchi et al., 2015), used only female NSG mice.
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Whilst other studies (Ali et al., 2012, Kanakry et al., 2013b, Betts et al., 2017 2018) have
demonstrated that GVHD can develop in both humanised female and male mice, a
comparison of subclinical and clinical disease in humanised male NSG mice remains to be
undertaken.
Both humanised NSG mice with subclinical or clinical GVHD were engrafted with similar
proportions of human leukocytes as shown indirectly by histology of spleens and directly by
flow cytometry of peripheral blood (week 3) and spleens (at end-point). This suggests that a
difference in GVHD development between these two groups is unlikely to be due to a dose
effect. However, the splenic hCD4+:hCD8+ T cell ratios were significantly greater in
humanised mice with clinical GVHD compared to mice with subclinical GVHD. This finding
is consistent with observations that disease development in humanised NSG mice is mediated
by hCD4+ T cells (King et al., 2009). Furthermore, the high CD4+:CD8+ T cell ratios in
humanised mice with clinical GVHD parallels with studies in humans, in which high
CD4+:CD8+ T cell ratios indicate greater disease severity (Huttunen et al., 2015, Budde et al.,
2017). These observations contrast other findings in humanised NSG mice, where increased
hCD4+:hCD8+ T cell ratios correlated with reduced disease severity following IL-21 blockade
to prevent GVHD (Hippen et al., 2012). However, this treatment reduced the number of
hCD4+ (and hCD8+) T cells, indicating that the absolute number of hCD4+ T cells may also
be important for GVHD development.
Serum hIFN-γ concentrations were significantly increased in humanised NSG mice with
clinical GVHD compared to those with subclinical GVHD. There was also a trend of
increased hIFN-γ expression in the spleens and livers of mice with clinical GVHD. Reduced
serum IFN-γ has been used as a marker to demonstrate a reduction in disease severity in
allogeneic (Wilhelm et al., 2010) and humanised mouse models (Gregoire-Gauthier et al.,
2012) following treatments to prevent GVHD. However, the current study is the first to
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demonstrate that increased serum hIFN-γ concentrations in humanised mice are associated
with clinical GVHD. It would be of value to determine if blockade or knockdown of hIFN-γ
prevents GVHD in humanised NSG mice to directly establish a role for this cytokine in this
disease model.
The current study further demonstrated the presence of hFoxP3+ Tregs in the spleens, livers
and small intestines of humanised NSG mice. This data parallels earlier studies that
demonstrated the presence of Treg cells in blood, spleens and livers of humanised NSG mice
(Abraham et al., 2012). Collectively, these studies demonstrate that hFoxP3+ Tregs can traffic
to target organs in this humanised mouse model of GVHD. This is important, as Treg cells
need to migrate to target organs to interact with effector T cells to promote anti-inflammatory
effects and reduce GVHD severity (Nguyen et al., 2007). In the current study there was a
trend of increased FoxP3+ Tregs in the small intestines of mice with clinical GVHD
compared to subclinical GVHD. Although this result is contrary to expectations, it may
reflect a compensatory attempt to suppress the effector T cells mediating intestinal damage in
mice with clinical GVHD. Alternatively, the increased intestinal FoxP3 expression may
represent FoxP3lo expressing T cells, which can differentiate to Th17 cells (Miyara et al.,
2009), consistent with the hIL-17 expression in the small intestines of mice with clinical
GVHD compared to mice with subclinical GVHD. This increased intestinal IL-17 expression
is consistent with the role of IL-17 in GVHD development (Carlson et al., 2009). Moreover,
depletion of donor Th17 cells can delay GVHD (Kappel et al., 2009). However, the role of
IL-17 in GVHD is complicated, with IL-17 also showing a protective role in intestinal
GVHD (Varelias et al., 2017). Thus, the increased IL-17 expression in the small intestines of
mice with clinical GVHD may reflect increased pathology or a compensatory mechanism to
protect against intestinal GVHD in these mice.
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In conclusion, the current study identified increases in splenic hCD4+:hCD8+ T cell ratios,
serum hIFN-γ concentrations and intestinal hIL-17 in humanised mice with clinical GVHD
compared to mice with subclinical GVHD, consistent with observations in human HSCT
recipients with GVHD. These cellular and molecular changes could therefore be used as
potential biomarkers in this preclinical model. Furthermore, this data provides insight into
GVHD development in this preclinical model, which may aid investigation of potential
therapeutics due to the ability to target human cells and investigate human immune responses
in these humanised mice.
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3.2.

Abstract

Graft-versus-host disease (GVHD) remains a major problem after allogeneic haematopoietic
stem cell transplantation, a curative therapy for haematological malignancies. Previous
studies have demonstrated a role for the adenosine triphosphate (ATP)-gated P2X7 receptor
channel in allogeneic mouse models of GVHD. In this study, injection of human peripheral
blood mononuclear cells (PBMCs) into immunodeficient NOD-SCID-IL2Rγnull (NSG) mice
established a humanised mouse model of GVHD. This model was used to study the effect of
P2X7 blockade in this disease. From five weeks post-PBMC injection, humanised mice
exhibited clinical signs and histopathology characteristic of GVHD. The P2X7 antagonist,
Brilliant Blue G (BBG), blocked ATP-induced cation uptake into both murine and human
cells in vitro. Injection of BBG (50 mg/kg) into NSG mice did not affect engraftment of
human leukocytes (predominantly T cells), or the clinical score and survival of mice. In
contrast, BBG injection significantly reduced circulating human interferon (IFN)-γ, which
was produced by human CD4+ and CD8+ T cells. BBG also reduced human T cell infiltration
and apoptosis in target organs of GVHD. In conclusion, the P2X7 antagonist BBG reduced
circulating IFN-γ in a humanised mouse model of GVHD supporting a potential role for
P2X7 to alter the pathology of this disease in humans.
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3.3.

Introduction

Allogeneic haematopoietic stem cell transplantation (HSCT) is a current curative therapy for
a range of haematological malignancies, including leukaemia and lymphoma (Markey et al.,
2014). A common complication following transplantation is the development of graft-versushost disease (GVHD), which arises in approximately half of HSCT recipients worldwide
(Jagasia et al., 2012). GVHD is mediated by transplanted donor immune cells attacking
“foreign” host tissue, resulting in inflammatory damage to healthy host tissue. The initial host
tissue damage by pre-conditioning regimes used to treat cancer causes a pro-inflammatory
environment, which in turn leads to activation of donor CD4+ T cells through host antigen
presenting cells (Ferrara et al., 2009). CD4+ T cells then release additional pro-inflammatory
cytokines including interferon (IFN)-γ and interleukin (IL)-17, directly causing damage to
tissue, as well as activating cytotoxic CD8+ T cells which further exacerbate disease (Yi et
al., 2009, Gartlan et al., 2015). Current therapies aim to prevent GVHD by preventing these
T cell responses through general immunosuppression, leaving a patient vulnerable to
subsequent infection or relapse, demonstrating a vital need for novel therapeutics (Holtan et
al., 2014).
The purinergic system comprises a complex network of extracellular signalling molecules
and plasma membrane receptors, and is involved in a range of physiological processes
including inflammation and immunity (Cekic and Linden, 2016). Adenosine triphosphate
(ATP) is a common signalling molecule in this system, acting as both an autocrine activation
molecule, and a danger associated molecular pattern when released by damaged or dying
cells (Junger, 2011). In these contexts, extracellular ATP predominantly mediates its effects
through activation of the P2X7 receptor (Junger, 2011). P2X7 is an ATP-gated cation
channel, whereby activation by ATP allows the flux of Ca2+, K+ and other cations including
fluorescent dyes (De Marchi et al., 2016). P2X7 is present on numerous immune cell types
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including antigen presenting cells and T cells (Geraghty et al., 2016). Activation of the P2X7
receptor can result in a variety of downstream signalling events including cytokine release,
reactive oxygen species formation and cell proliferation (Wiley et al., 2011).
Extracellular ATP and P2X7 have emerging roles in GVHD. In allogeneic mouse models,
extracellular ATP accumulates at sites of inflammatory damage, whilst P2X7 is upregulated
on dendritic cells (DCs) in lymphoid tissues and livers of mice with severe GVHD (Wilhelm
et al., 2010). Notably, pharmacological blockade or genetic deletion of P2X7 reduces disease
severity and improves survival in allogeneic mouse models of GVHD (Wilhelm et al., 2010,
Fowler et al., 2014, Zhong et al., 2016). Studies investigating the role of P2X7 in human
GVHD are limited, but it has been shown that P2X7 expression is higher in colon biopsies
from HSCT patients (Wilhelm et al., 2010). Additionally, the presence of a loss-of-function
P2RX7 single nucleotide polymorphism (E496A) in either the donor or recipient cells
correlates to reduced survival after allogeneic HSCT (Lee et al., 2007).
Therefore, the current study aimed to investigate the effect of the P2X7 antagonist, Brilliant
Blue G (BBG), in a pre-clinical humanised mouse model of GVHD. BBG prevented ATPinduced dye uptake into splenic DCs from NOD-SCID-IL2Rγnull (NSG) mice and peripheral
blood T cells from humans. NSG mice engrafted with human (h) peripheral blood
mononuclear cells (PBMCs) demonstrated increased P2X7 expression in the spleen and small
intestine. Injection of BBG did not alter the engraftment of human leukocytes or the clinical
signs of GVHD in these mice. In contrast, injection of BBG caused a significant reduction in
serum hIFN-γ concentrations, and reduced human T cell infiltration and apoptosis in target
organs, suggesting a potential role for P2X7 in GVHD pathogenesis in humans.
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3.4.

Methods

3.4.1. Antibodies for Flow Cytometry
Fluorescein isothiocyanate (FITC) conjugated mouse anti-hCD4 (clone: RPA-T4), mouse
anti-hCD8 (clone: RPA-T8) and mouse anti-hCD45 (clone: HI30) monoclonal antibodies
(mAb); R-phycoerythrin (PE) conjugated mouse anti-hCD3 (clone: UCHT1) and mouse
anti-hCD8 (clone: RPA-T8) mAb; peridinin chlorophyll protein (PerCP-Cy5.5) conjugated
mouse anti-hCD4 (clone: L200) and rat anti-mCD45 (clone: 30-F11) mAb; allophycocyanin
(APCy) conjugated mouse anti-hCD3 (clone: UCHT1) and mouse anti-hCD19 (clone:
HIB19) mAb were obtained from BD Pharmingen (San Jose, CA, USA). PE-conjugated
hamster anti-murine (m) CD11c mAb (clone: N418) was from BioLegend (San Diego, CA,
USA).
3.4.2. Cells
Human multiple myeloma RPMI8226 cells were obtained from the European Collection of
Cell Cultures (Wiltshire, UK). Murine macrophage RAW264.7 cells were obtained from the
American Type Culture Collection (Manassas, VA, USA). Cells were maintained in RPMI
1640 medium containing 2 mM GlutaMAX (Thermo Fisher Scientific, Waltham, MA, USA)
and 10% heat-inactivated foetal bovine serum (FBS) (Bovogen Biologicals; East Keller,
Australia) at 37°C/5% CO2. Cell lines were checked every two months for Mycoplasma spp.
infections, using a MycoAlertTM Mycoplasma detection Kit (Lonza; Basel, Switzerland) as
per the manufacturer’s instructions. Cells were routinely negative for Mycoplasma spp.
3.4.3. Mice
Mouse experiments were approved by the Animal Ethics Committee, University of
Wollongong (Wollongong, Australia). C57BL/6 mice were obtained from Australian
BioResources (Moss Vale, Australia). P2X7 knock-out (KO) mice (Solle et al., 2001),
backcrossed onto a C57BL/6 background (Tran et al., 2010) were bred at the University of
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Wollongong. Deletion of the P2RX7 gene was periodically confirmed as described (Solle et
al., 2001). Female NSG mice, originally obtained from The Jackson Laboratory (Bar Harbor,
ME, USA), were bred at the Westmead Animal Research Facility (Westmead, Australia).
NSG mice were housed in filter top cages in Tecniplast (Buggugiate, Italy) isolation cabinets,
and provided with autoclaved food and water, ad libitum.
3.4.4. Isolation of Human PBMCs
Experiments with human blood were approved by the Human Ethics Committee, University
of Wollongong. Blood was collected by venepuncture into VACUETTE® lithium heparin
tubes (Greiner Bio-One; Frickenhausen, Germany). Whole blood was diluted with an equal
volume of sterile phosphate buffered saline (PBS) (Thermo Fisher Scientific), underlaid with
Ficoll-Paque PLUS (GE Healthcare; Uppsala, Sweden) and centrifuged (560 x g for 30 min).
hPBMCs were collected and washed with two volumes of PBS by centrifugation (430 x g for
5 min) and resuspended in PBS.
3.4.5. Humanised Mouse Model of GVHD
NSG mice were injected intra-peritoneally (i.p) with 10 x 106 hPBMCs in 100 μL sterile PBS
(hPBMC group), or with 100 μL sterile PBS alone (control group) (day 0). At 3 weeks posthPBMC injection, mice were checked for engraftment by immunophenotyping of tail vein
blood. Mice were monitored up to week 8 or 10 for signs of GVHD using a scoring system
(involving a score out of 2, for each of the following five criteria; weight loss, hunching,
decreased activity, fur ruffling, and skin involvement) giving a total clinical score out of 10.
Mice were euthanised at 8 or 10 weeks post-injection of hPBMCs, or earlier if exhibiting a
clinical score of ≥ 8 or a weight loss of ≥ 10%, according to the approved animal ethics
protocol. For BBG blockade, mice were injected with 10 x 106 hPBMCs as above, and with
either 200 μL sterile saline (saline group), or 200 μL sterile saline containing BBG (50
mg/kg) (BBG group) (Sigma-Aldrich; St Louis, MO, USA) on days 0 (1 h post-hPBMC
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injection), 2, 4, 6 and 8. This regime was based on our previous study in which BBG (46
mg/kg) injected i.p. every 2-3 days was shown to have a therapeutic effect in ALS mice
(Bartlett et al., 2017), and another study in which i.p. injection of P2X7 antagonists from
days 0-10 was shown to have a therapeutic effect in an allogeneic mouse model of GVHD
(Wilhelm et al., 2010).
3.4.6. Immunophenotyping by Flow Cytometry
Tail vein blood (50 μL) was collected into 200 μL of citrate solution (Sigma-Aldrich), diluted
with PBS and centrifuged (500 x g for 5 min). Spleens from euthanised mice were
homogenised and filtered through 70 μm nylon filters (Falcon Biosciences, New York, NY,
USA) and centrifuged (300 x g for 5 min). Blood and spleen cells were incubated with
ammonium chloride potassium lysis buffer (150 mM NH4Cl, 1 mM KHCO3, 0.1 mM
Na2CO3, pH 7.3) for 5 min and washed in PBS (300 x g for 5 min). Cells were washed in PBS
containing 2% FBS (300 x g for 3 min), and incubated for 30 min with fluorochrome
conjugated mAb, including respective isotype controls. Cells were washed with PBS (300 x g
for 3 min) and data was collected using a BD Biosciences LSRII Flow Cytometer (using band
pass filters 515/20 for FITC, 575/26 for PE, 675/40 for PerCP-Cy5.5, and 660/20 for APCy).
The relative percentages of cells were analysed using FlowJo software v8.7.1 (TreeStar Inc.;
Ashland, OR, USA) (Figure S3.1. and Figure S3.2.).
3.4.7. Histological Analysis
Tissues from euthanised mice were incubated overnight in neutral buffered (10%) formalin
(Sigma-Aldrich). Fixed tissues were removed, coated in paraffin, sectioned (5 μm) and
stained with haematoxylin and eosin (POCD; Artarmon, Australia). Histological changes
were assessed using a Leica (Wetzlar, Germany) DMIL inverted light microscope at 4x
objective and images captured using a Motic (Causeway Bay, Hong Kong) Moticam 2
microscope camera, and using Motic Images Plus software v2.0.
90

3.4.8. Isolation of RNA
Tissues removed from euthanised mice were stored in RNAlater (Sigma-Aldrich) at -20°C
until required. RNA was isolated using TRIzol reagent (Thermo Fisher Scientific) as per the
manufacturer’s instructions. Isolated RNA was immediately converted to complementary
DNA (cDNA), using the qScript cDNA Synthesis Kit (Quanta Biosciences, Beverly, MA,
USA) as per the manufacturer’s instructions, and stored at -80°C. cDNA was checked by
PCR amplification of the house keeping gene glyceraldehyde 3-phosphate dehydrogenase
(Invitrogen, Carlsbad, CA, USA) for 35 cycles (95°C for 1 min, 55°C for 1 min, and 72°C for
1 min) and a holding temperature of 4°C. Purity and size of amplicons were confirmed by 2%
agarose gel electrophoresis.
3.4.9. Quantitative Real-Time PCR
Quantitative real-time PCR (qPCR) reactions were performed using TaqMan Universal
Master Mix II (Thermo Fisher Scientific) according to the manufacturer’s instructions, with
primers

for

FAM-labelled

(Mm99999915_g1)

and

murine

mIL-1β

glyceraldehyde

(Mm00434228_m1),

3-phosphate
and

dehydrogenase

VIC-labelled

mP2X7

(Mm01199503_m1), and primers for FAM-labelled human hypoxanthine phosphoribosyl
transferase 1 (Hs99999909_m1) and hIL-1β (Hs01555410_m1), and VIC-labelled hIFN-γ
(Hs00989291_m1), hIL-17 (Hs00936345_m1), and hP2X7(B) (AIOIXC2) (Thermo Fisher
Scientific), as indicated. qPCR cycles consisted of two initial steps of 50°C for 2 min, and
95°C for 10 min and 40 cycles of 95°C for 15 s, and 60°C for 1 min. qPCR reactions were
conducted in triplicate, and were performed on a Roche Diagnostics (Indianapolis, IN, USA)
LightCycler 480, and analysis was conducted using LightCycler480 software v1.5.1.
3.4.10. Immunoblotting
Cell lysates were prepared and immunoblotting was performed as described (Bartlett et al.,
2013). Briefly, cell lysates (15 μg protein per lane) were loaded into a Mini-PROTEAN
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TGXTM Precast Gel (Bio-Rad, Hercules, CA, USA) and electrophoresed. Proteins were
transferred to a nitrocellulose membrane (Bio-Rad) using a Bio-Rad Trans-Blot Turbo
Blotting System. Membranes were washed with Tris-buffered saline (250 mM NaCl and 50
mM Tris, pH 7.5) containing 0.2% Tween-20 (TBST) and blocked overnight at 4°C with
blocking solution (TBST containing 5% milk powder). Membranes were incubated with
rabbit anti-mP2X7 (extracellular epitope) antibody (Ab) (1:500) (Alomone Labs; Jerusalem,
Israel) for 2 h at room temperature (RT), washed with TBST and incubated with peroxidaseconjugated goat anti-rabbit immunoglobulin G (1:1000) (Rockland Immunochemicals;
Limerick, PA, USA) for 1 h at RT. Membranes were washed with TBST and incubated with
SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific) and images
collected using an Amersham Imager600 (GE Healthcare).
3.4.11. ATP-induced YO-PRO-12+ Uptake Assay
P2X7 pore formation was quantified by measuring ATP-induced YO-PRO-12+ uptake as
previously described (Spildrejorde et al., 2014). Briefly, cells in NaCl medium (145 mM
NaCl, 5 mM KCl, 5 mM glucose and 10 mM HEPES, pH 7.4) at 37°C were incubated in the
absence or presence of BBG for 15 min, and then incubated with 1 μM YO-PRO-1 iodide
(Molecular Probes, Eugene, OR, USA) in the absence or presence of 1 mM ATP (SigmaAldrich) for 10 min. Incubations were stopped by addition of ice-cold NaCl medium
containing 20 mM MgCl2 (MgCl2 medium) and centrifugation (300 x g for 3 min). Cells were
incubated with PE-conjugated anti-mCD11c or APCy-conjugated anti-hCD3 mAb,
respectively where indicated, for 15 min and washed with NaCl medium. Data was collected
using an LSRII Flow Cytometer (band-pass filter 515/20 for YO-PRO-12+, 575/25 for PE and
660/20 for APCy) and FACSDiva software version 8.0. Geometric mean fluorescence
intensity of YO-PRO-12+ uptake was analysed using FlowJo software (Figure S3.3.).
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3.4.12. Immunohistochemistry
Paraffin-embedded formalin fixed tissues were sectioned (5 μm) and mounted on Snowcoat
slides (Leica) coated with porcine gelatin (Sigma-Aldrich). To identify T cells, tissue sections
were deparaffinised and heat induced epitope retrieval was performed by incubating in
sodium citrate buffer (10 mM trisodium citrate dehydrate (Sigma-Aldrich) and 0.05% Tween20) for 20 min at 95°C. Before all subsequent steps, tissue sections were washed with Trisbuffered saline (138 mM NaCl, 2.7 mM KCl and 50 mM Tris, pH 7.5) containing 0.05%
Tween-20 (TBST2). Tissue sections were blocked with PBS containing 20% goat serum
(Thermo Fisher Scientific) and 3% bovine serum albumin (BSA) (Amresco, Solon, OH,
USA) for 30 min at RT, and subsequently incubated with rabbit anti-hCD3 mAb (clone:
EP449E) (1:50) (Abcam, Cambridge, UK) in TBST2 containing 1% BSA overnight at 4°C.
Endogenous peroxidase was quenched by incubating with 3% hydrogen peroxide in PBS
containing 1% BSA for 20 min at RT. Tissue sections were then incubated with horseradish
peroxidase-conjugated goat anti-rabbit immunoglobulin G (1:250) (Invitrogen) in TBST
containing 1% BSA for 15 min at RT. Finally, tissue sections were incubated with 3,3
diaminobenzidine tetrachloride (Sigma-Aldrich) for 5 min at RT, counterstained with
haematoxylin and dehydrated. To identify apoptotic cells, an In situ Apoptosis Detection Kit
(Abcam) was used as per the manufacturer’s instructions. Immunohistochemistry images
were captured using a Leica DMRB microscope and Leica Application Software version 4.3.
3.4.13. ELISA
Blood, collected via cardiac puncture from euthanised mice, was incubated for 1 h at RT and
centrifuged (1,700 x g for 10 min). Supernatants were re-centrifuged (1,700 x g for 10 min)
and sera stored at -80°C. Serum cytokine concentrations were measured using hIFN-γ, hIL17, hIL-4 and mIL-1β Ready-Set-Go! ELISPOT Kits (eBioscience, San Diego, CA, USA) as
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per the manufacturer’s instructions. Absorbance (450 and 570 nm) was measured using a
SpectraMax Plus 384 (Molecular Devices, Sunnyvale, CA, USA).
3.4.14. Intracellular Staining
Splenocytes, following ammonium chloride potassium buffer lysis, were incubated for 4 h in
RPMI 1640 medium containing 2 mM L-glutamine (Thermo Fisher Scientific), 10% FBS,
1% non-essential amino acids (Thermo Fisher Scientific), 55 μM mercaptoethanol (Thermo
Fisher Scientific), 100 U/mL penicillin/100 μg/mL streptomycin (Thermo Fisher Scientific),
50 ng/mL phorbol 12-myristate 13-acetate (Sigma-Aldrich), 1 μg/mL ionomycin (SigmaAldrich), and 1 μg/mL GolgiStopTM (BD Biosciences). Cells were centrifuged (300 x g for 5
min) and washed once with PBS (300 x g for 5 min). Staining was performed using the BD
Biosciences Intracellular Stain Kit as per the manufacturer’s instructions, mAb added and
incubated for 30 min at RT. Cells were washed with PBS and data was collected using an
LSRII Flow Cytometer (band-pass filter 515/20 for FITC, 575/25 for PE, 675/40 for PerCPCy5.5 and 660/20 for APCy) and FACSDiva software version 8.0. The percentage of hIFN-γ+
and hIL-17+ cells was analysed using FlowJo software (Figure S3.4.).
3.4.15. Statistical Analysis
Data is given as mean ± standard error of the mean (SEM). Statistical differences were
calculated using Student’s t-test for single comparisons or one-way analysis of variance
(ANOVA) with Tukey’s post-hoc test for multiple comparisons. Weight and clinical score
were analysed using a repeated measures two-way ANOVA. Survival was compared using
the log-rank (Mantel-Cox) test. Correlations between cytokines were assessed using
Spearman correlation. All statistical analyses and graphs were generated using GraphPad
Prism 5 for PC (GraphPad Software, La Jolla, CA, USA). P < 0.05 was considered
significant for all tests.
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3.5.

Results

3.5.1. NSG Mice Injected with hPBMCs Engraft Predominantly Human
CD3+ T Cells and Exhibit Clinical Signs of GVHD
NSG mice injected with hPBMCs develop GVHD from 4 weeks (King et al., 2008). In the
current study, NSG mice were injected i.p. with 10 x 106 freshly isolated hPBMCs (hPBMC
group) or saline (control group), and observed for signs of GVHD development for up to 8
weeks. At 3 weeks post-hPBMC injection, mice were checked for engraftment of human
cells. hPBMC-injected mice demonstrated engraftment of human leukocytes (14.4 ± 2.7%
hCD45+ mCD45- cells, n = 9), whilst as expected, no human leukocytes were observed in
three randomly selected control mice (Figure 3.1.a.). In hPBMC-injected mice the majority of
hCD45+ cells were T cells (97.5 ± 0.3% hCD3+ hCD19- cells, n = 9) (Figure 3.1.b.). NSG
mice injected with hPBMCs demonstrated no human B cell (hCD3- hCD19+) engraftment
(data not shown), and the remaining human leukocytes were negative for both hCD3 and
hCD19 (2.5 ± 0.3%, n = 9) (Figure 3.1.c.).
Analysis of spleens from mice euthanised at end point confirmed the absence of human
leukocytes in control mice (n = 9) (Figure 1d). hPBMC-injected mice engrafted large
amounts of human leukocytes (86.4 ± 2.0% hCD45+ mCD45- cells, n = 9), whilst as
expected, no human leukocytes were observed in control mice (n = 9) (Figure 3.1.d.). The
majority of human leukocytes in the spleen were T cells (98.3 ± 0.2% hCD3+ hCD19- cells, n
= 9) (Figure 3.1.e.). No human B cells (hCD3- hCD19+) were found in the spleen (data not
shown), and the remaining cells were negative for both hCD3 and hCD19 (1.7 ± 0.3%, n = 9)
(Figure 3.1.f.). Analysis of human T cells (hCD3+) revealed that hPBMC-injected mice
demonstrated a significantly higher percentage of hCD4+ T cells (69.6 ± 6.6%, n = 9)
compared to hCD8+ T cells (27.6 ± 6.4%, n = 9) (P = 0.0121) (Figure 3.1.g.).
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As stated above, mice were observed for signs of GVHD for up to 8 weeks. Weight changes
were similar between hPBMC-injected and control mice from weeks 1-4, with both groups
demonstrating weight gain. However, hPBMC-injected mice steadily began to lose weight
from day 30, while saline-injected control mice maintained a weight of over 110% of their
starting weight throughout the 8 week observation period (P = 0.4154) (Figure 3.1.h.).
Saline-injected control mice did not show any signs of GVHD, and maintained a clinical
score of 0 over the observation period (n = 9). In contrast, hPBMC-injected mice displayed
clinical signs of GVHD from day 30, first evident as fur ruffling, followed by hunching,
reduced activity, weight loss, and/or areas of scaly skin patches. hPBMC-injected mice had a
mean clinical score of 4.3 ± 1.1 at end point. The clinical scores between the two groups were
significantly different over 8 weeks (n = 9) (P = 0.0038) (Figure 3.1.i.). hPBMC-injected
mice succumbed to disease from day 40, with a median survival time (MST) of 54 days, and
exhibited a 55% mortality rate by end point, compared to 100% survival of control mice (P =
0.0101) (Figure 3.1.j.).
3.5.2. NSG Mice Injected with hPBMCs Show Histological Evidence of GVHD
and Increased Murine P2X7 Expression
Histological analysis of the target organs; liver, small intestine and skin, revealed that mice
injected with hPBMCs displayed greater leukocyte infiltration and tissue damage compared
to tissues from control mice (Figure 3.2.a.). Compared to control mice, hPBMC-injected mice
demonstrated mildly increased leukocyte infiltration, loss of structural integrity and apoptosis
of cells in the liver (Figure 3.2.a.), mild damage in the small intestine with increased
apoptotic cells and rounded villi (Figure 3.2.a.), and lastly mild leukocyte infiltration and
epidermal thickening in the skin compared to control mice (Figure 3.2.a.).
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Figure 3.1. Engraftment of human leukocytes and development of GVHD in NOD-SCID-IL2Rγnull (NSG)

mice. (a-g) NSG mice were injected intra-peritoneally (i.p.) with either 10 x 106 human (h) peripheral
blood mononuclear cells (PBMCs) (n = 9) or an equal volume of saline (control) (n = 9), and
monitored for clinical signs of graft-versus-host disease (GVHD) over 8 weeks. (a-g) The percentage
of human leukocytes in (a-c) blood at 3 weeks post-hPBMC injection and (d-f) spleens at end point
were determined by flow cytometry. (a, d) hCD45+ leukocytes are expressed as a percentage of total
mCD45+ and hCD45+ leukocytes. (b, e) hCD3+ hCD19- cells and (c, f) hCD3- hCD19- cells are
expressed as a percentage of total hCD45+ leukocytes. (g) hCD4+ and hCD8+ T cell subsets are
expressed as a percentage of total hCD3+ leukocytes. Data represents group means ± SEM; symbols
represent individual mice; * P < 0.05 compared to hCD8+ T cells. (h-j) NSG mice were monitored for
(h) weight loss, (i) clinical score and (j) survival. Data represents (h, i) group means ± SEM, or (j)
percent survival (control, n = 9, hPBMC n = 9); * P < 0.05 and ** P < 0.005 compared to control
mice.
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P2X7 expression is up-regulated in host tissues in allogeneic mouse models of GVHD
(Wilhelm et al., 2010, Zhong et al., 2016). Therefore, mP2X7 expression in the spleen, liver
and small intestine was analysed by qPCR. mP2X7 expression was increased two-fold in the
spleens from hPBMC-injected mice (2.6 ± 0.6, n = 7) compared to spleens from control mice
(1.2 ± 0.6, n = 4), but this difference did not reach statistical significance (P = 0.1656)
(Figure 3.2.b.). Hepatic mP2X7 expression was similar in hPBMC-injected (5.5 ± 0.6, n = 6)
and control mice (6.9 ± 1.4, n = 3) (P = 0.4160) (Figure 3.2.c.). mP2X7 expression was
approximately two-fold greater in the small intestines from hPBMC-injected mice (16.9 ±
2.7, n = 6) compared to control mice (9.9 ± 6.2, n = 4), but this did not reach statistical
significance (P = 0.2668) (Figure 3.2.d.).
3.5.3. NSG Mice Express Full-Length Functional P2X7 Receptors
The data above (Figure 3.2. b-d) demonstrates that NSG mice express P2X7, but it remained
unknown if NSG mice express functional P2X7. Immunoblotting using an antibody against
the extracellular domain of P2X7 demonstrated a major band at 81 kDa, corresponding to
full-length P2X7 (Masin et al., 2012) in the positive control RAW264.7 macrophages and in
NSG splenocytes (n = 2) (Figure 3.3.a.).
To determine if NSG mice express functional P2X7, RAW264.7 cells or splenic leukocytes
from mice were incubated in the absence or presence of ATP, and YO-PRO-12+ uptake
assessed by flow cytometry. ATP induced YO-PRO-12+ uptake into positive control
RAW264.7 cells (n = 4) and CD11c+ splenic DCs from C57BL/6 mice (n = 4), but not
negative control CD11c+ splenic DCs from P2X7 KO mice (n = 3) (Figure 3.3.b.). Notably,
ATP also induced YO-PRO-12+ uptake into CD11c+ splenic DCs from NSG mice (n = 5)
(Figure 3.3b). This uptake was 50% lower than that of RAW264.7 macrophages (P < 0.005),
but three-fold greater than that of C57BL/6 CD11c+ splenic DCs (P < 0.005) (Figure 3.3.b.).

98

Figure 3.2. NOD-SCID-IL2Rγnull (NSG) mice injected with human leukocytes develop graftversus-host disease (GVHD). (a-d) NSG mice injected intra-peritoneally (i.p.) with either human (h)
peripheral blood mononuclear cells (hPBMCs) or saline (control) (day 0) (from Figure 1) were
monitored for clinical signs of graft-versus-host disease (GVHD) over 8 weeks. (a) Tissue sections
(liver, small intestine and skin) from control (top panel) or hPBMC-injected mice (bottom panel) at
end point were stained with haematoxylin and eosin and captured by microscopy. Each image is
representative of two mice per group; bar represents 100 μm. (b-d) The relative expression of murine
(m) P2X7 in (b) spleen, (c) liver and (d) small intestine from mice at end point was examined by
qPCR. Data represents group means ± SEM (n = 4-7); symbols represent individual mice.

99

Figure 3.3 NOD-SCID-IL2Rγnull (NSG) mice express full-length functional P2X7. (a) Lysates of
RAW264.7 (RAW) macrophages and splenocytes from NSG mice were examined by immunoblotting
using an anti-P2X7 antibody. Image is representative of two independent experiments. (b) RAW264.7
cells or splenocytes from C57BL/6, P2X7 KO or NSG mice in NaCl medium containing 1 μM YOPRO-12+ were incubated in the absence or presence of 1 mM adenosine triphosphate (ATP) for 10 min
at 37°C. The mean fluorescence intensity of YO-PRO-12+ uptake into RAW264.7 cells or CD11c+
splenic dendritic cells (DCs) was then assessed by flow cytometry. ATP-induced YO-PRO-12+ uptake
was determined as the difference between YO-PRO-12+ uptake in the presence and absence of ATP.
Data represents group means ± SEM (n = 3 - 5); symbols represent individual replicates (RAW264.7
cells) or mice (splenic CD11c+ DCs); ** P < 0.005 and *** P < 0.0001 compared to C57BL/6.

3.5.4. BBG Prevents ATP-Induced Cation Uptake into Human and Murine
Leukocytes
Since its initial use in rodent models of multiple sclerosis (Matute et al., 2007), spinal cord
injury (Peng et al., 2009) and Huntington’s disease (Díaz-Hernández et al., 2009), BBG has
been used in over 40 studies to establish the role of P2X7 in various disorders (Bartlett et al.,
2014) including our group in a murine model of amyotrophic lateral sclerosis (Bartlett et al.,
2017). To confirm that BBG can block hP2X7 and mP2X7, human RPMI8226 and murine
RAW264.7 cells, both of which express endogenous P2X7 (Farrell et al., 2010,
Constantinescu et al., 2010), were pre-incubated with increasing concentrations of BBG and
then ATP-induced YO-PRO-12+ uptake was assessed. BBG exhibited a concentrationdependent inhibition of ATP-induced YO-PRO-12+ uptake, with maximal inhibition at 1 μM
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in both cell types, and half maximal inhibitory concentrations (IC50) of 99.0 ± 1.2 nM and
59.7 ± 1.2 nM in RPMI8226 cells and RAW264.7 cells, respectively (Figure 3.4.a.). These
IC50 values are similar to that known for recombinant hP2X7 and mP2X7 (Bartlett et al.,
2014).
To confirm that BBG can block P2X7 in primary leukocytes, hPBMCs and NSG splenocytes
were pre-incubated in the absence or presence of BBG, and then ATP-induced YO-PRO-12+
uptake was assessed. ATP induced significant YO-PRO-12+ uptake into hCD3+ T cells, which
was reduced by 95% by pre-incubation with BBG (P < 0.0001, n = 3) (Figure 3.4.b.). ATP
induced significant YO-PRO-12+ uptake into NSG CD11c+ splenic DCs, which was reduced
92% by pre-incubation with BBG (Figure 3.4.c.) (P < 0.0001, n = 3). Basal uptake of YOPRO-12+ in the absence or presence of BBG was similar for each respective cell subtype
(Figure 3.4.b, c.).

Figure 3.4. Brilliant Blue G (BBG) prevents adenosine triphosphate (ATP)-induced cation
uptake into human and murine leukocytes. (a) Human RPMI8226 and murine RAW264.7 cells, (b)
human peripheral blood mononuclear cells (PBMCs) or (c) NOD-SCID-IL2Rγnull (NSG) splenocytes
in NaCl medium were pre-incubated for 15 min at 37°C in the absence or presence of (a) BBG as
indicated or (b, c) 1 μM BBG. Cells were then incubated with 1 μM YO-PRO-12+ in the absence or
presence of 1 mM adenosine triphosphate (ATP) for 10 min at 37°C. The mean fluorescence intensity
of YO-PRO-12+ uptake into (a) RPMI8226 or RAW264.7 cells, (b) hCD3+ T cells or (b) NSG splenic
CD11c+ dendritic cells (DCs) was then assessed by flow cytometry. (a) ATP-induced YO-PRO-12+
uptake is represented as a percentage of maximal ATP response in the absence of BBG. (a-c) Data
represents group means ± SEM (n = 3); *** P < 0.0001 compared to respective basal.
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3.5.5. BBG Does Not Affect Engraftment of Human Cells or Prevent GVHD in
NSG Mice
To investigate whether P2X7 blockade can prevent disease in a humanised mouse model of
GVHD, NSG mice were injected with hPBMCs and the P2X7 antagonist BBG (50 mg/kg)
was subsequently injected every two days from days 0 to 8. Mice were monitored for weight
loss and signs of GVHD for up to 10 weeks. To determine if BBG affected engraftment of
human cells, blood was collected at 3 weeks post-hPBMC injection and cells analysed by
flow cytometry. BBG-injected mice demonstrated a similar level of human leukocytes (10.4
± 1.3% hCD45+ mCD45- cells, n = 14) compared to saline-injected (vehicle control) mice
(10.6 ± 1.4% hCD45+ mCD45- cells, n = 16) (P = 0.9179) (Figure 3.5.a.). In both groups of
mice, the majority of hCD45+ cells were T cells, which did not differ between BBG-injected
mice (97.2 ± 0.4% hCD3+ hCD19- cells, n = 14) and saline-injected mice (97.4 ± 0.4%
hCD3+ hCD19- cells, n = 16) (P = 0.7014) (Figure 3.5.b.). Neither group of mice
demonstrated engraftment of B cells (hCD3- hCD19+) (data not shown). The remaining
hCD45+ cells were negative for both hCD3 and hCD19, and the percentage of these cells did
not differ between BBG-injected mice (2.7 ± 0.4%, n = 14) and saline-injected mice (2.5 ±
0.4%, n = 16) (P = 0.8291) (Figure 3.5.c.).
Analysis of spleens from all mice euthanised at end point demonstrated human leukocytes
comprised the majority of total murine and human leukocytes. BBG-injected mice engrafted
a similar level of human leukocytes (56.3 ± 5.0% hCD45+ mCD45- cells, n = 13) compared
to saline-injected mice (56.2 ± 6.2% hCD45+ mCD45- cells, n = 15) (P = 0.9899) (Figure
3.5.d.). The majority of human leukocytes in the spleen were T cells, and both BBG-injected
mice (97.1 ± 0.6% hCD3+ hCD19- cells, n = 13) and saline-injected mice (95.4 ± 0.6%
hCD3+ hCD19- cells, n = 15) demonstrated similar percentages of T cells (P = 0.2481)
(Figure 3.5.e.). No human B cells (hCD3- hCD19+) were found in the spleens (data not
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shown). The remaining hCD45+ cells were negative for both hCD3 and hCD19, and
percentages of these cells did not differ between BBG-injected mice (2.7 ± 0.6%, n = 15) and
saline-injected mice (2.7 ± 0.6%, n = 15) (P = 0.5325) (Figure 3.5.f.). Analysis of the human
T cells (hCD3+) revealed that BBG- and saline-injected mice contained similar percentages of
hCD4+ T cells (67.0 ± 4.1%, n = 13 vs. 72.7 ± 4.3%, n = 15, respectively, P = 0.3515). BBGand saline-injected mice also contained similar percentages of hCD8+ T cells (24.0 ± 3.6%, n
= 13 vs 22.3 ± 4.1%, n = 15, respectively, P = 0.7583). In both BBG- and saline-injected
mice, the percentage of hCD4+ T cells was significantly higher than hCD8+ T cells (P <
0.0001) (Figure 3.5.g.).
As stated above, mice were observed for signs of GVHD for up to 10 weeks. Both BBG- and
saline-injected humanised mice began to lose weight from day 30 (P = 0.8450) (Figure
3.5.h.). Both BBG- and saline-injected mice began to exhibit signs of mild GVHD at day 35,
and both BBG- and saline-injected mice, exhibited similar clinical scores at end point (5.3 ±
0.5, n = 16 vs. 4.9 ± 0.6, n = 14, respectively). The clinical scores between the two groups
were not significantly different over 8 weeks (P = 0.8356) (Figure 3.5.i.). Survival was also
similar in both BBG-injected mice (MST of 64 days, and mortality rate of 57%, n = 16) and
saline-injected mice (MST of 60 days and mortality rate of 62%, n = 14), (P = 0.9874 for
mortality rate) (Figure 3.5.j.).
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Figure 3.5 Brilliant Blue G (BBG) does not affect engraftment of human cells. (a-j) NOD-SCIDIL2Rγnull (NSG) mice were injected intra-peritoneally (i.p.) with 10 x 106 human (h) peripheral blood
mononuclear cells (PBMCs), and subsequently with saline (control) (n = 14) or saline containing
Brilliant Blue G (BBG) (50 mg/kg) (n = 16) every two days (from days 0-8), and monitored for
clinical signs of graft-versus-host disease (GVHD) over 10 weeks. (a-g) The percentage of human
leukocytes in (a-c) blood at 3 weeks post-hPBMC injection and (d-f) spleens at end point were
determined by flow cytometry. (a, d) hCD45+ leukocytes are expressed as a percentage of total
mCD45+ and hCD45+ leukocytes. (b, e) hCD3+ hCD19- cells and (c, f) hCD3- hCD19- cells are
expressed as a percentage of total hCD45+ leukocytes. (g) hCD4+ and hCD8+ T cell subsets are
expressed as a percentage of total hCD3+ leukocytes. Data represents group means ± SEM; symbols
represent individual mice; *** P < 0.0001 compared to hCD8+ T cells. (h-j) NSG mice were
monitored for (a) weight loss, (b) clinical score, and (c) survival. Data represents (h, i) group means ±
SEM or (j) percent survival (saline n = 14, BBG n = 16).
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3.5.6. BBG Reduces Histological Evidence of GVHD in Humanised Mice
BBG- and saline-injected humanised mice demonstrated similar damage to the liver with
some leukocyte infiltration, apoptosis of cells and fibrosis (Figure 3.6.a.). Both BBG- and
saline-injected humanised mice demonstrated structural damage to the small intestine;
however, BBG-injected humanised mice exhibited decreased leukocyte infiltration compared
to saline-injected humanised mice (Figure 3.6.a.). BBG-injected humanised mice also
exhibited mildly decreased leukocyte infiltrates in the dermis, decreased apoptotic cells and
reduced basal vacuolar change of the skin compared to that of saline-injected humanised
mice (Figure 3.6.a.).
Immunohistochemistry of the target organs, liver, small intestine and skin, was used to
determine if the leukocyte infiltrates observed above included human T cells. T cells
(indicated by black arrows) were identified in the liver, and to a lesser extent in the small
intestine and skin (Figure 3.6.b.). T cell infiltration in the liver, small intestine and skin
appeared to be reduced in BBG-injected mice compared to saline-injected mice (Figure
3.6.b.). To confirm tissue damage in the liver, small intestine and skin, these target organs
were analysed for evidence of apoptosis (fragmented DNA) by immunohistochemistry.
Apoptotic cells (indicated by red arrows) were evident in the liver and small intestine, and to
a lesser extent in the skin (Figure 3.6.c.). Apoptosis in these organs appeared to be reduced in
BBG-injected mice compared to saline-injected mice (Figure 3.6.c.).
Figure 3.6. Brilliant Blue G (BBG) does not prevent graft-versus-host disease (GVHD) in
humanised mice. (a-c) NOD-SCID-IL2Rγnull (NSG) mice injected intra-peritoneally (i.p.) with 10 x
106 human (h) peripheral blood mononuclear cells (PBMCs) (day 0), and with saline (control) or 50
mg/kg Brilliant Blue G (BBG) (from Figure 5) were monitored for clinical signs of GVHD over 10
weeks. Tissue sections (liver, small intestine, and skin) from hPBMC-injected mice injected with
saline (control) or BBG at end point were stained with (a) haematoxylin and eosin, (b) anti-hCD3
monoclonal antibody with 3,3’-diaminobenzidine tetrachloride detection system and haematoxylin, or
(c) terminal deoxynucleotidyl transferase deoxyuridine triphosphate nick-end labelling with 3,3’diaminobenzidine tetrachloride detection system and methyl green. Images were captured by
microscopy with each image representative of (a) four, or (b, c) two mice per group; bars represent
100 μm; (b) black arrow heads indicate T cells, and (c) red arrow heads indicate apoptotic cells. ►
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3.5.7. BBG-Injected Mice Demonstrate Similar mP2X7 and hP2X7 Expression
in GVHD Target Organs
To determine whether injection of BBG altered expression of murine (host) or human (donor)
P2X7 expression in the spleens and target organs of GVHD, tissues from humanised mice
were analysed by qPCR. mP2X7 expression was similar in spleens of BBG-injected mice
(4.6 ± 1.0, n = 6) and saline-injected mice (5.7 ± 0.5, n = 6) (P = 0.5446) (Figure 3.7.a.).
mP2X7 expression in the liver was reduced by 58% in BBG-injected mice (1.6 ± 0.3, n = 4)
compared to saline-injected mice (3.9 ± 1.2, n = 5), however this difference did not reach
statistical significance (P = 0.1619) (Figure 3.7.b.). Conversely, mP2X7 expression was
increased almost two-fold in the small intestines of BBG-injected mice (2.8 ± 0.7, n = 6)
compared to saline-injected mice (1.6 ± 0.3, n = 5), but this did not reach statistical
significance (P = 0.1763) (Figure 3.7.c.). hP2X7 expression was decreased by 74% in the
spleens of BBG-injected mice (3.0 ± 0.9, n = 5) compared to saline-injected mice (11.4 ± 3.5,
n = 6) and this difference approached statistical significance (P = 0.0595) (Figure 3.7.d.). In
contrast, hP2X7 expression was similar in the livers and small intestines of BBG-injected
mice (6.3 ± 2.6, n = 5, and 7.6 ± 2.9, n = 5, respectively) compared to saline-injected mice
(3.7 ± 1.1, n = 4, and 5.7 ± 1.8, n = 6, respectively) (P = 0.4296 and 0.5642, respectively)
(Figure 3.7.e., f.).
3.5.8. BBG Reduces Serum Human IFN-γ in Humanised Mice
IFN-γ and IL-17 are important pro-inflammatory cytokines implicated in the pathogenesis of
GVHD (Yi et al., 2009, Gartlan et al., 2015). To determine if BBG treatment altered the
amount of these cytokines, serum hIFN-γ and hIL-17 concentrations in humanised mice were
assessed by ELISA. hIFN-γ was present in the serum of all mice for which samples were
available (Figure 3.8.a.). Notably, treatment with BBG significantly reduced the amount of
serum hIFN-γ in BBG-injected mice (10.0 ± 2.4 ng/mL, n = 12), which was 54% lower than
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Figure 3.7. Brilliant Blue G (BBG) does not impact expression of mP2X7 or hP2X7 in tissues in
humanised mice. (a-f) NOD-SCID-IL2Rγnull (NSG) mice injected intra-peritoneally (i.p.) with 10 x
106 human peripheral blood mononuclear cells (day 0), and with saline (control) or 50 mg/kg Brilliant
Blue G (BBG) (from Figure 5) were monitored for clinical signs of GVHD over 10 weeks. The
relative expression of (a-c) murine (m) P2X7 and (d-f) hP2X7 in (a, d) spleen, (b, e) liver, and (c, f)
small intestine from mice at end point were examined by qPCR. Data represents group means ± SEM
(n = 4-6); symbols represent individual mice.

that of saline-injected mice (21.8 ± 2.4 ng/mL, n = 13) (P = 0.0023) (Figure 3.8.a.). In
contrast, hIL-17 was only detected in the serum from four BBG-injected mice (33%) and two
saline-injected mice (15%) for which samples were available (Figure 3.8.b.). The amount of
hIL-17 in the serum of BBG-injected mice (40.8 ± 21.1 pg/mL, n = 4) was almost ten-fold
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greater than that of saline-injected mice (4.4 ± 4.0 pg/mL, n = 2), however this difference did
not reach statistical significance (P = 0.1031) (Figure 3.8.b.).
To determine the potential source of hIFN-γ and hIL-17, splenocytes were isolated from
humanised mice and the intracellular expression of hIFN-γ and hIL-17 was analysed by flow
cytometry. Both hCD4+ and hCD8+ T cells produced hIFN-γ and to a lesser extent hIL-17
(Figure 3.8.c, d). The percentage of hIFN-γ-producing hCD8+ T cells was four-fold greater
than hIFN-γ-producing hCD4+ T cells from BBG-injected mice (32.6 ± 7.1% vs 8.1 ± 2.1%,
respectively, n = 4) and saline-injected mice (39.0 ± 18.9% vs 10.2 ± 7.3%, respectively, n =
3), but this only reached statistical significance in the BBG-injected group (P = 0.0165)
(Figure 3.8.c.). The percentage of hIL-17-producing hCD4+ and hCD8+ T cells in BBGinjected mice (3 ± 4% vs. 2 ± 1%, n = 4, respectively) was similar to saline-injected mice (2 ±
1% vs. 2 ± 1%, n = 3, respectively) (P = 0.5046 and 0.8437, respectively) (Figure 3.8.d.).
To determine if expression of IFN-γ and IL-17 were altered in the spleens, and target organs
of GVHD, tissues from humanised mice were analysed by qPCR. hIFN-γ expression was 1.5fold greater in the spleens of BBG-injected mice (9.4 ± 3.9, n = 6) compared to salineinjected mice (6.4 ± 1.2, n = 6), but this difference did not reach statistical significance (P =
0.4825) (Figure 3.8.e.). hIFN-γ expression was similar in livers of BBG-injected mice (1.4 ±
0.1, n = 6) and saline-injected mice (1.6 ± 0.3, n = 6) (P = 0.6549) (Figure 3.8.f.). hIFN-γ
expression was two-fold greater in the small intestines of BBG-injected mice (2.5 ± 1.1, n =
3) compared to saline-injected mice (1.2 ± 0.1, n = 4) but again this difference did not reach
statistical significance (P = 0.2050) (Figure 3.8.g.). hIL-17 expression in spleens of BBGinjected mice (9.6 ± 6.3, n = 5) was similar to saline-injected mice (13.9 ± 4.0, n = 6) (P =
0.5441) (Figure 3.8.h.). hIL-17 was not detected in the livers of either BBG-injected mice (n
= 2) or saline-injected mice (n = 4) (Figure 3.8.i.). hIL-17 expression was two-fold greater in
the small intestines of BBG-injected mice (6.3 ± 2.2, n = 5) compared to saline-injected mice
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(2.6 ± 1.3, n = 4), but this difference did not reach statistical significance (P = 0.2263)
(Figure 3.8.j.).
3.5.9. BBG Does Not Alter Murine or Human IL-1β Expression in Humanised
Mice
Activation of P2X7 causes IL-1β maturation and release from antigen presenting cells
(Englezou et al., 2015), a pro-inflammatory cytokine implicated in the pathogenesis of
GVHD (McCarthy Jr et al., 1991). Moreover, P2X7-mediated IL-1β release is involved in the
production of IFN-γ (Ghiringhelli et al., 2009) and IL-17 (Zhao et al., 2013). Given the
identity of the antigen presenting cells involved in human T cell activation in our humanised
model of GVHD remains unknown and since mIL-1β can stimulate human cells (Huang et
al., 1988, Vandenabeele et al., 1990), the expression of both mIL-1β and hIL-1β in the
spleen, liver and small intestine from these mice was analysed by qPCR. mIL-1β expression
was 3-fold greater in the spleens of BBG-injected mice (6.3 ± 2.8, n = 3) compared to salineinjected mice (2.0 ± 0.9, n = 5), but this difference did not reach statistical significance (P =
0.1183) (Figure 3.9.a.). mIL-1β expression was similar in the livers and small intestines of
BBG- injected (2.7 ± 1.2, n = 5 and 2.5 ± 0.5, n = 6, respectively) and saline-injected mice
(2.7 ± 0.7, n = 4 and 1.9 ± 0.6, n = 6, respectively) (P = 0.9552 and 0.4829, respectively)
(Figure 3.9.b, c). In contrast to mIL-1β, hIL-1β expression was approximately 50% lower in
the spleens of BBG-injected mice (2.2 ± 1.1, n = 5) compared to saline-injected mice (5.0 ±
2.1, n = 5), but this difference did not reach statistical significance (P = 0.2986) (Figure
3.9.d.). hIL-1β expression was not detected in livers or small intestines from either BBG- or
saline-injected mice (both n = 5) (data not shown). Therefore, given the broad expression of
mIL-1β within the humanised mice, serum mIL-1β was assessed by ELISA. However, mIL1β was not detected in the serum from BBG-injected (0.0 ± 0.0, n = 12) or saline-injected
mice (0.0 ± 0.0, n = 11) using an ELISA with a reported sensitivity of 8 pg/mL (eBioscience).

110

111

◄ Figure 3.8. Brilliant Blue G (BBG) significantly reduces serum human interferon (IFN)-γ in
humanised mice. (a-j) NOD-SCID-IL2Rγnull (NSG) mice were injected intra-peritoneally (i.p.) with
10 x 106 human (h) peripheral blood mononuclear cells (PBMCs) (day 0), and with saline (control) or
50 mg/kg Brilliant Blue G (BBG) (from Figure 5). Concentrations of serum (a) hIFN-γ, and (b) hIL17 were analysed by ELISA. Data represents group means ± SEM (saline n = 12, BBG n = 13); **P <
0.005 compared to saline-injected mice. (c, d) Splenocytes were incubated in complete RPMI 1640
medium containing phorbol 12-myristate 13-acetate and ionomycin for 4 h, and the percentage of
hCD4+ and hCD8+ T cells producing intracellular (c) hIFN-γ or (d) hIL-17 was determined by flow
cytometry. Data represents group means ± SEM (saline n = 3, BBG = 4); symbols represent individual
mice; * P < 0.05 compared to corresponding hCD4+ T cells. (e-j) The relative expression of (e-g)
hIFN-γ and (h-j) hIL-17 in (e, h) spleen, (f, i) liver and (g, j) small intestine from mice at end point
were examined by qPCR. Data represents group means ± SEM (n = 2-6); symbols represent
individual mice. ND = not detected.

Figure 3.9. Brilliant Blue G (BBG) does not alter relative expression of human or murine IL-1β
in humanised mice. (a-d) NOD-SCID-IL2Rγnull (NSG) mice were injected intra-peritoneally (i.p.)
with 10 x 106 human (h) peripheral blood mononuclear cells (PBMCs) (day 0), and with saline
(control) or 50 mg/kg Brilliant Blue G (BBG) (from Figure 5). The relative expression of (a-c) murine
(m) interleukin (IL)-1β and (d) hIL-1β in (a, d) spleen, (b) liver and (c) small intestine from mice at
end point were examined by qPCR. Data represents group means ± SEM (n = 3-6); symbols represent
individual mice.

3.6.

Discussion

This study aimed to investigate the effect of the P2X7 antagonist, BBG, in a pre-clinical
humanised mouse model of GVHD. Injection of BBG into humanised mice did not alter
human leukocyte engraftment or disease progression, as assessed by weight loss, clinical
score and survival. However, treatment with BBG significantly reduced serum hIFN-γ.
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Intracellular hIFN-γ was detected in both splenic hCD4+ and hCD8+ T cells of humanised
mice, with a larger proportion (four-fold) of hIFN-γ+ hCD8+ T cells than hIFN-γ hCD4+ T
cells. However, splenic hCD4+ T cells were more frequent (three-fold) than hCD8+ T cells in
humanised mice, and therefore the relative contribution of each subset to circulating IFN-γ
production needs to be further elucidated. Pharmacological blockade or genetic deficiency of
P2X7 has also been shown to reduce serum IFN-γ in allogeneic mouse models of GVHD
(Wilhelm et al., 2010, Fowler et al., 2014). Additionally, P2X7 activation of the NLRP3
inflammasome and subsequent IL-1β production promotes the generation of IFN-γ+ CD8+ T
cells in mice (Ghiringhelli et al., 2009). Combined, these findings support a potential role for
P2X7 in GVHD pathology in humans, possibly through the regulation of T cell activation and
subsequent IFN-γ production. To this end, IFN-γ plays important roles in the up-regulation of
CXCR3 and subsequent trafficking of T cells to target tissues in allogeneic mouse models of
GVHD (Choi et al., 2012a). Conversely, others have suggested that IFN-γ+ CD8+ T cells and
IFN-γ+ CD4+ T cells are important in the initiation and progression of disease, respectively,
in an allogeneic mouse model of GVHD (Zhao et al., 2016). Nevertheless, it remains to be
determined if P2X7 functions through these mechanisms in allogeneic or humanised mouse
models of GVHD.
The current study also identified the presence of serum hIL-17 in a small proportion of
humanised mice (15-30%), and intracellular hIL-17 in an even smaller population of splenic
hCD4+ and hCD8+ T cells (2-3%) from these mice. Due to the relatively small populations, it
is not possible to positively determine the role of P2X7 on hIL-17 production in this
humanised mouse model of GVHD. However, the mean serum hIL-17 concentration was 10fold greater in BBG-injected mice compared to saline-injected mice. These results may
suggest P2X7 blockade promotes hIL-17 production in humanised mice, which contradicts
previous in vitro results in which P2X7 activation promoted hIL-17 production in T cells
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(Ghiringhelli et al., 2009). Others have shown that a shift from an IFN-γ-producing to an IL17-producing T cell phenotype exacerbates GVHD in an allogeneic mouse model of GVHD
(Pan et al., 2012). Similarly, increased numbers of IL-17-producing T cells were observed in
patients with more severe GVHD (Zhao et al., 2011). Investigating IL-17-producing T cells
at time points prior to end point or through increased sample sizes may assist in addressing
the role of P2X7 blockade in IL-17 production in humanised mice with GVHD.
Due to the variation observed in hIL-17 mRNA expression between humanised mice, and the
role of IL-1β in the differentiation of IL-17-producing T cells (Acosta-Rodriguez et al., 2007)
including models of P2X7 activation (Zhao et al., 2013), mIL-1β and hIL-1β was also
examined in the current study. mIL-1β, but not hIL-1β, mRNA expression was detected in the
livers and small intestines of humanised mice, with no differences observed between BBGand saline-treatments. In contrast both mIL-1β and hIL-1β mRNA expression was detected in
the spleens of humanised mice, with BBG treatment resulting in a 3-fold increase in mIL-1β
mRNA expression and a 50% decrease in hIL-1β mRNA expression. However, there was no
correlation between hIL-17 and hIL-1β, or between hIL-17 and mIL-1β mRNA expression
(results not shown), although n values are relatively small, limiting interpretation of this data.
Due to the inability to detect serum mIL-1β in these mice, serum mIL-1β could not be
compared with serum hIL-17 (hIFN-γ). The inability to detect serum mIL-1β was not limited
to this cytokine, as serum hIL-4 was not detected in initial experiments to establish the
humanised mouse model, despite detection of serum hIFN-γ in these mice (results not
shown).
As previously mentioned, injection of BBG into humanised mice did not alter disease
progression, as assessed by weight loss, clinical score and survival. However, histological
examination revealed that BBG reduced the infiltration of leukocytes into the small intestine
and skin in this humanised mouse model of GVHD. Moreover, there was also histological
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evidence of reduced tissue damage in these tissues from BBG-injected mice compared to
saline-injected mice, observations supported by immunohistochemical analysis of T cell
infiltrates and apoptosis. In contrast, BBG did not alter the proportion of hCD4+ or hCD8+ T
cells in blood and spleens of humanised mice. Others have reported that humanised NSG
mice exhibit leukocyte infiltration and tissue damage in the liver, small intestine and skin,
characteristic of GVHD (King et al., 2009). T cells are the main mediators of disease in this
humanised mouse model of GVHD (Covassin et al., 2013, Abraham et al., 2015). Consistent
with these reports, immunohistochemical analysis with a human CD3 specific mAb detected
T cells in the liver, small intestine and skin in humanised mice with GVHD. In support of this
observation,hP2X7 mRNA was detected in the livers and small intestines of humanised mice
using qPCR probes to the P2X7B splice variant, which is predominantly expressed in human
T cells (Adinolfi et al., 2010), with P2X7 present on both hCD4+ and hCD8+ T cells (Sluyter
and Wiley, 2014).
Collectively, the above data investigating the effect of the P2X7 antagonist, BBG, in a
humanised mouse model of GVHD both confirms findings from previous studies using P2X7
antagonists in allogeneic mouse models of GVHD, and provides additional novel insights.
Similar to allogeneic mouse models of GVHD (Wilhelm et al., 2010, Fowler et al., 2014,
Zhong et al., 2016), P2X7 antagonism reduced serum IFN-γ, immune infiltrates and tissue
damage in humanised mice with GVHD. By contrast, no therapeutic benefit (weight loss,
clinical score or survival) was observed in humanised mice with GVHD, but therapeutic
benefits were observed in allogeneic mouse models of GVHD (Wilhelm et al., 2010, Fowler
et al., 2014, Zhong et al., 2016). Besides obvious laboratory, species and mouse strain
differences, a number of other notable differences remain between these models of GVHD.
First, survival time in these allogeneic mouse models (Wilhelm et al., 2010, Fowler et al.,
2014) is at least half that compared to humanised mice. Thus, extended or delayed injection
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regimes may be required to show therapeutic benefits in humanised mice. Second, in the
allogeneic mouse models, P2X7 antagonists were injected daily for the first 10 days
(Wilhelm et al., 2010, Fowler et al., 2014) or twice weekly for 28 days (Zhong et al., 2016)
in contrast to five injections over the first 8 days in our humanised mouse model. Thus, more
frequent or extended injection regimes may be required to show therapeutic benefits with
BBG in humanised mice with GVHD. Third, the two studies that reported improved survival
in the allogeneic mouse models (Wilhelm et al., 2010, Fowler et al., 2014) used the P2X7
antagonists, pyridoxal-phopshate-6-azophenyl-2’,4-disulphonic acid, KN-62 or stavudine,
rather than BBG. Thus, testing of P2X7 antagonists other than BBG in humanised mice with
GVHD may be warranted. Although it should be noted that BBG at either 50 or 70 mg/kg
(i.p. twice weekly for 28 days) prevented weight loss in one allogeneic mouse model of
GVHD (Zhong et al., 2016), indicating BBG can display some therapeutic benefit in this
disease. Finally, in each of the allogeneic mouse models, recipient mice were first irradiated
(Wilhelm et al., 2010, Fowler et al., 2014, Zhong et al., 2016) , which causes ATP release
(Wilhelm et al., 2010). In contrast, the humanised mice in our study were not irradiated,
potentially eliminating this initial release of ATP, which may subsequently activate P2X7 to
promote disease. Thus, the therapeutic potential of P2X7 antagonists in irradiated humanised
mice with GVHD could be investigated.
Finally, this study showed that NSG mice demonstrate full-length functional P2X7. Firstly,
qPCR revealed expression of P2RX7 mRNA in the spleens, livers and small intestines of
NSG mice. Secondly, immunoblotting revealed a major band at 81 kDa, correlating to
glycosylated, full-length P2X7 (Pupovac et al., 2015). Finally, ATP induced YO-PRO-12+
uptake into splenic DCs from NSG mice, a process impaired by BBG, and which was absent
in splenic DCs from P2X7 KO mice. ATP-induced YO-PRO-12+ uptake into splenic DCs
from NSG mice was significantly higher than splenic DCs from C57BL/6 mice. This is most
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likely due to the absence and presence of a loss-of-function mutation (P451L) (Adriouch et
al., 2002) in NSG and C57BL/6 mice, respectively. Although it is yet to be formally
demonstrated that NSG mice are wild-type at this allele, NSG mice are derived from NOD
mice (Shultz et al., 2007), a strain known to encode a proline residue at amino acid position
451 (Syberg et al., 2012).
In conclusion, the current study demonstrates P2X7 blockade with BBG can significantly
reduce serum hIFN-γ, and inflammation and tissue damage in a humanised mouse model of
GVHD. The similar clinical course with skewing to Th17 suggests that clinically P2X7
blockade may be of additive benefit if combined with strategies that limit Th17, such as IL-6
receptor blockade (Koenecke et al., 2009). This study suggests a potential benefit for P2X7
blockade, but highlights the need to also address alternative pathways of immune activation.
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4.2. Abstract
Allogeneic haematopoietic stem cell transplantation (HSCT) is a frequent curative therapy for
numerous haematological malignancies. However, HSCT is limited by the occurrence of
graft-versus-host

disease

(GVHD),

with

current

therapies

restricted

to

general

immunosuppression. Activation of the P2X7 receptor by extracellular adenosine triphosphate
(ATP) causes tissue damage and subsequent inflammation exacerbates GVHD. Short-term
pharmacological blockade of P2X7 has been shown to reduce clinical disease and/or reduce
inflammatory markers in allogeneic and humanised mouse models of GVHD. The current
study demonstrates that long-term P2X7 blockade by intra-peritoneal injection of Brilliant
Blue G (BBG) thrice weekly for up to 10 weeks did not impact human (h) peripheral blood
mononuclear cell (PBMC) engraftment, predominantly T cells, in blood at 3 weeks posthPBMC injection or in spleens at end-point in humanised mice. Histological analysis
demonstrated long-term BBG treatment reduced leukocyte infiltration in the livers of
humanized mice. Immunohistochemical analysis demonstrated that BBG treatment reduced
liver apoptosis. Immunohistochemical analysis confirmed reduced human T cell infiltration
and apoptosis in livers from long-term BBG-treated humanised mice. Long-term BBG
treatment did not alter mRNA expression of pro-inflammatory markers in tissues or serum
human interferon (IFN)-γ concentrations. Therefore, this study demonstrates that P2X7
activation plays a role in GVHD pathogenesis in the livers of humanised mice, supporting a
role for this receptor in GVHD development in HSCT recipients.
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4.3.

Introduction

Allogeneic haematopoietic stem cell transplantation (HSCT) is a frequent curative method for
various haematological malignancies. However, a major side effect of this treatment is graftversus-host disease (GVHD). GVHD occurs in approximately half of HSCT recipients
(Jagasia et al., 2012) and results in damage to the liver, gastrointestinal tract and skin, with
the liver affected in approximately 50% of GVHD patients (Martin et al., 1990). GVHD
emerges due to transplanted effector T cells mounting an immune response against the host
(Billingham, 1965). This immune response is driven by release of cytokines and danger
associated molecular patterns (DAMP), which causes antigen presenting cells to release
cytokines resulting in activation of T cells (Reddy and Ferrara, 2003, Ferrara and Reddy,
2006, Ferrara et al., 2009). T cell activation leads to proliferation and differentiation of T cell
subsets such as Th1 cells which release interferon (IFN)-γ (Reddy and Ferrara, 2003, Ferrara
and Reddy, 2006), and Th17 cells which release interleukin (IL)-17, resulting in
inflammatory damage (Yi et al., 2009, Gartlan et al., 2015). Current therapies are largely
limited to general immunosuppression through the use of steroids (Jaglowski and Devine,
2014), highlighting the need for better therapies.
Targeting a pathway in one of the above stages of GVHD represents a potential therapeutic
strategy. Purinergic signalling is an important pathway of immune cell signalling (Yip et al.,
2009) and plays important roles in transplantation (Vergani et al., 2014, Apostolova and
Zeiser, 2016b, Castillo-Leon et al., 2018). Of all the purinergic receptors, the P2X7 receptor
is the most widely studied in immune and inflammatory responses (Di Virgilio et al., 2018).
Activation of P2X7 induces a number of downstream effects including DC activation and
cytokine release (Saez et al., 2017), T cell activation (Schenk et al., 2008) and inhibition of
regulatory T cells (Schenk et al., 2011). Thus, given the central role of these immune
processes in GVHD, blockade of P2X7 represents a potential therapeutic approach to limit
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GVHD development. In allogeneic mouse models the DAMP, adenosine triphosphate (ATP),
is released from damaged and dying cells, to promote GVHD (Wilhelm et al., 2010). ATP
exacerbates GVHD by activating P2X7 in allogeneic mouse models (Wilhelm et al., 2010,
Fowler et al., 2014, Zhong et al., 2016). Short term pharmacological blockade of P2X7 with
either KN-62, pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid or stavudine during the
first week post-transplantation can extend survival of recipient mice in these models
(Wilhelm et al., 2010, Fowler et al., 2014). Whilst, P2X7 blockade with Brilliant Blue G
(BBG) (50 or 75 mg/kg) twice per week for 4 weeks reduces weight loss and liver GVHD in
an allogeneic mouse model (Zhong et al., 2016). Finally, our group recently demonstrated
that short-term blockade of P2X7 with BBG (50 mg/kg, days 0, 2, 4, 6, 8) reduced serum
human (h) IFN-γ and tissue inflammation in a humanised non-obese diabetic severe
combined immunodeficient IL-2 gamma receptor null (NOD-SCID-IL2Rγnull; NSG) mouse
model of GVHD (Chapter 3).
To further extend the above observations ((Wilhelm et al., 2010, Fowler et al., 2014, Zhong
et al., 2016) and Chapter 3) to humans, the current study investigated the effect of long-term
P2X7 blockade with BBG (50 mg/kg; thrice weekly for up to 10 weeks) in a humanised NSG
mouse model of GVHD. Similar to our previous study (Chapter 3), injection of BBG did not
impact human leukocyte engraftment, weight loss, clinical score or survival. Notably, this
regime reduced leukocyte infiltration and apoptosis in the livers of mice, supporting a role for
P2X7 activation in GVHD pathogenesis in the liver.
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4.4.

Materials and Methods
4.4.1. Humanised Mouse Model of GVHD

Experiments with human blood and mice were approved by the Human Animal Ethics
Committees, respectively (University of Wollongong, Wollongong, Australia). Humanised
NSG mice were established as described (Chapter 3). Briefly, hPBMCs, isolated by density
centrifugation using Ficoll-Paque PLUS (GE Healthcare; Uppsala, Sweden), were injected
intra-peritoneally (i.p) (10 x 106 hPBMCs/mouse) into female NSG mice aged 5-7 weeks
(Westmead Animal Research Facility, Westmead, Australia) housed at the University of
Wollongong. Mice were injected i.p. 2 hours later with 200 μL of saline (saline group) or
saline containing BBG (Sigma-Aldrich; St Louis, MO, USA) (50 mg/kg; BBG group), then
thrice weekly (every second or third day apart) for up to 10 weeks. At 3 weeks post-hPBMC
injection, engraftment was examined by immunophenotyping of tail vein blood. Mice were
monitored up to 10 weeks for signs of clinical GVHD using a scoring system, giving a total
clinical score out of 10 as described (Chapter 3) and euthanised at 10 weeks post-hPBMC
injection, or earlier if the clinical score was ≥ 8 or weight loss was ≥ 10%, as per the
approved ethics protocol.
4.4.2. Immunophenotyping by Flow Cytometry
Tail vein blood and spleen cells were obtained from mice and lysed with ammonium chloride
potassium buffer and immunophenotyped as described (Chapter 3) with the addition of an
allophycocyanin conjugated mouse anti-hCD56 monoclonal antibody (clone: B159) (BD, San
Jose, CA, USA). Data was collected using a BD Fortessa-X20 Flow Cytometer using band
pass filters of 525/50 for fluorescein isothiocyanate, 586/15 for R-phycoerythrin, 695/40 for
peridinin chlorophyll protein and 670/30 for allophycocyanin. The relative percentages of
cells were analysed using FlowJo software v8.7.1 (TreeStar Inc.; Ashland, OR, USA) (Figure
S1 and Figure S2).
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4.4.3. Histological and Immunohistological Analysis
Formalin-fixed tissue sections (5 μm) were stained with haematoxylin and eosin (POCD;
Artarmon, Australia) for histological analysis. Other formalin-fixed tissue sections were also
stained with either rabbit anti-hCD3 mAb (clone: EP449E) (Abcam, Cambridge, UK) and
haematoxylin as described (Chapter 3) or an In situ Apoptosis Detection Kit (Abcam) as per
the manufacturer’s instructions. Total numbers of leukocyte and hCD3+ T cell infiltrates and
apoptotic cells in livers were quantified from captured images (Leica DMRB microscope,
Wetzlar, Germany) using FIJI is just ImageJ (FIJI) software (Schindelin et al., 2012). Data is
represented as the total number of cells measured per field of view. Epidermal thickness of
skin sections was measured as described (Chapter 7).
4.4.4. Quantitative Real-Time PCR
RNA was isolated using TRIzol reagent (Thermo Fisher Scientific) and converted to cDNA
using the qScript cDNA Synthesis Kit (Quanta Biosciences, Beverly, MA, USA) as per the
respective manufacturer’s instructions. Quantitative real-time PCR (qPCR) was performed as
described (Chapter 7) with the addition of a human tumour necrosis factor (TNF)-α
(Hs01113624_g1) primers (Thermo Fisher Scientific). Human gene expression was
normalised to cDNA from hPBMCs, directly isolated from a human donor. Murine gene
expression was normalised to cDNA from a spleen of a BALB/c mouse (Bartlett et al., 2017).
4.4.5. ELISA
Serum was obtained from mice as described (Chapter 3), and hIFN-γ and hIL-17
concentrations determined using respective Ready-Set-Go! ELISA Kits (eBioscience, San
Diego, CA, USA) as per the manufacturer’s instructions.
4.4.6. Statistical Analysis
Data is given as mean ± standard deviation (SD). Statistical differences were determined
using the Student’s t-test for single comparisons or one-way analysis of variance (ANOVA)
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with Tukey’s post-hoc test for multiple comparisons. Weight and clinical score over time
were compared using a repeated measures two-way ANOVA with Tukey’s post-hoc test for
multiple comparisons. Survival (median survival time; MST) was compared using the logrank (Mantel-Cox) test. Mortality was compared using Fisher’s exact test. All statistical
analyses and graphs were generated using GraphPad Prism 5 for PC (GraphPad Software, La
Jolla, CA, USA). P < 0.05 was considered significant for all tests.

4.5.

Results
4.5.1. BBG Does Not Impact Engraftment of Human Cells in NSG Mice

To determine if long-term P2X7 blockade can ameliorate disease development in a
humanised mouse model of GVHD, NSG mice injected with hPBMCs, were subsequently
injected with the P2X7 antagonist BBG (Sluyter, 2017) at 50 mg/kg or with saline thrice
weekly for up to 10 weeks. To investigate if human cell engraftment was affected by BBG
treatment, flow cytometric analysis of blood was conducted at 3 weeks post-hPBMC
injection (Supplementary Figure 4.1.). Mice injected with BBG demonstrated a similar
frequency of human leukocytes (13.2 ± 2.4% hCD45+ mCD45- cells, n = 10) compared to
mice injected with saline (control) (9.7 ± 2.8% hCD45+ mCD45- cells, n = 7) (P = 0.3561)
(Figure 4.1.a.). T cells comprised the majority of hCD45+ cells, and the frequencies of T cells
did not vary between mice injected with BBG (93.2 ± 1.4% hCD3+ hCD56- cells, n = 10) or
saline (91.6 ± 2.1% hCD3+ hCD56- cells, n = 7) (P = 0.5188) (Figure 4.1.b.). In all mice,
there was a small population of hCD3+ hCD56+ cells, potentially natural killer T (NKT) cells
(Ortaldo et al., 1991), but the frequency of these cells did not vary between mice injected
with BBG (3.1 ± 1.1% hCD3+ hCD56+ cells, n = 10) or saline (3.3 ± 1.0% hCD3+ hCD56+
cells, n = 7) (P = 0.8768) (Figure 4.1.c.). Both groups of mice demonstrated engraftment of a
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small proportion of natural killer (NK) cells (hCD3- hCD56+), which did not significantly
differ between mice injected with BBG (1.0 ± 0.3% hCD3- hCD56+ cells, n = 10) or saline
(2.3 ± 0.8% hCD3- hCD56+ cells, n = 7) (P = 0.1067) (Figure 4.1.d.). Finally, there was a
small population of cells that were neither T, NKT, nor NK cells; the frequency of which did
not vary between mice injected with BBG (2.7 ± 0.8% hCD3- hCD56- cells, n = 10) or saline
(2.8 ± 1.1% hCD3- hCD56- cells, n = 7) (P = 0.9854) (Figure 4.1.e.).
Splenocyte analysis at end point (Supplementary Figure 4.2.) showed human leukocytes
comprised the majority of total murine and human leukocytes. Mice injected with BBG
exhibited a similar frequency of human leukocytes (76.7 ± 3.2% hCD45+ mCD45- cells, n =
10) compared to mice injected with saline (71.4 ± 6.1% hCD45+ mCD45- cells, n = 7) (P =
0.4308) (Figure 4.1.f.). Similar to engraftment at 3 weeks post-hPBMC injection, T cells
comprised the majority of human leukocytes in the spleen, and both mice injected with BBG
(86.4 ± 5.2% hCD3+ hCD56- cells, n = 10) and mice injected with saline (96.1 ± 1.9% hCD3+
hCD56- cells, n = 7) demonstrated similar frequencies of T cells (P = 0.1390) (Figure 4.1.g.).
Similar to blood, there was a small population of hCD3+ hCD56+ cells, and the percentage of
these cells did not vary between mice injected with BBG (1.3 ± 0.6% hCD3+ hCD56+ cells, n
= 10) or saline (0.9 ± 0.1% hCD3+ hCD56+ cells, n = 7) (P = 0.5154) (Figure 4.1.h.). Few
mice demonstrated engraftment of NK cells in spleens at time of euthanasia, which did not
significantly differ between mice injected with BBG (0.7 ± 0.5% hCD3- hCD56+ cells, n =
10) or saline (0.1 ± 0.0% hCD3- hCD56+ cells, n = 7) (P = 0.3064) (Figure 4.1.i.). Finally,
there was a remaining population of cells that were neither T nor NK cells; the frequency of
which did not vary between mice injected with BBG (10 ± 4.2% hCD3- hCD56- cells, n = 10)
or saline (3.0 ± 2.0% hCD3- hCD56- cells, n = 7) (P = 0.1868) (Figure 4.1.j.).
Human T cell analysis (hCD3+) in spleens at end point (Supplementary Figure 4.2.) revealed
that mice injected with BBG or saline contained similar frequencies of hCD4+ T cells (71.3 ±
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4.7%, n = 10 vs. 75.6 ± 3.8%, n = 7, respectively, P = 0.5345) and hCD8+ T cells (17.9 ±
2.9%, n = 10 vs 14.6 ± 2.3%, n = 7, respectively, P = 0.4500) (Figure 4.1.k.). In both mice
injected with BBG or saline, the percentages of hCD4+ T cells were significantly greater than
that of hCD8+ T cells (both P < 0.0001 and P < 0.0001, respectively) (Figure 4.1.k.).

Figure 4.1. Long-term BBG treatment does not affect engraftment of human cells in a
humanised mouse model of GVHD (a-k) NOD-SCID-IL2Rγnull (NSG) mice were injected intraperitoneally (i.p.) with 10 x 106 human (h) peripheral blood mononuclear cells (hPBMCs), and
subsequently with saline (n = 7) or saline containing Brilliant Blue G (BBG) (50 mg/kg) (n = 10)
thrice weekly. The percentages of human leukocytes in (a-e) blood at 3 weeks post-hPBMC injection
and (f-k) spleens at end-point were determined by flow cytometry. (a, f) hCD45+ leukocytes are
expressed as a percentage of total mCD45+ and hCD45+ leukocytes. (b, g) hCD3+ hCD56-, (c, h)
hCD3+ hCD56+, (d, i) hCD3- hCD56+ and (e, j) hCD3- hCD56- cells are expressed as a percentage of
total hCD45+ leukocytes. (k) hCD4+ and hCD8+ T cell subsets are expressed as a percentage of total
hCD3+ leukocytes. Data represents group means ± SD; symbols represent individual mice; *** P <
0.0001 compared to corresponding hCD8+ T cells.
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4.5.2. BBG Does Not Prevent Clinical GVHD in NSG Mice
For up to 10 weeks, mice were monitored for weight loss and signs of GVHD. All mice
injected with BBG or saline exhibited weight loss from 4 weeks, with similar weight loss
between groups over the course of the study (P = 0.2853) (Figure 4.2.a.). Both groups of
mice began to show signs of mild GVHD from day 35, and both mice injected with BBG or
saline had similar clinical scores at end point (5.8 ± 0.5, n = 10 vs. 5.9 ± 0.7, n = 7,
respectively; P = 0.9494), and mean clinical scores over 10 weeks (P = 0.1286) (Figure
4.2.b.). Similar survival was also observed between mice injected with BBG (mortality of
90%, n = 10) or saline (mortality of 86.7%, n = 7) (P = 1.000) (Figure 2c), and mice injected
with BBG or saline also demonstrated similar MSTs (45.5 days vs. 52.0 days, respectively)
(P = 0.3014) (Figure 4.2.c.).

Figure 4.2. Long-term BBG treatment does not affect disease development in a humanised
mouse model of GVHD. (a-c) Saline- and BBG-injected humanised NOD-SCID-IL2Rγnull (NSG)
mice (Figure 1) were monitored for (a) weight loss, (b) clinical score (using a scoring system, giving a
total clinical score out of 10), and (c) survival for up to 10 weeks. Data represents (a, b) group means
± SD or (c) percent survival (saline n = 7; BBG n = 10).
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4.5.3. BBG Reduces Leukocyte Infiltration and Apoptosis in Livers of NSG
Mice
Short-term BBG has been shown to partly reduce leukocyte infiltrates, predominantly T cells,
and apoptosis in GVHD target organs including liver, small intestine and skin in humanised
NSG mice (Chapter 3). Therefore, to assess if long-term BBG treatment could reduce
leukocyte infiltration and damage, target tissues from humanised NSG mice were analysed
via histology. There were no histological differences in the small intestines or skin, including
epidermal thickening, of BBG- and saline-injected mice (Supplementary Figure 4.2.).
However, livers from mice injected with BBG demonstrated reduced histological damage
with less apoptotic cells (Figure 4.3.a.). Image analysis demonstrated a significant 52%
reduction in leukocytes in livers from BBG-injected mice (517 ± 244 cells/field of view; n =
9) compared to saline-injected mice (1082 ± 324 cells/field of view; n = 6) (P = 0.0020)
(Figure 4.3.a.).
To determine the identity of the cells above (Figure 4.3.a.), immunohistochemistry using an
anti-hCD3 mAb was conducted. Image analysis demonstrated a 55% reduction in CD3+ cell
infiltration in livers from BBG-injected mice (117 ± 157 cells/field of view; n = 4) compared
to saline-injected mice (263 ± 404 cells/field of view; n = 4), however this difference did not
reach statistical significance (P = 0.5263) (Figure 4.3.b.). Moreover, the number of hCD3+ T
cells detected (Figure 4.3.b.) represented only 24% of the total leukocytes detected by
histology (Figure 4.3.a.). Finally, an In Situ Apoptosis detection kit was used to confirm that
there was reduced apoptosis in the liver. Image analysis demonstrated there was a significant
57% decrease in apoptotic cells in livers from BBG-injected mice (65 ± 32 cells/field of
view; n = 4) compared to saline-injected mice (150 ± 47 cells/field of view; n = 4) (P =
0.0244) (Figure 4.3.c.).
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Figure 4.3. Long-term BBG treatment reduces leukocyte infiltration and apoptosis in livers of
mice in a humanised mouse model of GVHD. (a-c) Livers from saline- and BBG-injected
humanised NOD-SCID-IL2Rγnull (NSG) mice (Figure 1) at end-point were stained with (a)
haematoxylin and eosin, (b) anti-human (h) CD3 monoclonal antibody and haematoxylin or (c)
terminal deoxynucleotidyl transferase deoxyuridine triphosphate nick-end and methyl green. (a-c)
Images were captured by microscopy; representative images from one mouse per group shown; bar
represents 100 μm. Image analysis was used to quantitate the mean number of cells per field of view
from three different captured images per mouse. Data represents group means ± SD (saline n = 4-6;
BBG n = 4-9); symbols represent individual mice; * P < 0.05 or ** P < 0.01 to saline.
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4.5.4. BBG Does Not Impact Cytokine Expression in the Liver of NSG Mice
IFN-γ, IL-17 and TNF-α are important pro-inflammatory cytokines implicated in GVHD
pathogenesis (Yi et al., 2009, Gartlan et al., 2015). To investigate if long-term BBG
treatment alters these cytokines in the liver, hIFN-γ, hIL-17 and hTNF-α expression were
analysed by qPCR. hIFN-γ expression was similar in mice injected with BBG (2.8 ± 0.3, n =
7) or saline (3.0 ± 0.6, n = 7) (P = 0.7347) (Figure 4.4.a.). There was a two-fold increase in
hIL-17 expression in mice injected with BBG (4.0 ± 2.0, n = 7) compared to mice injected
with saline (1.8 ± 0.5, n = 7), but this did not reach statistical significance (P = 0.2940)
(Figure 4.4.b.). hTNF-α expression was low, and similar in mice injected with BBG (0.10 ±
0.03, n = 7) or saline (0.08 ± 0.03, n = 7) (P = 0.7754) (Figure 4.4.c.).
Short-term BBG treatment reduces serum IFN-γ in allogeneic (Wilhelm et al., 2010) and
humanised (Chapter 3) mouse models of GVHD. To determine if prolonged BBG treatment
could alter the amount of these cytokines, serum hIFN-γ and hIL-17 concentrations in
humanised NSG mice were assessed by ELISA. hIFN-γ was present in the serum of all mice
(Figure 4.4.d.). In contrast to previous data involving short-term BBG treatment (Chapter 3),
serum hIFN-γ concentrations were similar in mice injected with BBG (15.8 ± 3.5 ng/mL, n =
10) or saline (14.9 ± 3.2 ng/mL, n = 7) (P = 0.8462) (Figure 4.4.d.). hIL-17 was not detected
in the serum of any mice injected with BBG (n = 10) or saline (n = 7) using an ELISA with a
reported sensitivity of 4 pg/mL (eBioscience).
P2X7 expression is significantly increased in livers of mice with allogeneic GVHD (Wilhelm
et al., 2010). Therefore, to determine the impact of P2X7 blockade on expression of hP2X7
and mP2X7, livers of humanised NSG mice were analysed by qPCR. There was a four-fold
increase in relative hP2X7 expression in mice injected with BBG (8.7 ± 5.6, n = 7) compared
to mice injected with saline (2.0 ± 0.6, n = 7), however this did not reach statistical
significance (P = 0.2547) (Figure 4.4.e.). Relative mP2X7 expression was similar in mice
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injected with BBG (0.07 ± 0.02, n = 7) or saline (0.07 ± 0.01, n = 7) (P = 0.9986) (Figure
4.4.f.).

Figure 4.4. Long-term BBG treatment does not affect serum or liver inflammatory markers in
a humanised mouse model of GVHD. (a-f) cDNA from livers of saline- and BBG-injected
humanised NOD-SCID-IL2Rγnull (NSG) mice at end-point (Figure 1) were used to assess the relative
expression of human (h) (a) interferon (IFN)-γ, (b) interleukin (IL)-17, (c) tumour necrosis factor
(TNF)-α, (e) hP2X7, and (f) murine (m) P2X7 by qPCR. (d) Concentrations of serum hIFN-γ from
mice at end-point were analysed by ELISA. (a-f) Data represents group means ± SD (saline n = 7;
BBG n = 7-9); symbols represent individual mice.

4.6.

Discussion

The current study demonstrated that a long-term regime of P2X7 blockade using BBG (50
mg/kg i.p. thrice weekly for up to 10 weeks) can reduce liver inflammation and apoptosis in a
humanised mouse model of GVHD. Saline-injected control mice exhibited characteristic
leukocyte infiltration and apoptosis in the liver, consistent with previous observations in
humanised NSG mice (King et al., 2009, Vlad et al., 2009). The long-term regime of BBG
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reduced leukocyte infiltrates, including human T cells, into the livers compared to control
mice. This reduction was greater than our previous study using a short-term regime of BBG
(50 mg/kg i.p. on days 0, 2, 4, 6, 8) in humanised NSG mice (Chapter 3). Leukocyte
infiltrates are also reduced in livers from allogeneic mice following a long-term regime of
BBG (50 or 75 mg/kg i.p. twice weekly for four weeks) (Zhong et al., 2016). The long-term
BBG regime in the current study also reduced apoptosis in livers, an effect that was greater
than the previous short-term BBG regime in humanised NSG mice (Chapter 3). Similarly, the
long-term BBG regime in allogeneic mice also reduced inflammatory damage (Zhong et al.,
2016). The reduction in leukocyte infiltrates and apoptosis in livers is also similar to other
GVHD therapies in humanised mice (Vlad et al., 2009, Abraham et al., 2012, Ehx et al.,
2017). Notably, P2X7 blockade is an efficacious therapy in drug-induced inflammatory liver
damage (Hoque et al., 2012, Amaral et al., 2013). Thus, the current and past (Zhong et al.,
2016) studies indicate that P2X7 is important for liver GVHD development and that P2X7
represents a potential therapeutic target in HSCT to prevent this form of GVHD.
The current study demonstrated that a long-term regime of BBG did not impact clinical
disease in humanised mice. This result is similar to that of the short-term BBG regime in this
model (Chapter 3) but differs to that of a long-term BBG regime in the allogeneic mouse
model of GVHD above (Zhong et al., 2016). In the latter study, BBG prevented weight loss,
with a stronger effect observed with 75 mg/kg BBG compared to 50 mg/kg BBG, but clinical
score and survival were not reported. Nevertheless, since the larger dose of 75 mg/kg
significantly reduced histological GVHD and weight loss compared to the dose of 50 mg/kg
in this allogeneic mouse model, investigation of this or larger doses in a humanised mouse
model are warranted. Moreover further studies are required to reconcile why clinical GVHD
development in humanised mice is not altered by BBG, despite BBG impairing histological
liver GVHD in these mice. Finally, it should be noted that administration of BBG into
134

humanised NSG mice caused rapid weight gain, the reasons for which remain unknown.
However, P2X7 blockade with BBG or P2RX7 gene deficiency also induces weight gain in
C57BL/6 mice within one week (Costa-Junior et al., 2011). This previous study hypothesised
that a consensus motif similar to Janus kinase 2 within the C-terminus of P2X7 may be a
substrate of protein-tyrosine phosphatase 1B, which has known roles in obesity (Rondinone
et al., 2002). Thus, blockade of P2X7 may induce an initial weight gain in mice via
modulation of this phosphatase.
The long-term regime of BBG in the current study did not detect any differences in the
expression of hIFN-γ, hIL-17, and hTNF-α, or mP2X7 in the livers of humanised mice.
However, there was a 2-fold increase in hP2X7 in the liver, similar to the 1.7-fold increase in
the short-term regime (Chapter 3), but this did not reach statistical significance. This result is
somewhat unexpected given the reduced leukocyte infiltration and apoptosis in the livers of
these mice. This suggests that other molecules may be controlling T cell migration and T cellmediated damage in the livers of these mice. Alternatively, the similar expression of these
molecules may simply reflect the comparison of livers at end-stage disease, but this does not
explain observed differences in leukocyte infiltration and apoptosis. Analysis of liver samples
earlier in disease progression may reveal further differences between BBG- and saline-treated
mice.
Short-term (Chapter 3) but not long-term BBG treatment (the current study) reduced serum
hIFN-γ in humanised mice. The reason for this difference remains unknown, but suggests
long-term P2X7 blockade negates any benefits observed with short-term P2X7 blockade in
relation to serum hIFN-γ. This suggests that P2X7 blockade shortly after hPBMC
engraftment reduces the development of hIFN-γ-producing T cells in humanised mice,
similar to P2X7 deficiency reducing IFN-γ production early in disease development in
allogeneic mice (Ghiringhelli et al., 2009). However, P2X7 blockade at later stages of
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engraftment and GVHD development may promote development of hIFN-γ-producing T cells
in humanised NSG mice. Alternatively, comparison of serum hIFN-γ concentrations between
the current and previous (Chapter 3) studies indicates that the long-term regime with saline
reduced serum hIFN-γ compared to the short-term saline regime. This suggests long-term
injections of saline may reduce some disease parameters in this humanised mouse model of
GVHD. In support of this, injection of saline is used in other inflammatory disease models to
rescue mice from weight loss ((van der Fits et al., 2009) and Chapter 7).
Finally, the current study demonstrates that a long-term BBG regime does not affect
engraftment of donor human cells in NSG mice. Although the clinical benefits of this regime
were limited, this indicates long-term P2X7 blockade may permit reconstitution of the
immune system, an essential aim of HSCT (Paloczi, 2000). In the current study, the majority
of engrafted leukocytes were T cells, consistent with previous studies ((King et al., 2008,
King et al., 2009) and Chapter 3). Our previous study demonstrated that B cells are not
present in the blood or spleens of humanised NSG mice, but the identity of the remaining
human leukocytes remained unknown (Chapter 3). In the current study, NK cells constituted
a portion of the remaining leukocyte population, consistent with similar frequencies of NK
cells in humanised NSG mice observed by others (Gregoire-Gauthier et al., 2012, Tanaka et
al., 2012b). NK cells contribute to the graft-versus-leukemia effect but not GVHD in both
mice (Hüber et al., 2015) and humans (Ruggeri et al., 2002), suggesting that NSG mice
injected with hPBMCs could be potentially used to study the graft-versus-leukemia effect.
Importantly, BBG did not affect NK cell engraftment suggesting P2X7 blockade may not
impact graft-versus-leukemia immunity, another key aim of HSCT. The current study also
demonstrated, for the first time, that humanised NSG mice engraft a small proportion of NKT
cells (Koreck et al., 2002), although in the absence of additional markers these cells may
represent activated T cells instead or in part (Kelly-Rogers et al., 2006). NKT cells suppress
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GVHD in allogeneic HSCT in mice (Lan et al., 2001, Haraguchi et al., 2005, Schneidawind
et al., 2015) and higher numbers of NKT cells in humans correlates to reduced GVHD
(Rubio et al., 2012, Chaidos et al., 2012). BBG did not alter the percentage of these cells
indicating that P2X7 blockade does not affect engraftment of NKT cells. Thus, humanised
NSG mice may help elucidate the role of human NK and NKT cells in GVHD. It should be
noted that a limitation of the current study was that the flow cytometric analyses did not
include gating of singlets or dead cell exclusion using a viability dye. Thereby increasing the
likelihood of small errors in determining the proportions of human leukocyte subsets
especially rarer subsets such as NK and NKT cells.
The current study demonstrated that long-term P2X7 blockade does not impact human
leukocyte engraftment, weight loss, clinical score or mortality associated with GVHD.
However, this regime can reduce leukocyte infiltration and apoptosis in the liver. Therefore,
this study demonstrates that P2X7 activation plays a role in GVHD pathogenesis in the livers
of humanised mice, supporting a role for this receptor in GVHD development in HSCT
recipients. Moreover, given that long-term P2X7 blockade does not affect donor human
leukocyte engraftment or appear to have any other adverse effects, P2X7 may represent a
potential therapeutic target to reduce liver GVHD in HSCT recipients.
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5.2.

Abstract

Allogeneic haematopoietic stem cell transplantation (HSCT) is a curative therapy for a
number of haematological malignancies, but is limited by the development of graft-versushost disease (GVHD). CD39 and CD73 form an ecto-enzymatic pathway that hydrolyses
extracellular adenosine 5’-triphosphate (ATP) to adenosine, which respectively exacerbate or
alleviate disease in allogeneic mouse models of GVHD. The current study aimed to explore
the role of the CD39/CD73 pathway and adenosine receptor (AR) blockade in a humanised
mouse

model

of

GVHD.

Immunodeficient

non-obese

diabetic-severe

combined

immunodeficiency-IL-2 receptor γnull (NSG) mice were injected with human peripheral blood
mononuclear cells (PBMCs), and subsequently injected with the CD39/CD73 antagonist αβmethylene-ADP (APCP) (50 mg/kg) or saline for 7 days, or the AR antagonist caffeine (10
mg/kg) or saline for 14 days. Mice predominantly engrafted human CD4+ and CD8+ T cells,
with smaller proportions of human regulatory T (Treg) cells, invariant natural killer T (iNKT)
cells, monocytes and dendritic cells (DCs). Neither APCP or caffeine altered engraftment of
these human leukocyte subsets. APCP (CD39/CD73 blockade) augmented GVHD as shown
through increased weight loss and worsened liver histology. This treatment also increased
serum human IL-2 concentrations and decreased the frequency of human CD39-CD73-CD4+
T cells. In contrast, caffeine (AR blockade) did not alter GVHD severity or human serum
cytokine concentrations (IL-2, IL-6, IL-10 or TNFα). In conclusion, blockade of CD39/CD73
but not ARs augments disease in a humanised mouse model of GVHD. These results indicate
that CD39/CD73 blockade maintains sufficient extracellular ATP concentrations to promote
GVHD in this model.
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5.3.

Introduction

Allogeneic haematopoietic stem cell transplantation (HSCT) is a common curative therapy
for numerous haematological malignancies. However, 30-60% of transplant recipients
develop graft-versus-host disease (GVHD) as a result of the donor T cells recognising the
recipient tissue as ‘foreign’ (Jagasia et al., 2012). The first stage of GVHD is characterised by
the initial release of cytokines, such as TNF-α and IL-6, from damaged tissue caused by the
underlying disease or pre-conditioning regimes. Following this, activation of CD4+ T cells by
antigen presenting cells, such as dendritic cells (DC), can cause release of T helper-1 (Th1)
cytokines such as TNF-α, IFN-γ and IL-2. Finally, both CD4+ and CD8+ T cells migrate to
the liver, gastrointestinal tract and skin to cause inflammatory damage of these tissues
(Ferrara et al., 2009). Alternatively, IL-10 can suppress immune responses and can
potentially reduce GVHD (Blazar et al., 1998). The T cell subsets regulatory T (Treg) cells
and invariant natural killer T (iNKT) cells can also reduce GVHD severity (Schneidawind et
al., 2013).
Purinergic signalling includes the plasma membrane P1 and P2 receptors. P1 or adenosine
receptors (AR; A1, A2A, A2B and A3) are activated by extracellular adenosine, while P2
receptors (P2X1-7 and P2Y1, 2, 4, 6, 8, 11-14) are activated by a range of extracellular nucleotides
including adenosine 5’-triphosphate (ATP) (Burnstock, 2007). Purinergic receptors are
important in inflammation and immunity, and are expressed on immune cells including
antigen presenting cells and T cells (Di Virgilio and Vuerich, 2015). In general activation of
P2 receptors by extracellular ATP exerts pro-inflammatory effects (Idzko et al., 2014). In
contrast, hydrolysis of ATP to adenosine by a pathway involving ecto-nucleoside
triphosphate diphosphohydrolase-1 (CD39) and ecto-5’-nucleotidase (CD73) commonly
results in anti-inflammatory effects via activation of ARs (Antonioli et al., 2013).
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ATP, released from activated, damaged or dying cells, can activate P2 receptors and promote
inflammatory responses in transplantation (Castillo-Leon et al., 2018). Moreover, P2 receptor
activation can promote development of GVHD. Extracellular ATP can be released from
damaged cells in GVHD (Wilhelm et al., 2010) and subsequently activate P2X7 to promote
disease development in allogeneic (Wilhelm et al., 2010, Fowler et al., 2014, Zhong et al.,
2016) and humanised (Chapter 3) mouse models of GVHD. Likewise, P2Y2 activation by
ATP can promote leukocyte infiltration and tissue damage in allogeneic models of GVHD
(Klambt et al., 2015). In contrast, activation of ARs can limit GVHD development (Lappas et
al., 2010, Han et al., 2013). Moreover, pharmacological blockade of ARs with caffeine
(Tsukamoto et al., 2012) or A2A with SCH58261 (Wang et al., 2013) or genetic deletion of
A2A (Tsukamoto et al., 2012, Wang et al., 2013) worsens disease in allogeneic mouse models
of GVHD. Similarly, pharmacological blockade of CD39 and CD73 with αβ-methylene-ADP
(APCP), which prevents adenosine generation and increases extracellular ATP (Moody et al.,
1984, Covarrubias et al., 2016), augments GVHD in allogeneic mouse models (Wang et al.,
2013). However, the roles of the CD39/CD73 pathway and ARs in a humanised mouse model
of GVHD have not been reported.
Using pharmacological approaches, the current study aimed to investigate the role of the
CD39/CD73 pathway and AR blockade in disease development in a humanised mouse model
of GVHD. In this model, immunodeficient non-obese diabetic-severe combined
immunodeficiency-IL-2 receptor γnull (NSG) mice are injected with human peripheral blood
mononuclear cells (PBMC) and develop clinical signs of GVHD over 10 weeks (Chapter 3).
CD39/CD73 blockade with APCP, but not AR blockade with caffeine, augments GVHD in
humanised mice. These results support the known roles of extracellular ATP in promoting
GVHD, but do not provide evidence that extracellular adenosine can limit GVHD in this
humanised model.
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5.4.

Materials and Methods

5.4.1. Humanised Mouse Model of GVHD
Experiments involving human blood and mice were approved by the respective Human and
Animal Ethics Committees (University of Wollongong, Wollongong, Australia). A
humanised mouse model of GVHD was used as described (Chapter 3). Briefly, hPBMCs,
isolated by density centrifugation using Ficoll-Paque PLUS (GE Healthcare; Uppsala,
Sweden), were injected intra-peritoneally (i.p.) (10 x 106 hPBMCs/mouse) into female NSG
mice aged 5-7 weeks (Australian BioResources; Moss Vale, Australia). For CD73 blockade,
humanised mice were injected i.p. daily with APCP (Sigma-Aldrich; St Louis, MO, USA)
(50 mg/kg) or saline 2 hours following hPBMC injection and then daily over the next 6 days
(Tsukamoto et al., 2012). For AR blockade, mice were injected i.p. daily with caffeine
(Sigma-Aldrich) (10 mg/kg) or saline 2 hours following hPBMC injection and then daily for
the next 13 days (Tsukamoto et al., 2012). At 3 weeks post-hPBMC injection, mice were
checked for engraftment by immunophenotyping of tail vein blood. Mice were monitored for
signs of GVHD using a scoring system, giving a total clinical score out of 10, as described
(Chapter 3). Mice were euthanised at 10 weeks post-injection of hPBMCs, or earlier if
exhibiting a clinical score of ≥ 8 or a weight loss of ≥ 10%, according to the approved animal
ethics protocol.
5.4.2. Immunophenotyping by Flow Cytometry
Tail vein blood (week 3) and spleen cells (end-point) were obtained from mice and lysed with
ammonium chloride potassium buffer and immunophenotyped as described (Chapter 3) using
the antibodies listed in Table 5.1 and the gating strategy depicted in the Supplementary
Figures S1 and S2. Data was collected using a BD (San Jose, CA, USA) Fortessa-X20 Flow
Cytometer (using band pass filters 450/50 for BV421, 710/50 for BV711, 525/50 for FITC,
586/15 for PE, 695/40 for PerCP-Cy5.5, 780/60 for PE-Cy7 and 670/30 for APCy). The
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relative percentages of cells were analysed using FlowJo software v8.7.1 (TreeStar Inc.;
Ashland, OR, USA) (FigureS1 and S2).
Table 5.1. Monoclonal antibodies used for flow cytometry.

Target
CD14
CD127
CD3
CD45
CD8
CD25
CD3
CD83
CD4
CD45
CD73
Vα24-Jα14
CD19
CD39

Fluorochrome
BV421
BV421
BV711
FITC
FITC
PE
PE
PE
PerCP-Cy5.5
PerCP-Cy5.5
PE-Cy7
PE-Cy7
APCy
APCy

Clone*
MϕP9
HIL-7R-M21
UCHT1
HI30
RPA-T8
M-A251
UCHT1
HB15e
L200
30-F11
AD2
6B11
HIB19
TU66

*All antibodies mouse anti-human except clone 30-F11 (rat anti-mouse); all antibodies from BD
Biosciences except clone 6B11 (BioLegend).

5.4.3. Histological Analysis
Formalin-fixed tissue sections (5 μm) were stained with haematoxylin and eosin (POCD;
Artarmon, Australia) and histology assessed as described (Chapter 3).
5.4.4. Cytokine Analysis by a Flow Cytometric Multiplex Assay
Serum was obtained from mice at end-point as described (Chapter 3) and cytokine
concentrations were measured using a human Th1 LEGENDPlex kit (BioLegend; San Diego,
CA, USA) as per the manufacturer’s instructions.
5.4.5. Statistical Analysis
Data is given as mean ± standard error of the mean (SEM). Statistical differences were
calculated using Student’s t-test for single comparisons or one-way analysis of variance
(ANOVA) with Tukey’s post-hoc test for multiple comparisons. Weight and clinical score
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were analysed using a repeated measures two-way ANOVA. Survival (MST) was compared
using the log-rank (Mantel-Cox) test. Mortality was compared using Fisher’s exact test. All
statistical analyses and graphs were generated using GraphPad Prism 5 for PC (GraphPad
Software; La Jolla, CA, USA). P < 0.05 was considered significant for all tests.

5.5.

Results

5.5.1. APCP Does Not Impact hPBMC Engraftment in NSG Mice
To investigate a role for the CD39/CD73 pathway in GVHD development in humanised NSG
mice, these mice were injected with the CD39/CD73 inhibitor, APCP, using the same regime
efficacious in an allogeneic mouse model of GVHD (Tsukamoto et al., 2012). First, to
investigate whether APCP (CD39/CD73 blockade) altered hPBMC engraftment in NSG
mice, 3 weeks post-hPBMC injection blood cells from APCP- (n = 9) or saline-injected (n =
9) mice were analysed by flow cytometry. APCP- and saline-injected mice demonstrated
similar frequencies of human leukocytes (hCD45+mCD45- cells), calculated as a percentage
of total leukocytes (hCD45+mCD45-/(hCD45+mCD45- and hCD45-mCD45+)) (22.1 ± 3.9%
and 22.2 ± 5.4%, respectively, P = 0.9869) (Figure 5.1.a.). These human leukocytes from
APCP- and saline-injected mice predominately comprised T cells (hCD3+hCD19-) (99.5 ±
0.1% and 99.3 ± 0.3%, respectively, P = 0.4897) (Figure 5.1.b.), with a small amount of nonB/T cells (hCD3- hCD19-) (0.5 ± 0.1% and 0.7 ± 0.3%, respectively, P = 0.4897) (Figure
5.1.c.).
A.t end-point, splenocytes from APCP- (n = 9) and saline-injected (n = 8) mice were
analysed by flow cytometry. APCP- and saline-injected mice demonstrated similar
frequencies of human leukocytes (75.1 ± 9.4% and 90.2 ± 3.0%, respectively, P = 0.1691)
(Figure 5.1.d.). One APCP-injected mouse revealed a human leukocyte frequency of only
9.7% (Figure1d) but was included in subsequent analyses. APCP- and saline-injected mice
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demonstrated similar frequencies of human T cells (92.5 ± 1.9% and 95.1 ± 1.6%,
respectively, P = 0.3128) (Figure 5.1.e.), which comprised both hCD4+ T cells (58.3 ± 6.5%
and 64.0 ± 7.0%, respectively, P = 0.5558) and hCD8+ T cells (29.6 ± 6.0% and 19.2 ± 3.3%,
respectively, P = 0.1633) (Figure 5.1.f.). Both APCP- and saline-injected mice demonstrated
greater frequencies of hCD4+ T cells than hCD8+ T cells (P = 0.0053 and P < 0.0001,
respectively) (Figure 5.1.f.).
To investigate whether APCP altered the frequency of CD39+/- and/or CD73+/- human T cells,
these markers on hCD4+ and hCD8+ T cells from the spleens of humanised mice were
analysed by flow cytometry. APCP-injected mice, compared to saline-injected mice,
demonstrated a trend of increased hCD39+hCD73-hCD4+ T cells (10.2 ± 4.1% and 5.5 ±
2.1%, respectively, P = 0.3441) and hCD39-hCD73+hCD4+ T cells (13.1 ± 5.5% and 3.7 ±
0.9%, respectively, P = 0.1347), but a similar frequency of hCD39+hCD73+hCD4+ T cells
(1.3 ± 0.4% and 0.8 ± 0.4%, respectively, P = 0.4247). Conversely, the frequency of
hCD39-hCD73-hCD4+ T cells was significantly reduced in APCP-injected mice compared to
saline-injected mice (75.4 ± 5.8% and 89.9 ± 2.4%, respectively, P = 0.0441) (Figure 5.1.g.).
In contrast to hCD4+ T cells, APCP- and saline injected mice demonstrated similar
frequencies of hCD39+hCD73-hCD8+ T cells (41.4 ± 3.0% and 36.4 ± 5.0%, respectively, P =
0.3867), hCD39-hCD73+hCD8+ T cells (3.8 ± 1.0% and 2.8 ± 0.6, respectively, P = 0.4342),
hCD39+hCD73+hCD8+ T cells (5.5 ± 1.6% and 4.1 ± 1.2, respectively, P = 0.5035) and
hCD39-hCD73-hCD8+ T cells (49.3 ± 4.6% and 56.7 ± 5.8, respectively, P = 0.3247) (Figure
5.1.h.).
Previous studies have demonstrated that increased proportions of iNKT and Treg cells
correlate to reduced GVHD severity in allogeneic mouse models of GVHD (Schneidawind et
al., 2013), but the presence of human iNKT cells in humanised NSG mice is unknown.
Therefore, the presence and frequency of human iNKT cells (hCD45+hCD3+hCD19147

hVα24-Jα18+), as well as human Treg cells (hCD45+hCD3+hCD4+hCD25+hCD127lo), in the
spleens of these mice was examined. APCP- and saline-injected mice demonstrated the
presence and similar frequencies of iNKT cells (2.4 ± 1.0% and 1.4 ± 0.4%, respectively, P =
0.3674) (Figure 5.1.i.). APCP- and saline-injected mice also demonstrated similar frequencies
of Treg cells (1.4 ± 0.6 and 0.9 ± 0.2%, respectively, P = 0.4983) (Figure 5.1.j.).
Previously, our group observed that the spleens of humanised mice at end-point do not
contain human B cells (Chapter 3). Consistent with this observation, the remaining human
leukocytes in the spleens of APCP- and saline-injected mice were negative for CD19, with
similar frequencies of CD3-CD19- cells present in both groups of mice (7.5 ± 1.9% and 3.2 ±
1.0%, respectively, P = 0.0703) (Figure 5.1.k.). Therefore, this remaining non-B/T cell
population (hCD45+hCD3-hCD19-) was further analysed to determine if these cells were
human monocytes (hCD14+hCD83-) or DCs (hCD14-hCD83+). APCP- and saline-injected
mice demonstrated small but similar frequencies of human monocytes (0.03 ± 0.02% and
0.001 ± 0.001%, respectively, P = 0.1804) (Figure 5.1.l.) and human DCs (0.4 ± 0.2% and
0.3 ± 0.1%, respectively, P = 0.6066) (Figure 5.1.m.).
5.5.2. APCP Augments Clinical and Histological GVHD in Humanised Mice
To investigate whether APCP (CD39/CD73 blockade) impacted GVHD development, the
above mice were monitored for disease development for up to 10 weeks. APCP-injected mice
(n = 9) demonstrated significantly greater weight loss over the 10 weeks than saline-injected
mice (n = 9) (P = 0.0350) (Figure 5.2.a.). APCP-mice demonstrated signs of GVHD
(classified as a score clinical score ≥ 3) from 38 days onwards, while saline-injected mice
demonstrated signs of GVHD from 45 days, however, clinical scores were similar over 10
weeks (P = 0.1711) (Figure 5.2.b.). Moreover, APCP- and saline-injected mice exhibited
identical median survival times (MST) (57 days and 57 days, respectively, P = 0.2634) and
similar mortality over 10 weeks (100% and 78%, respectively, P = 0.2059) (Figure 5.2.c.).
148

GVHD affects the liver, gastrointestinal tract and skin in humans (Glucksberg et al., 1974),
and in allogeneic (Schroeder and DiPersio, 2011) and humanised (King et al., 2009) mouse
models. APCP-injected mice exhibited greater leukocyte infiltration and histological damage
of the liver compared to saline-injected mice (Figure 5.2.d.). In contrast, the small intestines
of APCP- and saline-injected mice exhibited similar amounts of leukocyte infiltration, crypt
epithelial cell apoptosis and structural damage including rounding of villi (Figure 5.2.d.).
Similarly, the skin of APCP- and saline-injected mice displayed similar amounts of leukocyte
infiltration, with similar but minimal amounts of basal epithelial cell apoptosis and epidermal
thickening (Figure 5.2.d.).
5.5.3. APCP Blockade Increases Serum hIL-2 Concentrations in Humanised
Mice
An important part of GVHD development is the pro-inflammatory cytokine storm that drives
immune cell proliferation and inflammatory damage (Ferrara et al., 2009). Therefore, to
determine if APCP altered cytokine production in humanised mice, serum hIL-2, hIL-6, hIL10, hTNF-α and hIFN-γ concentrations from APCP- (n = 9) and saline-injected (n = 8) mice
were analysed by a flow cytometric multiplex assay. APCP-injected mice demonstrated a
significant increase in serum hIL-2 concentrations (3.2 ± 0.5 pg/mL) compared to salineinjected mice (1.6 ± 0.3 pg/mL) (P = 0.0080) (Figure 5.2.e.). In contrast, APCP- and salineinjected mice demonstrated similar serum concentrations of hIL-6 (3.9 ± 1.5 pg/mL, and 1.4
± 0.7 pg/mL, respectively, P = 0.1743) (Figure 5.2.f.), hIL-10 (22.2 ± 4.1 pg/mL, and 19.1 ±
3.1 pg/mL, respectively, P = 0.7621) (Figure 5.2.g.), and TNF-α (21.3 ± 6.5 pg/mL, and 16.6
± 3.4 pg/mL, respectively, P = 0.7851) (Figure 5.2.h.). Serum hIFN-γ concentrations in both
treatment groups exceeded the highest standard (>10,000 pg/mL) and thus could not be
compared (data not shown). Attempts to reassess serum hIFN-γ concentrations by ELISA
were unsuccessful (results not shown), possibly due to freeze-thawing of serum.
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Figure 5.1. APCP reduces human CD4+CD39-CD73- cells in a humanised mouse model of GVHD

(a-m) The percentage of human leukocytes in (a-c) blood at 3 weeks post-hPBMC injection
and (d-m) spleens at end-point from humanised NSG mice injected with saline (control) or
the CD39/CD73 inhibitor APCP (50 mg/kg) were determined by flow cytometry. (a, d)
hCD45+ leukocytes are expressed as a percentage of total (mCD45+ and hCD45+) leukocytes.
(b, e) T cells (hCD3+hCD19-) and (c, k) non-B/T cells (hCD3-hCD19-) are expressed as a
percentage of hCD45+ leukocytes. (f) hCD4+ and hCD8+ T cell subsets are expressed as a
percentage of hCD3+ leukocytes. ** P < 0.005, *** P < 0.0001 compared to hCD8+ T cells.
(g, h) The expression of hCD39 and hCD73 was analysed on (g) hCD4+ and (h) hCD8+ T cell
subsets. * P < 0.05 compared to respective saline control. (i) iNKT cells (hVα24-Jα18+) are
expressed as a percentage of hCD3+hCD19- T cells and (j) Treg cells (hCD25+hCD127lo) are
expressed as a percentage of hCD3+ T cells. (l) monocytes (hCD14+CD83-) and (m) DCs
(hCD14-CD83+) are expressed as a percentage of non-B/T cells. Data represents group means
± SEM; symbols represent individual mice (saline n = 9, APCP n = 8-9).
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5.5.4. Caffeine Does Not Impact hPBMC Engraftment in NSG Mice
The above data suggests that decreased adenosine and/or increased ATP production due to
APCP-mediated blockade of CD39/CD73 worsens GVHD in humanised NSG mice. Thus, a
role for ARs using the broad-spectrum AR antagonist, caffeine, in this process was examined
using the same regime efficacious in an allogeneic mouse model of GVHD (Tsukamoto et al.,
2012). First, to determine if caffeine altered hPBMC engraftment, 3 weeks post-hPBMC
injection blood cells from caffeine- (n = 13) and saline-injected (n = 15) mice were analysed
by flow cytometry. Caffeine- and saline-injected mice demonstrated similar frequencies of
human leukocytes (23.5 ± 3.5% and 28.5 ± 4.7%, respectively, P = 0.4135) (Figure 5.3.a.),
which comprised T cells (92.5 ± 1.1% and 94.2 ± 0.7%, respectively, P = 0.1897) (Figure
5.3.b.), and non-B/T cells (7.5 ± 1.1% and 5.8 ± 0.7%, respectively, P = 0.1897) (Figure
5.3.c.).
At end-point, splenocytes from caffeine- (n = 13) and saline-injected (n = 14) mice were
analysed by flow cytometry. Caffeine- and saline-injected mice demonstrated similar
frequencies of human leukocytes (72.2 ± 6.2% and 75.6 ± 3.8%, respectively, P = 0.6346)
(Figure 5.3.d.). One caffeine-injected mouse revealed a human leukocyte frequency of only
11.2% (Figure 5.3.d.) but was included in subsequent analyses. Caffeine- and saline-injected
mice demonstrated similar frequencies of human T cells (96.1 ± 1.0% and 93.7 ± 1.9%,
respectively, P = 0.2934) (Figure 5.3.e.), which comprised hCD4+ T cells (51.7 ± 4.4% and
52.7 ± 3.4%, respectively, P = 0.8658) and hCD8+ T cells (13.5 ± 2.3% and 18.5 ± 4.0%,
respectively, P = 0.3011). Both caffeine- and saline-injected mice demonstrated greater
frequencies of hCD4+ than hCD8+ T cells (P < 0.0001 and P < 0.0001, respectively) (Figure
5.3.f.).
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APCP

Figure 5.2 CD73 blockade augments disease in a humanised mouse model of GVHD.
(a-i) Humanised NSG mice injected with saline (control) or the CD39/CD73 inhibitor APCP (50
mg/kg) were monitored for (a) weight loss, (b) clinical score and (c) survival over 10 weeks. * P <
0.05 compared to saline-injected mice. Data represents (a, b) group means ± SEM or (c) percent
survival (saline n = 9, APCP n = 9). (d) Tissue sections (liver, small intestine, and skin) were stained
with haematoxylin and eosin and images were captured by microscopy, with each image
representative of eight mice per group; bar represents 100 μm. (e-h) Concentrations of serum human
(e) IL-2, (f) IL-6, (g) IL-10 and (h) TNF-α were analysed using a flow cytometric multiplex assay. * P
< 0.05 compared to respective saline control. Data represents group means ± SEM (saline n = 8,
APCP n = 9).

Caffeine-

and

saline

injected

mice

demonstrated

similar

frequencies

of

hCD39+hCD73-hCD4+ T cells (14.2 ± 4.6% and 11.0 ± 3.6%, respectively, P = 0.5926),
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hCD39-hCD73+hCD4+ T cells (3.2 ± 1.0% and 5.3 ± 1.9, respectively, P = 0.3572),
hCD39+hCD73+hCD4+ T cells (0.8 ± 0.2% and 0.7 ± 0.3, respectively, P = 0.9430) and
hCD39-hCD73-hCD4+ T cells (81.8 ± 4.4% and 83.0 ± 3.5, respectively, P = 0.8425) (Figure
5.3.g.). Caffeine- and saline-injected mice also demonstrated similar frequencies of
hCD39+hCD73-hCD8+ T cells (33.3 ± 6.2% and 39.5 ± 5.4%, respectively, P = 0.4544),
hCD39-hCD73+hCD8+ T cells (3.3 ± 0.7% and 5.9 ± 2.8%, respectively, P = 0.3922),
hCD39+hCD73+hCD8+ T cells (4.9 ± 1.4% and 5.2 ± 2.0%, respectively, P = 0.9055) and
hCD39-hCD73-hCD8+ T cells (57.4 ± 6.9% and 50.6 ± 6.0%, respectively, P = 0.4627)
(Figure 5.3.h.).
Caffeine- and saline-injected mice also demonstrated similar frequencies of iNKT cells (3.1 ±
0.9% and 1.6 ± 0.3%, respectively, P = 0.1088) (Figure 5.3.i.) and Treg cells (0.8 ± 0.1% and
0.9 ± 0.2%, respectively, P = 0.8964) (Figure 5.3.j.). Caffeine- and saline-injected mice
demonstrated similar frequencies of non-B/T cells (4.1 ± 1.1% and 5.8 ± 1.9%, respectively,
P = 0.4381) (Figure 5.3.k.), which included similar frequencies of monocytes (0.2 ± 0.1%, n
= 11 and 0.3 ± 0.1%, n = 10 respectively, P = 0.5873) (Figure3l) and DCs (0.6 ± 0.2%, n = 11
and 0.4 ± 0.2%, n = 10 respectively, P = 0.7984) (Figure 5.3.m.).
5.5.5. Caffeine Does Not Impact Clinical or Histological GVHD in Humanised
Mice
To determine if caffeine (AR blockade) impacted GVHD development, the above mice were
monitored for disease development for up to 10 weeks. Caffeine- (n = 13) and saline-injected
(n = 15) mice demonstrated similar weight loss (P = 0.7574) (Figure 5.4.a.) and clinical
scores (P = 0.0846) (Figure 5.4.b.) over 10 weeks. Moreover, caffeine- and saline-injected
mice exhibited similar MSTs (47 days and 45 days, respectively, P = 0.8741) and mortality
over 10 weeks (87% and 87%, respectively, P = 1.000) (Figure 5.4.c.).
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Caffeine- and saline-injected mice demonstrated similar amounts of leukocyte infiltration and
histological damage of the liver, small intestine and skin (Figure 5.4.d.). Moreover, the small
intestines from mice from either group exhibited similar amounts of structural damage
including enterocyte loss, crypt epithelial cell apoptosis and rounding of villi (Figure 5.4.d.).
Similarly, skin from both caffeine- and saline-injected mice displayed mild basal epithelial
cell apoptosis and epidermal thickening (Figure 5.4.d.).
5.5.6. Caffeine Does Not Impact Serum Cytokine Concentrations in a
Humanised Mouse Model of GVHD
Finally, to determine if caffeine altered cytokine production in humanised mice, serum hIL-2,
hIL-6, hIL-10, hIFN-γ and hTNF-α concentrations were analysed as above. Caffeine- (n =
12) and saline-injected (n = 11) mice demonstrated similar concentrations of serum hIL-2
(1.5 ± 0.4 pg/mL and 1.0 ± 0.3 pg/mL, respectively, P = 0.7556), hIL-6 (2.9 ± 1.3 pg/mL and
3.7 ± 2.8 pg/mL, respectively, P = 0.6577), and hIL-10 (23.0 ± 2.6 pg/mL and 26.8 ± 6.4
pg/mL, respectively, P = 0.8594). There was a trend of increased hTNF-α concentration in
caffeine-injected mice, which approached but did not achieve statistical significance (18.6 ±
3.2 pg/mL and 13.7 ± 3.3 pg/mL, respectively, P = 0.0852). Serum hIFN-γ concentrations in
both treatment groups exceeded the highest standard (>10,000 pg/mL) and thus could not be
compared (data not shown). Attempts to reassess serum hIFN-γ concentrations by ELISA
were unsuccessful (results not shown), possibly due to freeze-thawing of serum.
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Figure 5.3. Caffeine does not impact human leukocyte engraftment in a humanised mouse model
of GVHD. (a-m) The percentage of human leukocytes in (a-c) blood at 3 weeks post-hPBMC
injection and (d-m) spleens at end-point from humanised NSG mice injected with saline (control) or
the AR antagonist caffeine (10 mg/kg) were determined by flow cytometry. (a, d) hCD45+ leukocytes
are expressed as a percentage of total (mCD45+ and hCD45+) leukocytes. (b, e) T cells
(hCD3+hCD19-) and (c, k) non-B/T cells (hCD3-hCD19-) are expressed as a percentage of hCD45+
leukocytes. (f) hCD4+ and hCD8+ T cell subsets are expressed as a percentage of hCD3+ leukocytes.
*** P < 0.0001 compared to hCD8+ T cells. (g, h) The expression of hCD39 and hCD73 was
analysed on (g) hCD4+ and (h) hCD8+ T cell subsets. (i) iNKT cells (hVα24-Jα18+) are expressed as a
percentage of hCD3+ hCD19- T cells and (j) Treg cells (hCD25+hCD127lo) are expressed as a
percentage of hCD3+ T cells. (l) monocytes (hCD14+CD83-) and (m) DCs (hCD14-CD83+) are
expressed as a percentage of non-B/T cells. Data represents group means ± SEM; symbols represent
individual mice (saline n = 15, caffeine n = 13).
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Figure 5.4. Caffeine does not impact disease in a humanised mouse model of GVHD.
(a-i) Humanised NSG mice injected with saline (control) or the AR antagonist caffeine (10 mg/kg)
were monitored for (a) weight loss, (b) clinical score, and (c) survival over 10 weeks. Data represents
(a, b) group means ± SEM or (c) percent survival (saline n = 9, caffeine n = 9). (d) Tissue sections
(liver, small intestine, and skin) were stained with haematoxylin and eosin and images were captured
by microscopy, with each image representative of 13 mice per group; bar represents 100 μm. (e-h)
Concentrations of serum human (e) IL-2, (f) IL-6, (g) IL-10 and (h) TNF-α were analysed using a
flow cytometric multiplex assay. Data represents group means ± SEM (saline n = 15, caffeine n = 13).
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5.6.

Discussion

Accumulation of extracellular adenosine resulting from the CD39/CD73 pathway and
subsequent activation of ARs is important in limiting disease in allogeneic mouse models of
GVHD (Tsukamoto et al., 2012, Wang et al., 2013). However, the role of this signalling axis
in humanised mouse models of GVHD remained unknown. The current study demonstrated
that CD39/CD73 blockade with APCP increases weight loss, liver GVHD and serum hIL-2
concentrations, and decreases the frequency of hCD39-hCD73-hCD4+ T cells in humanised
mice. In contrast, blockade of ARs with caffeine did not impact clinical or histological
GVHD or associated leukocytes or inflammatory markers. It is unlikely that caffeine failed to
block ARs in the humanised mice, as this same caffeine regime augmented GVHD in
allogeneic mice (Tsukamoto et al., 2012) and caffeine impairs both murine and human ARs
with similar efficacy (El Yacoubi et al., 2000, Abo-Salem et al., 2004). Thus, the results of
this study do not support a role for AR activation in limiting GVHD in humanised mice.
Rather, this study supports a role for extracellular ATP in augmenting GVHD in this model.
Blockade of CD39 and/or CD73 with APCP maintains or increases extracellular ATP
concentrations (Moody et al., 1984, Covarrubias et al., 2016). This ATP in turn may
subsequently act on P2X7 and/or P2Y2 to promote GVHD in humanised mice. These P2
receptors are involved in GVHD progression in humanised (Chapter 3) and/or allogeneic
models (Wilhelm et al., 2010, Fowler et al., 2014, Zhong et al., 2016, Klambt et al., 2015) of
this disease, although the role of P2Y2 in the former remains to be elucidated.
The current study demonstrates that CD39/CD73 blockade with APCP augments liver GVHD
in humanised mice. This finding is similar to the increased liver GVHD in CD73 deficient
mice compared to wild-type mice in allogenic GVHD (Tsukamoto et al., 2012, Wang et al.,
2013). The inability of AR blockade with caffeine to augment liver GVHD in humanised
mice supports the concept that extracellular ATP rather than adenosine contributes to liver
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GVHD in humanised mice. In support of this, ATP activation of P2X7 worsens liver GVHD
in an allogeneic mouse model (Wilhelm et al., 2010), and pharmacological blockade of P2X7
reduces liver GVHD in both allogeneic (Wilhelm et al., 2010, Zhong et al., 2016) and
humanised (Chapter 3) mouse models of this disease.
The current study also demonstrated the presence of serum hIL-2, hIL-6, hIL-10, hTNF-α and
hIFN-γ in humanised mice with GVHD, and implicates a pro-inflammatory role for hIL-2 in
GVHD development in this model. Consistent with this, administration of low dose IL-2 in
allogeneic and humanised mouse models of GVHD results in the activation of effector T cells
(Abraham et al., 2017, Pérol et al., 2014), which circumvent any potential clinical benefits
imparted by the expanded Treg cell population in these mice (Pérol et al., 2014). Notably, coadministration of IL-10 with IL-2 can limit the expansion of effector T cells and increase
survival in humanised mice with GVHD (Abraham et al., 2017). However in the current
study, hIL-10 concentrations where similar in APCP- and saline-injected mice suggesting that
any potential effects of hIL-10 on hIL-2 was the same between treatments. Finally, in the
current study, serum concentrations of hIL-2, hIL-6, hIL-10 and hTNF-α were in the pg/mL
range, which contrasted the 1000-fold greater amounts of serum hIFN-γ. Thus, this suggests
hIFN-γ may have a major role in disease development in this humanised mouse model of
GVHD. Consistent with this, P2X7 blockade in this model reduced histological GVHD,
which coincided with reduced concentrations of serum hIFN-γ (Chapter 3), but the impact of
P2X7 blockade on serum hIL-2 remains to be elucidated.
The current study demonstrated that APCP but not caffeine decreases human
CD39-CD73-CD4+, but not CD39-CD73-CD8+ T cells. The reduced frequency of human
CD39-CD73-CD4+ T cells due to APCP treatment may be due a compensatory mechanism
that involves upregulating CD39 and/or CD73 to increase ATP degradation and promote
adenosine generation. This is supported by the trend of increased frequencies of human
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CD39+CD73-CD4+ and CD39-CD73+CD4+ T cells following APCP treatment. However,
these increases were not statistically significant and there was no increased trend in human
CD39+CD73+CD4+ T cells in these mice. Thus, the reason for the reduced frequency of
human CD39-CD73-CD4+ T cells following APCP treatment requires further elucidation.
The current study confirms that NSG mice injected with hPBMCs engraft hCD4+ and hCD8+
T cells as well as Tregs, but shows for the first time that humanised NSG mice also engraft
human iNKT cells. This engraftment of human iNKT cells suggests that this model could be
used to study these cells in vivo and allow manipulation of these cell types to alter disease
outcomes. In allogeneic mouse models of GVHD, both host (Zeng et al., 1999) and donor
(Kim et al., 2007) iNKT cells can attenuate disease, whilst adoptive transfer of these cells can
prevent GVHD in such models (Schneidawind et al., 2015). The current study also
demonstrates that humanised NSG mice engraft human monocytes and DCs. Previous studies
have shown that NSG mice engraft human monocytes and DCs when injected with human
cord blood (Audigé et al., 2017), and engraft human monocytes when injected with hPBMCs
(Palamides et al., 2016, Jodeleit et al., 2017). Similarly, SCID mice injected with hPBMCs
engraft human DCs (Seldon et al., 2015), but the current study is the first to demonstrate DC
engraftment in NSG mice injected with hPBMCs. Human T cells recognise murine major
histocompatibility complex I and II molecules in NSG mice to cause GVHD (King et al.,
2009), but the identity of the APCs involved remains to be determined. However it is known
that both host and donor APCs are involved in GVHD development in allogeneic mouse
models of this disease (Shlomchik et al., 1999, Markey et al., 2009). The engraftment of
human monocytes and DCs in NSG mice suggests that human T cells may at least in part be
activated by human antigen presenting cells in this model.
Although these results demonstrate that AR blockade with caffeine has no impact on disease,
caffeine is a broad-spectrum adenosine receptor antagonist which may confound
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interpretation of its effects in the current study. Furthermore, caffeine is an antagonist of
phosphodiesterases (Choi et al., 1988) and γ-aminobutyric acid receptors (Nistri and Berti,
1984, Vigh and Lasater, 2003), and can promote calcium release from intracellular stores
(Nistri and Berti, 1984, Vigh and Lasater, 2003) further confounding interpretation of current
findings. Therefore, the future use of more selective AR antagonists such as SCH 52861,
which worsened GVHD in allogeneic mouse models (Lappas et al., 2010), is warranted in
humanised mouse models of GVHD to further explore a role for ARs in this model.
Alternatively, deletion of specific ARs (or CD39 or CD73) in NSG mice may provide further
insight into ATP and adenosine signalling pathways in the development of GVHD in
humanised mice. This was not performed in this study due to issues with dissolving SCH
58261, and the ethically unnecessary use of mice.
In conclusion, CD39/CD73 blockade with APCP, but not AR blockade with caffeine,
augmented GVHD in humanised mice. These results support the known roles of extracellular
ATP in promoting GVHD but do not support evidence that extracellular adenosine can limit
GVHD in this humanised model.
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6.2.

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative method for blood
cancers and other blood disorders, but is limited by the development of graft-versus-host
disease (GVHD). GVHD results in inflammatory damage to the host liver, gastrointestinal
tract and skin, resulting in high rates of morbidity and mortality in HSCT recipients.
Activation of the A2A receptor has been previously demonstrated to reduce disease in
allogeneic mouse models of GVHD using CGS 21680. This study aimed to investigate the
effect of A2A activation on disease development in a humanised mouse model of GVHD.
Immunodeficient non-obese diabetic-severe combined immunodeficiency-interleukin (IL)-2
receptor γnull (NSG) mice injected with human (h) peripheral blood mononuclear cells
(hPBMCs), were treated with either the A2A agonist CGS 21680 or vehicle control. Contrary
to the beneficial effect of A2A activation in allogeneic mouse models, CGS 21680 increased
weight loss, and failed to reduce the clinical score or increase survival in this humanised
mouse model of GVHD. Moreover, CGS 21680 reduced T regulatory cells and increased
serum human IL-6 concentrations. Conversely, CGS 21680 reduced serum human tumour
necrosis factor (TNF)-α concentrations and leukocyte infiltration into the liver, indicating that
A2A activation can, in part, reduce molecular and histological GVHD in this model. Notably,
CGS 21680 also prevented healthy weight gain in NSG mice not engrafted with hPBMCs
suggesting that this compound may be suppressing appetite or metabolism. Therefore, the
potential benefits of CGS 21680 in reducing GVHD in HSCT recipients may be limited and
confounded by adverse impacts on weight, decreased T regulatory cell frequency and
increased IL-6 production.

164

6.3.

Introduction

Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative method for
numerous haematological malignancies and other blood disorders; however, HSCT is limited
by the development of graft-versus-host disease (GVHD) (Jaglowski and Devine, 2014).
GVHD develops in up to 60% of HSCT recipients (Jagasia et al., 2012), due to donor T cells
recognising ‘foreign’ host cells (Billingham, 1965). GVHD begins when damage caused by
the conditioning regime or the underlying disease promotes the release of inflammatory
cytokines such as tumour necrosis factor (TNF)-α and interleukin (IL)-6. Subsequently,
activation of T cells by dendritic cells (DCs) results in the further release of TNF-α as well as
interferon (IFN)-γ, IL-2 and IL-6 to promote inflammation, and subsequent activation of
CD8+ T cells to exacerbate this inflammation. Conversely, T regulatory (Treg) cells and
invariant natural killer T (iNKT) cells can reduce pro-inflammatory effects in GVHD to limit
disease development or progression (Schneidawind et al., 2013).
Adenosine receptors (A1, A2A, A2B and A3) are cell-surface G-protein coupled receptors
activated by extracellular adenosine (Fredholm et al., 2011a). Extracellular adenosine is often
produced as a result of ATP hydrolysis mediated by the sequential action of ecto-nucleoside
triphosphate diphosphohydrolase-1 (CD39), and ecto-5’-nucleotidase (CD73) (Ferrero et al.,
2018, Apostolova and Zeiser, 2016a). The A2A receptor is expressed on numerous immune
cell subsets including DCs and T cells (Burnstock and Boeynaems, 2014). Notably,
CD39/CD73-mediated production of adenosine and subsequent activation of A2A is an
important anti-inflammatory mechanism (Deaglio et al., 2007). In allogeneic mouse models
of transplantation, adenosine production by the CD39/CD73 pathway and subsequent
activation of adenosine receptors prevents tissue damage and reduces graft rejection (Vergani
et al., 2014). In allogeneic mouse models of GVHD, genetic deficiency or pharmacological
blockade of CD73 with αβ-methylene ADP (APCP) (Tsukamoto et al., 2012), which results
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in reduced extracellular adenosine, worsens disease. Similarly, genetic deficiency
(Tsukamoto et al., 2012, Wang et al., 2013) or pharmacological blockade of A2A with
SCH58261 (Wang et al., 2013) also worsens GVHD severity in these models. Conversely,
activation of A2A with ATL-146e can ameliorate GVHD in allogeneic mouse models (Lappas
et al., 2010, Han et al., 2013). However, the action of A2A activation in humanised mouse
models or HSCT patients remains to be explored.
Allogeneic mouse models are often used to investigate potential therapeutics for GVHD, yet
therapies investigated in these models often do not translate to the clinic. This lack of
translation is possibly due to species differences. In an attempt to address this, preclinical
“humanised” mouse models have been developed (Shultz et al., 2007). A commonly used
humanised mouse model involves injection of human peripheral blood mononuclear cells
(hPBMCs) into immunodeficient non-obese diabetic severe-combined immunodeficiency-IL2 receptor γnull (NSG) mice. Due to defective T and B cells, and a lack of natural killer (NK)
cells, these mice readily engraft hPBMCs (King et al., 2008), and subsequently develop
GVHD due to the ability of human T cells to recognise the major histocompatibility complex
(MHC) I and II of NSG mice (King et al., 2009, Brehm et al., 2018). As such, humanised
NSG mice have been widely used as a model of GVHD (Pino et al., 2010, Hippen et al.,
2011, Ali et al., 2012, Bruck et al., 2013, Søndergaard et al., 2013, Abraham et al., 2015,
Gregoire-Gauthier et al., 2015, Hilger et al., 2016, Ehx et al., 2017).
Using the A2A agonist CGS 21680 (Klotz et al., 1998), this study aimed to investigate the
effect of A2A activation on GVHD development in a humanised mouse model. CGS 21680
did not impact clinical score or survival of mice. However, CGS 21680 reduced leukocyte
infiltration into livers, and reduced serum hTNF-α concentrations indicative of reduced
GVHD severity. Conversely, CGS 21680 worsened weight loss, reduced Treg cell frequency
and increased serum hIL-6 concentrations indicating worsened GVHD. Notably, CGS 21680
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also prevented weight gain in NSG mice not engrafted with hPBMCs. This suggests that
appetite or metabolism may be negatively impacted by CGS 21680. Therefore, the adverse
impact on weight, Treg cells and IL-6 caused by CGS 21680 may confound the potential
benefits of this agonist in reducing GVHD in HSCT recipients.

6.4.

Materials and Methods

6.4.1. Humanised Mouse Model of GVHD
Experiments involving human blood and mice were approved by the respective Human and
Animal Ethics Committees of the University of Wollongong (Wollongong, Australia). A
humanised mouse model of GVHD was used as described (Chapter 3). Briefly, female NSG
mice aged 6-8 weeks (Australian BioResources, Moss Vale, Australia) were injected
intraperitoneally (i.p.) daily (days -2 to day 11) with saline/0.2% DMSO (Sigma-Aldrich, St
Louis, MO, USA) (vehicle) or vehicle containing CGS 21680 (Tocris Bioscience, Bristol,
UK) (0.1 mg/kg). hPBMCs, isolated by density centrifugation using Ficoll-Paque PLUS (GE
Healthcare; Uppsala, Sweden) and resuspended in Dulbecco’s phosphate-buffer saline
(ThermoFisher, Waltham, MA, USA), were injected i.p. (day 0) (10 x 106 hPBMCs/mouse).
At

3

weeks

post-hPBMC

injection,

mice

were

checked

for

engraftment

by

immunophenotyping of tail vein blood. Mice were monitored for signs of GVHD using a
scoring system, giving a total clinical score out of 10, as described (Chapter 3). Mice were
euthanised at 10 weeks post-injection of hPBMCs, or earlier if exhibiting a clinical score of ≥
8 or a weight loss of ≥ 10%, according to the approved animal ethics protocol.
6.4.2. Immunophenotyping by Flow Cytometry
Tail vein blood (week 3) and spleen cells (end-point) were obtained from mice and lysed with
ammonium chloride potassium buffer and immunophenotyped as described (Chapter 3) using
the antibodies listed in Table 1. Data was collected using a BD Fortessa-X20 Flow Cytometer
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(using band pass filters 450/50 for BV421, 710/50 for BV711, 525/50 for FITC, 586/15 for
PE, 695/40 for PerCP-Cy5.5, 780/60 for PE-Cy7 and 670/30 for APCy). The relative
percentages of cells were analysed using FlowJo software v8.7.1 (TreeStar Inc.; Ashland,
OR, USA).
Table 6.1. Monoclonal antibodies used for flow cytometry.

Fluorochrome
BV711

Clone*
UCHT1

CD4

PerCP-Cy5.5

L200

CD8

FITC

RPA-T8

CD14

BV421

MϕP9

CD19

APCy

HIB19

CD25

PE

M-A251

CD39

APCy

TU66

CD45

FITC

HI30

CD45

PerCP-Cy5.5

30-F11

CD73

PE-Cy7

AD2

CD83

PE

HB15e

CD127

BV421

HIL-7R-M21

Vα24-Jα14 TCR

PE-Cy7

6B11

CD3

Target

*All antibodies were mouse anti-human except clone 30-F11 (rat anti-mouse); all antibodies were
from BD Biosciences except clone 6B11 (BioLegend). Abbreviations: APCy, allophycocyanin; BV,
brilliant violet; Cy, cyanin; FITC, fluorescein isothiocyanate; PE, phycoerythrin; PerCP, peridinin
chlorophyll protein; TCR, T cell receptor.

6.4.3. Histological Analysis
Formalin-fixed tissue sections (5 μm) were stained with haematoxylin and eosin (POCD;
Artarmon, Australia), and histology assessed, as described (Chapter 3).
6.4.4. Cytokine Analysis by a Flow Cytometric Multiplex Assay
Serum was obtained from mice at end-point as described (Chapter 3) and cytokine
concentrations were measured using a Th1 LEGENDPlex kit (BioLegend, San Diego, CA,
USA) as per the manufacturer’s instructions.
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6.4.5. Statistical Analysis
Data is given as mean ± standard error of the mean (SEM). Statistical differences were
calculated using Student’s t-test for single comparisons or one-way analysis of variance
(ANOVA) with Tukey’s post-hoc test for multiple comparisons. Weight and clinical score
were analysed using a repeated measures two-way ANOVA. Survival (median survival time;
MST) was compared using the log-rank (Mantel-Cox) test. Proportion of engraftment and
mortality were compared using Fisher’s exact test. All statistical analyses and graphs were
generated using GraphPad Prism 5 for PC (GraphPad Software, La Jolla, CA, USA). P < 0.05
was considered significant for all tests.

6.5.

Results

6.5.1. CGS 21680 Does Not Impact Initial hPBMC Engraftment in NSG Mice
NSG mice, injected with hPBMCs and either control vehicle (n = 25) or the A2A agonist CGS
21680 (Klotz et al., 1998) (n = 25) daily (days -2 to 11), were monitored (from day 0) for up
to 10 weeks. To determine whether CGS 21680 affected initial hPBMC engraftment, blood
was collected 3 weeks post-hPBMC injection and cells immunophenotyped by flow
cytometry. Three mice from each group did not demonstrate human leukocytes
(hCD45+mCD45-) in their blood at 3 weeks (results not shown). In the remaining mice,
human leukocytes were observed in the blood with frequency of these cells calculated as a
percentage of total leukocytes [hCD45+mCD45-/(hCD45+mCD45- + hCD45-mCD45+)]. CGS
21680- and vehicle-injected mice demonstrated similar frequencies of human leukocytes
(21.8 ± 2.8% and 22.8 ± 3.2%, respectively, P = 0.8221) (Fig 1a). The proportion of human
leukocyte engraftment was the same in CGS 21680- and vehicle-injected mice (both 90%, P
= 1.000). The majority of these human leukocytes were T cells (95.7 ± 0.8% and 97.3 ±
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0.6%, respectively, P = 0.1086) (Fig 1b). The remaining cells were non-B/T cells (3.8 ± 0.9
% and 3.4 ± 0.6%, respectively, P = 0.7502) (Fig 1c).
6.5.2. CGS 21680 Reduces Human Treg Cells in Humanised NSG Mice
To determine if CGS 21680 impacted hPBMC engraftment at end-point, splenocytes from
CGS 21680- (n = 20) and vehicle-injected mice (n = 20) were analysed by flow cytometry.
Human leukocytes were absent in the spleens of the same three mice from each group that
failed to show hPBMC engraftment at 3 weeks (results not shown). Frequencies of human
leukocytes in mice engrafted at three weeks were similar in CGS 21680- and vehicle-injected
mice (70.5 ± 3.2% and 65.1 ± 6.0%, respectively, P = 0.4348) at end-point (Figure 6.1.d.).
Similar to blood at 3 weeks post-hPBMC injection, the majority of engrafted human
leukocytes in both groups of mice were T cells, which did not differ between CGS 21680(93.4 ± 1.8%) and vehicle-injected mice (93.6 ± 1.5%) (P = 0.9546) (Figure 6.1.e.). Further
analysis of human T cells demonstrated that CGS 21680- and vehicle-injected mice
demonstrated similar engraftment of hCD4+ T cells (67.2 ± 3.0% and 58.3 ± 3.7%,
respectively, P = 0.0713) and hCD8+ T cells (18.0 ± 2.3% and 24.4 ± 3.3%, respectively, P =
0.1260). Both CGS 21680- and vehicle-injected mice demonstrated greater engraftment of
hCD4+ than hCD8+ cells (P < 0.0001 and P < 0.0001, respectively) (Figure 6.1.f.).
To investigate whether CGS 21680 effected CD39 and/or CD73 on human T cells, these
ecto-nucleotidases on hCD4+ and hCD8+ T cell subsets from the spleens of mice were
examined. CGS 21680-injected demonstrated a trend of increased hCD39+hCD73-hCD4+ T
cells compared to vehicle-injected mice (15.6 ± 3.0% and 9.1 ± 2.0%, respectively, P =
0.0796). Conversely, CGS 21680-injected mice demonstrated significantly reduced
frequencies of hCD39-hCD73+hCD4+ T cells (2.5 ± 0.7% and 8.9 ± 2.6, respectively, P =
0.0227), and a reduced trend of hCD39+hCD73+hCD4+ T cells (1.3 ± 0.3% and 3.1 ± 1.1%,
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respectively, P = 0.1137) compared to vehicle-injected mice. However, CGS 21680- and
vehicle-injected mice demonstrated similar frequencies of hCD39-hCD73-hCD4+ T cells
(80.6 ± 3.0% and 78.8 ± 4.1%, respectively, P = 0.7358) (Figure 6.1.g.). CGS 21680- and
vehicle-injected mice demonstrated similar frequencies of hCD39+hCD73-hCD8+ T cells
(40.6 ± 5.9% and 39.7 ± 5.0%, respectively, P = 0.9036), hCD39-hCD73+hCD8+ T cells (3.0
± 1.0% and 4.2 ± 1.2%, respectively, P = 0.4508), hCD39+hCD73+hCD8+ T cells (4.0 ± 1.1%
and 7.3 ± 2.2%, respectively, P = 0.1877) and hCD39-hCD73-hCD8+ T cells (52.3 ± 4.7%
and 51.4 ± 5.9%, respectively, P = 0.9137) (Figure 6.1.h.).
In allogeneic mouse models increased frequencies of iNKT and Treg cells correlates with
reduced GVHD (Schneidawind et al., 2013). Therefore, the frequency of human iNKT cells
(hCD45+hCD3+hCD19-hVα24-Jα18+)

and

human

Treg

cells

(hCD45+hCD3+hCD4+hCD25+hCD127lo) in spleens from mice were examined. CGS 21680injected mice, compared to vehicle-injected mice, demonstrated a reduced trend of iNKT
cells (2.7 ± 0.6% and 4.7 ± 1.1%, respectively, P = 0.1223) (Figure 6.1.i.) and significantly
reduced Treg cells (0.4 ± 0.1% and 0.9 ± 0.2%, respectively, P = 0.0130) (Figure 6.1.j.).
Our group has previously shown that at end-point the spleens of humanised mice do not
contain human B cells (Chapter 3). Similarly, in the current study the remaining human
leukocytes in the spleens of mice were negative for CD19 (results not shown). CGS 21680and vehicle-injected mice demonstrated small but similar frequencies of CD3-CD19- cells
present in both groups of mice (3.2 ± 0.8% and 4.7 ± 0.8%, respectively, P = 0.1783)
(Figure1k). To determine if human monocytes (hCD14+hCD83-) or DCs (hCD14-hCD83+)
were present, the remaining non-B/T cell population (hCD45+hCD3-hCD19-) was analysed.
CGS 21680- and vehicle-injected mice demonstrated similar but low frequencies of
monocytes (0.4 ± 0.2% and 0.6 ± 0.2%, respectively, P = 0.6127) (Figure1l) and DCs (0.2 ±
0.1%, and 0.7 ± 0.3%, respectively, P = 0.1160) (Figure1m).
171

172

◄ Figure 6.1. CGS 21680 reduces human T regulatory cells in humanised NSG mice.
(a - m) NSG mice were injected daily with either saline/0.2% DMSO (vehicle) or vehicle containing
CGS 21680 (0.1 mg/kg) (day -2 to day 11), and with 10 x 106 hPBMCs (day 0). The percentages of
human (h) leukocytes and subsets in (a-c) blood at 3 weeks post-hPBMC injection and (d-m) spleens
at end-point were determined by flow cytometry. (a, d) Human leukocytes (hCD45+mCD45-) are
expressed as a percentage of total mCD45+ and hCD45+ leukocytes. Three mice from each group did
not engraft hCD45+ leukocytes (not shown). (b, e) hCD3+hCD19- cells and (c, k) hCD3-hCD19- cells
are expressed as a percentage of total hCD45+ leukocytes. (f) hCD4+ and hCD8+ T cell subsets are
expressed as a percentage of total hCD3+ leukocytes. ** P < 0.005, *** P < 0.0001 compared to
hCD8+ T cells. (g-h) hCD39 and hCD73 expression was analysed on (g) hCD4+ and (h) hCD8+ T cell
subsets. * P < 0.05 compared to vehicle. (i) Invariant natural killer T (iNKT) cells
(hCD45+hCD3+hCD19-hVα24-Jα18+) are expressed as a percentage of hCD3+hCD19- T cells and (j) T
regulatory (Treg) cells (hCD45+hCD3+hCD4+hCD25+hCD127lo) are expressed as a percentage of
hCD3+ T cells. * P < 0.05 compared to vehicle. (l) Monocytes (hCD14+hCD83-) and (m) dendritic
cells (DCs) (hCD14-hCD83+) are expressed as a percentage of hCD45+hCD3-hCD19- cells. Data
represents group means ± SEM (vehicle n = 20-22, CGS 21680 n = 20-22); symbols represent
individual mice.

6.5.3. CGS 21680 Worsens Weight Loss in Humanised NSG Mice
To investigate whether CGS 21680 impacts GVHD, the above mice were monitored for
weight loss and other signs of GVHD for up to 10 weeks. One engrafted saline-injected
mouse died unexpectedly overnight from unknown causes and was excluded from the
following analyses. In those mice which had engrafted hPBMCs, CGS 21680-injected mice
(n = 22) demonstrated significantly greater weight loss over the 10 weeks than vehicleinjected mice (n = 21) (P = 0.0020) (Figure 6.2.a.). However, both CGS 21680- and vehicleinjected mice demonstrated signs of GVHD (classified as a score clinical score > 3) from 35
days onwards with similar scores (P = 0.8008) (Figure 6.2.b.), survival (MST; 41 days, and
43 days, respectively, P = 0.6730) and mortality rates (90% and 82%, respectively, P =
0.6640) (Figure 6.2.c.) over the 10 weeks.
6.5.4. CGS 21680 Prevents Healthy Weight Gain in NSG Mice Not Engrafted
with hPBMCs
As noted above, three NSG mice from each treatment group did not engraft hPBMCs.
Nevertheless, these mice were also monitored for weight loss and signs of GVHD for 10
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weeks as per the engrafted mice above. CGS 21680-injected mice gained significantly less
weight over the 10 weeks compared to vehicle-injected mice (P = 0.0029) (Figure 6.2.d.).
Both CGS 21680- and vehicle-injected mice demonstrated similar but minimal clinical signs
of GVHD over the 10 weeks (mean clinical scores of 0.4 ± 0.2 and 0.3 ± 0.2) (P = 0.4557)
(Figure 6.2.e.) consistent with the lack of hPBMC engraftment. Moreover, all CGS 21680and vehicle-injected mice not engrafted with hPBMCs survived the entire 10 weeks (Figure
6.2.f.).

Figure 6.2. CGS 21680 worsens weight loss in NSG and humanised NSG mice. (a - f) NSG mice
were injected daily with either saline/0.2% DMSO (vehicle) or vehicle containing CGS 21680 (0.1
mg/kg) (day -2 to day 11), and with 10 x 106 hPBMCs (day 0). NSG mice engrafted with hPBMCs
were monitored for (a) weight loss, (b) clinical score, and (c) survival over 10 weeks. Data represents
(a, b) group means ± SEM or (c) percent survival (vehicle n = 22, CGS 21680 n = 21). ** P < 0.005
compared to vehicle-injected mice. (d – f) Mice which were not engrafted with hCD45+ leukocytes at
3 weeks (blood) and at 10 weeks (spleen) (results not shown) were monitored for (d) weight loss, (e)
clinical score, and (f) survival. Data represents (d, e) group means ± SEM or (f) percent survival
(vehicle n = 3, CGS 21680 n = 3). ** P < 0.005 compared to vehicle-injected mice.

6.5.5. CGS 21680 Reduces Liver Infiltrates in Humanised NSG Mice
Tissues from mice which had engrafted hPBMCs (n = 20 per group) were examined by
histology. Livers from CGS 21680-injected mice demonstrated reduced leukocyte infiltration
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but similar structural damage compared to vehicle-injected mice (Figure 6.3.). CGS 21680injected mice demonstrated mildly reduced leukocyte infiltration into small intestine of
vehicle-injected mice, but there were no structural differences, with all mice demonstrating
minimal rounding of villi and crypt cell apoptosis (Figure 6.3.). CGS 21680- and vehicleinjected mice demonstrated similar skin histology, with all mice demonstrating leukocyte
infiltration and epidermal thickening (Figure 6.3.).

Figure 6.3. CGS 21680 reduces liver infiltrates in humanised NSG mice. NSG mice were injected
daily with either saline/0.2% DMSO (vehicle) or vehicle containing CGS 21680 (0.1 mg/kg) (day -2
to day 11), and with 10 x 106 hPBMCs (day 0). Tissue sections (liver, small intestine, and skin) from
hPBMC-engrafted mice were stained with haematoxylin and eosin. Images were captured by
microscopy with each image representative of twenty mice per group; bars represent 100 μm.

6.5.6. CGS 21680 Increases Serum hIL-6 but Reduces hTNF-α in Humanised
NSG Mice
The pro-inflammatory cytokine storm that preludes immune cell infiltration and
inflammatory damage of target organs is an important stage of GVHD pathogenesis (Ferrara
et al., 1999). Therefore, to determine if CGS 21680 impacts human cytokines, a multiplex
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assay was used to analyse concentrations of serum hIL-2, hIL-6, hIL-10, hTNF-α, and hIFN-γ
from CGS 21680-injected mice (n = 15) and vehicle-injected (n = 18).
Mean serum hIL-2 concentrations were 83% lower in CGS 21680-injected mice compared to
vehicle-injected mice but this was not significantly different (7.0 ± 1.2 pg/mL and 41.8 ±
28.1 pg/mL, respectively; P = 0.2379) (Fig 3a). CGS 21680-injected mice demonstrated a
significant four-fold increase in hIL-6 concentrations compared to vehicle-injected mice
(141.0 ± 79.3 pg/mL and 35.4 ± 27.8 pg/mL, respectively; P < 0.0001). There was an 89%
decrease in serum hIL-10 in CGS 21680-injected mice compared to vehicle-injected mice,
but this did not reach statistical significance (18.9 ± 4.8 pg/mL and 170.0 ± 93.1 pg/mL,
respectively; P = 0.0800) (Fig 4c). There was a significant 75% decrease in hTNF-α
concentrations in CGS 21680-injected mice compared to vehicle-injected mice (18.9 ± 4.8
pg/mL, and 77.0 ± 40.1 pg/mL, respectively; P = 0.0411) (Fig 4d). hIFN-γ concentrations in
both treatment groups exceeded the highest standard (>10,000 pg/mL) (data not shown) and
could not be compared.

Figure 6.4. CGS 21680 impacts serum cytokines in humanised NSG mice. (a - d) NSG mice were
injected daily with either saline/0.2% DMSO (vehicle) or vehicle containing CGS 21680 (0.1 mg/kg)
(day -2 to day 11), and with 10 x 106 hPBMCs (day 0). Concentrations of serum human (a) interleukin
(IL)-2, (b) IL-6, (c) IL-10, and (d) tumour necrosis factor (TNF)-α from hPBMC-engrafted mice were
analysed by a flow cytometric multiplex assay. Data represents group means ± SEM (vehicle n = 18,
CGS 21680 n = 15); * P < 0.05, *** P < 0.0001 compared to vehicle-injected mice.
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6.6.

Discussion

Previous studies have shown that the CD73/A2A pathway reduces disease severity in
allogeneic mouse models of GVHD (Tsukamoto et al., 2012, Wang et al., 2013, Lappas et
al., 2010, Han et al., 2013). However, the effect of A2A activation in humanised mouse
models or in HSCT patients has not been reported. Using a humanised NSG mouse model of
GVHD, the current study demonstrated that the A2A agonist CGS 21680 had opposing roles
in disease development. CGS 21680 did not affect clinical score or mortality in humanised
mice but reduced GVHD severity, as indicated by decreased leukocyte infiltration into the
liver and serum hTNF-α in these mice. Unexpectedly, CGS 21680 increased weight loss and
serum hIL-6, and reduced the frequency of Tregs, indicating that this A2A agonist worsens
these disease parameters in this humanised mouse model of GVHD.
CGS 21680 reduced leukocyte infiltration into the liver and serum hTNF-α indicating GVHD
is reduced, at least in part, in humanised mice. This indicates that A2A activation has
beneficial roles in this model. This finding parallels similar observations in allogeneic mouse
models of GVHD where the A2A agonist ATL-146e reduces histological damage, leukocyte
infiltration in livers and serum TNF-α (Lappas et al., 2010, Han et al., 2013). Conversely,
pharmacological blockade or genetic deficiency of CD73, which limits extracellular
adenosine (Bruns, 1980), worsens liver histology in allogeneic mouse models of GVHD
(Tsukamoto et al., 2012, Wang et al., 2013). Of note, in allogeneic and humanised mouse
models of GVHD, increased TNF-α levels correspond with disease severity (Kuroiwa et al.,
2001, Abraham et al., 2015) and blockade of this cytokine impairs GVHD in both of these
models (Hill et al., 1999, King et al., 2009). Thus, collectively these studies suggest a crucial
role for TNF-α in GVHD, and that activation of A2A can limit this in both allogeneic and
humanised mouse models of this disease.

177

Contrary to above, the current study suggests that CGS 21680 worsens aspects of GVHD in
humanised mice as evidenced through increased weight loss. This indicates that A2A
activation by this agonist also has adverse roles in this model. Weight loss is a common
indicator of disease severity in mouse models of GVHD (Naserian et al., 2018). The dose of
CGS 21680 (0.1 mg/kg) used in this study is sufficient to prevent disease in mouse models of
acute lung inflammation (Impellizzeri et al., 2011), pleurisy (da Rocha Lapa et al., 2012) and
collagen-induced arthritis (Mazzon et al.). These studies reported no effect of CGS 21680 on
weight, suggesting weight loss in CGS 21680-injected humanised mice is due in part to
worsened GVHD. Supporting this, serum IL-6 was also increased in humanised mice.
Although, hIL-6 has not been previously detected in the serum of humanised mice (GregoireGauthier et al., 2012, Abraham et al., 2015, Abraham et al., 2017), and its role in humanised
mouse models of GVHD remains to be elucidated, IL-6 is implicated in GVHD progression
in allogeneic mouse models (Koenecke et al., 2009, Tawara et al., 2011). In the current study,
the increased serum hIL-6 concentrations were unexpected, as previously ATL-146e reduced
serum IL-6 concentrations in allogeneic mouse models of GVHD (Lappas et al., 2010, Han et
al., 2013). Moreover, CGS 21680 reduces IL-6 release from ex vivo anti-CD3/anti-CD28stimulated murine effector T cells (Romio et al., 2011). Conversely, increased serum IL-6
concentrations correlate to disease severity as a result of A2A blockade in an allogeneic mouse
model of GVHD (Wang et al., 2013). The reason for increased serum hIL-6 concentrations in
CGS 21680-injected humanised mice remains unknown but supports the concept that A2A
activation with this agonist has adverse roles in this model.
In the current study, the frequency of Treg cells was also reduced in CGS 21680-injected
humanised mice. This further supports the concept that A2A activation with this agonist has
detrimental roles in humanised mice. Treg cells inversely correlate to GVHD progression in
allogeneic (Edinger et al., 2003) and humanised mouse models (Cao et al., 2009), as well as
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in HSCT recipients (Rieger et al., 2006, Fondi et al., 2009). The observed reduction in Treg
cells was contrary to expectations, as in allogeneic mouse models ATL-146e increases Treg
cells to ameliorate disease development (Lappas et al., 2010, Han et al., 2013). The
mechanism by which CGS 21680 decreases Treg cells in the current study remains to be
established. However, CGS 21680 reduced, albeit not significantly, serum hIL-2 and hIL-10
in humanised mice. These cytokines are important for maintenance of Treg cells in
humanised mice (Abraham et al., 2012, Abraham et al., 2017). Thus a decrease in one or both
of these cytokines may have contributed to the lower frequency of Treg cells in CGS 21680injected mice. Alternatively, although not mutually exclusive to the above, IL-6 with IL-1β
reduces Treg cell numbers through their conversion to Th1 and/or Th17 cells (Gu et al.,
2016b). Thus, the increased IL-6 in CGS 21680-injected mice may have contributed to the
reduction in Treg cells. However, it should be noted that the amount of hIL-1β mRNA
(Chapter 3) and serum hIL-1β (Abraham et al., 2017) in humanised mice is negligible,
thereby potentially limiting the ability of hIL-6 to convert Treg cells to Th cells in this model.
Concerning the above comparisons between CGS 21680 and ATL-146e in GVHD, it should
be noted that these compounds differ pharmacologically, which may explain their differing
effects in this disease. ATL-146e has two-fold greater affinity than CGS 21680 for human
A2A (Ki of 45 ± 15 nM and 82 ± 18 nM, respectively) (Sullivan et al., 2001) and a three-fold
greater affinity for murine A2A (4 ± 1.9 nM and 13 ± 3.5 nM, respectively) (Lappas et al.,
2005). Thus, these differences may be contributing to the varying effects of these two
compounds in GVHD progression. As discussed above, ATL-146e could not be used in
humanised NSG mice due to the lack of commercial availability.
The current study also demonstrated that CGS 21680 prevented healthy weight gain in NSG
mice not engrafted with hPBMCs. This suggests that this A2A agonist may be suppressing
appetite or metabolism in these mice, which may also be contributing to the increased weight
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loss in hPBMC-engrafted NSG mice in addition to GVHD. In rats, CGS 21680, at the same
dose used in the current study, is sufficient to prevent weight gain by reducing food intake
(Mingote et al., 2008, Micioni Di Bonaventura et al., 2012). Moreover, CGS 21680 at this
same dose increases energy expenditure in mice to prevent diet-induced obesity (Gnad et al.,
2014) and causes hypothermia (Carlin et al., 2018). The reasons for the different effects of
CGS 21680 on mouse weight in these and the current studies compared to those discussed
above (Impellizzeri et al., 2011, da Rocha Lapa et al., 2012, Mazzon et al., 2011) remains
unknown, but may reflect strain differences. CGS 21680-mediated effects on metabolism and
weight were observed in C57BL/6 mice (Gnad et al., 2014, Carlin et al., 2018) and NSG
mice (this study), whilst CGS 21680 was reported to have no such effects in CD1, Swiss and
DBA/1 mice (Impellizzeri et al., 2011, da Rocha Lapa et al., 2012, Mazzon et al., 2011).
Finally, it should be noted that IL-6 can potentially impact mouse body weight, as genetic
deficiency of IL-6 promotes obesity (Wallenius et al., 2002). Thus, the increased weight loss
observed in CGS 21680-injected humanised mice may be mediated via an IL-6-dependent
mechanism.
In summary, the A2A agonist CGS 21680 has opposing effects in a humanised mouse model
of GVHD. Moreover, CGS 21680 can prevent weight gain in healthy NSG mice. As
discussed above, CGS 21680 does not alter weight in all mouse strains, whilst adverse effects
on weight have not been reported for the A2A agonist ATL-146e. Therefore, the therapeutic
efficacy of A2A activation with certain agonists in HSCT recipients or a subset of these
patients may be limited by adverse effects on weight as well as decreased Treg cell frequency
and increased IL-6 production.
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7.2.

Abstract

Psoriasis is a chronic inflammatory skin disorder, characterised by epidermal hyperplasia
(acanthosis) and leukocyte infiltration of the skin. Current therapies are inadequate,
highlighting the need for new therapeutic targets. The P2X7 receptor is implicated in the
pathogenesis of psoriasis. This study investigated the role of P2X7 in imiquimod (IMQ)induced psoriasis-like inflammation. Topically-applied IMQ caused two-fold greater ear
swelling in BALB/c mice compared to C57BL/6 mice, which encode a partial loss-offunction missense mutation in the P2RX7 gene. However, there was no difference in
histological skin pathology (acanthosis and leukocyte infiltration) between the two strains.
IMQ treatment up-regulated P2X7 expression in skin from both mouse strains. Additionally,
IMQ induced ATP release from cultured human keratinocytes, a process independent of cell
death. Injection of the P2X7 antagonist Brilliant Blue G (BBG) but not A-804598 partly
reduced ear swelling compared to vehicle-injected control mice. Neither antagonist altered
skin pathology. Moreover, no difference in ear swelling or skin pathology was observed
between C57BL/6 and P2X7 knock-out (KO) mice. Flow cytometric analysis of IMQ-treated
skin from C57BL/6 and P2X7 KO mice demonstrated similar leukocyte infiltration, including
neutrophils, macrophages and T cells. In conclusion, this study demonstrates that P2X7 is not
essential for development of IMQ-induced psoriasis-like inflammation, but does not exclude
a role for this receptor in psoriasis development in humans or other mouse models of this
disease.

7.3. Introduction
Psoriasis affects 1-3% of the general population of Western countries, reducing quality of life
and posing a significant economic burden (Lebwohl et al., 2014). In the USA alone, psoriasis
is estimated to cost $112 billion per year (Brezinski et al., 2015). Inflammation and hyper184

proliferation of keratinocytes in psoriasis results in epidermal hyperplasia (acanthosis) and
plaque- or pustular-like skin lesions (Nestle et al., 2009b). This characteristic inflammation is
driven by infiltrating leukocytes, including neutrophils, macrophages and T cells (Nestle et
al., 2009a). These leukocytes exert their effects by release of pro-inflammatory cytokines
such as interferon gamma (IFN-γ) (Nestle et al., 2009a, Nestle et al., 2009b), which promotes
the hyper-proliferation of keratinocytes, with the resulting cell damage exacerbating
inflammation and leading to plaque formation (Nestle et al., 2009a).
The imiquimod (IMQ)-induced psoriasis-like inflammation mouse model is a valuable model
for studying psoriasis pathogenesis. This model involves application of AldaraTM cream,
containing IMQ, which causes epidermal hyperplasia and immune infiltration similar to
psoriasis in humans (van der Fits et al., 2009). IMQ treatment results in scaling and
thickening of skin as well as infiltration of immune cells 48-72 hours after first application
(van der Fits et al., 2009). This model has been well characterised (Flutter and Nestle, 2013)
and used in some 200 different studies to date (Hawkes et al., 2017).
The ATP-gated P2X7 receptor channel has been implicated in a number of skin diseases
including psoriasis (Geraghty et al., 2016). P2X7 is present on keratinocytes (Greig et al.,
2003) and immune cells important in psoriasis including neutrophils (Karmakar et al., 2016),
macrophages (De Torre-Minguela et al., 2016) and T cells (MacLeod et al., 2014), where its
activation can drive cytokine release and potentially promote inflammation (Geraghty et al.,
2016). Notably, IFN-γ can up-regulate the expression of P2X7 in primary keratinocytes
(Pastore et al., 2007) and P2X7 expression is increased in human psoriatic lesions (Pastore et
al., 2007, Killeen et al., 2013). A functional role for P2X7 in psoriasis has also been
suggested. Injection of the P2X7 agonist 3’-O-(4-benzoyl)benzoyl ATP into normal human
skin explants induces increased expression of cytokines and other molecules commonly
associated with psoriasis, including interleukin (IL)-1β, IL-6 and tumour necrosis factor alpha
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(TNF-α) (Killeen et al., 2013). Importantly, these responses could be prevented through
pharmacological blockade of P2X7 (Killeen et al., 2013). P2X7 activation of skin migrating
dendritic cells also promoted Th17 responses (Killeen et al., 2013), a T cell subtype known to
contribute to psoriasis pathogenesis (Zheng et al., 2007).
This study investigated the role of P2X7 in the pathogenesis of psoriasis using a murine
model of IMQ-induced psoriasis-like inflammation. Results indicate that P2X7 is upregulated in psoriatic skin in both BALB/c and C57BL/6 mice, which encode the wild-type
(P451) or partial loss-of function (451L) allele, respectively (Adriouch et al., 2002). IMQ
also induced ATP release from human keratinocytes. However, pharmacological blockade or
genetic deletion of P2X7 showed a limited role for P2X7 in this murine model of psoriasis.

7.4. Materials and Methods
7.4.1. Cells
Human HaCaT keratinocytes and murine J774 macrophages were obtained and cultured as
described (Farrell et al., 2010, Sluyter and Vine, 2016). Cell lines were checked for
Mycoplasma spp. infections every two months, using a MycoAlertTM Mycoplasma detection
kit (Lonza, Basal, Switzerland) as per the manufacturer’s instructions. Cells were routinely
negative for Mycoplasma spp.
7.4.2. Mice
Female and male mice (aged 6-10 weeks) were used in experiments conducted under protocol
AE14/10, which was approved by the University of Wollongong Animal Ethics Committee
(Wollongong, Australia). BALB/c and C57BL/6 mice were obtained from Australian
BioResources (Moss Vale, Australia). P2X7 knock-out (KO) mice (Solle et al., 2001)
backcrossed onto a C57BL/6 background (Tran et al., 2010), were maintained at the
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University of Wollongong and genotyped as described (Solle et al., 2001). All mice were
housed in open top cages and provided with food and water, ad libitum. All mice were
housed in a temperature-controlled environment with a 12 h light/12 h dark cycle.
7.4.3. Murine Model of IMQ-Induced Psoriasis-Like Inflammation
A total of 25 mg of AldaraTM cream (1.25 mg IMQ) (iNova Pharmaceuticals, Thornleigh,
Australia) was applied to both sides of one ear of each mouse and the contralateral ear
remained untreated (control) (days 0-5) as described (Riol-Blanco et al., 2014). Prior to
treatment mice were weighed and ear measurements were recorded using Interapid (Rolle,
Switzerland) spring-loaded calipers (days 0-6). In some experiments, Brilliant Blue G (BBG)
or A-804598 (both Sigma-Aldrich, St Louis, MO, USA) (final concentration 50 mg/kg in
mice), and their respective diluent controls (saline or dimethyl sulfoxide (DMSO),
respectively), were injected every second day (as indicated). Mice were sacrificed on day 6
and ears collected.
7.4.4. Histological Analysis
Ears from euthanised mice were incubated overnight in neutral buffered (10%) formalin
(Sigma-Aldrich). Fixed tissues were removed, embedded in paraffin, sectioned (5 μm) and
stained with haematoxylin and eosin (POCD, Artarmon, Australia). Histology was observed
using a Leica (Wetzlar, Germany) DM500 inverted light microscope, with images captured
and processed using Leica application suite software version 4.7. Acanthosis (epidermal
thickness) was measured using ImageJ software version 1.48 (National Institutes of Health,
Bethesda, MD, USA).
7.4.5. Isolation of RNA and cDNA Synthesis
Ears from euthanised mice were stored in RNAlater (Sigma-Aldrich) at -20°C until required.
RNA was isolated using the ISOLATE II RNA Mini Kit (Bioline, London, UK) as per the
manufacturer’s instructions. Briefly, tissue in lysis buffer containing 1% (v/v) β187

mercaptoethanol (Sigma-Aldrich) was homogenised (two 20 second cycles at 5500 rpm) in a
Bertin Technologies (Montigny-le-Bretonneux, France) Precellys 24 tissue homogeniser.
Isolated RNA was immediately converted to cDNA using the qScript cDNA Synthesis Kit
(Quanta Biosciences, Gaithersburg, MD, USA) as per the manufacturer’s instructions. cDNA
was checked by PCR amplification of the house keeping gene glyceraldehyde 3-phosphate
dehydrogenase (Invitrogen, Carlsbad, CA, USA) for 35 cycles at 95°C for 1 min, 55°C for 1
min and 72°C for 1 min and a holding temperature of 4°C. Purity and size of amplicons were
confirmed by a 2% agarose gel electrophoresis.
7.4.6. Quantitative Real-Time Polymerase Chain Reaction
qPCR reactions were performed using TaqMan Universal Master Mix II (Thermo Fisher
Scientific, Waltham, Massachusetts, USA) according to the manufacturer’s instructions with
primers for FAM-labelled GAPDH (Mm99999915_g1) and VIC-labelled P2RX7
(Mm01199503_m1) (Thermo Fisher Scientific). qPCR cycles consisted of an initial step of
50°C for 2 min, followed by 50°C for 10 min, and 40 cycles at 95°C for 15 s, and 60°C for 1
min. qPCR reactions were conducted in triplicate on a Roche Diagnostics (Indianapolis, IN,
USA) LightCycler 480 and analysis was conducted using LightCycler480 software version
1.5.1.
7.4.7. ATP Release Assay
ATP release assays were performed as described (Mizumoto et al., 2003). Briefly, HaCaT
keratinocytes were plated in 12-well plates (Greiner Bio-One, Frickenhausen, Germany) at a
concentration of 2 x 105 cells/well in RPMI 1640 medium containing 2 mM L-glutamine, 1%
non-essential amino acids (all Thermo Fisher Scientific), and 10% (v/v) heat-inactivated
foetal bovine serum (Bovogen Biologicals, Keller East, Australia), and incubated for 24 h at
37°C/5% CO2. Cells were washed thrice with PBS (Thermo Fisher Scientific), and incubated
in 1 mL PBS containing DMSO or 1 µg/mL IMQ (Sigma-Aldrich) in DMSO for 30 min at
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37°C/5% CO2. The final concentration of DMSO in both groups was 0.1%. Cells were then
centrifuged through 10% bovine serum albumin (4,000 x g for 3 min) and cell free
supernatants were stored in duplicate at -20°C until required. ATP concentrations in
supernatants were assessed using a Bioluminescence ATP Assay Kit (Sigma-Aldrich) as
described (Mansfield and Hughes, 2014). The amount of lactate dehydrogenase (LDH) in
supernatants was determined using a Cytotoxicity Detection Kit (LDH) (Roche Diagnostics)
as per the manufacturer’s instructions using a Molecular devices (Sunnyvale, CA, USA)
Spectramax Plus 384 plate reader.
7.4.8. ATP-Induced Ethidium+ Uptake Assay
P2X7 pore formation was quantified by measuring ATP-induced ethidium+ uptake as
described (Bartlett et al., 2013). Briefly, J774 cells in NaCl medium (145 mM NaCl, 5 mM
KCl, 5 mM glucose and 10 mM HEPES, pH 7.5) were pre-incubated in the absence or
presence of BBG or A-804598 (as indicated) for 15 min at 37°C. Cells were then incubated
with 25 μM ethidium bromide (Sigma-Aldrich) in the absence or presence of 1 mM ATP
(Sigma-Aldrich) for 10 min. Incubations were stopped by addition of ice-cold NaCl medium
containing 20 mM MgCl2 (MgCl2 medium) and cells were washed with NaCl medium (300 x
g for 3 min). Data was collected using a BD Biosciences (San Jose, CA, USA) LSRFortessa
X-20 flow cytometer (using band-pass filter 530/30 for ethidium+) and FACSDiva software
version 8.0. Mean fluorescence intensity (MFI) of ethidium+ uptake was analysed using
FlowJo software version 8.7.1. (TreeStar Inc., Ashland, OH, USA).
7.4.9. Immunophenotyping
CD16/32 Fc Block (clone 2-4G2), Brilliant Violet (BV)450-conjugated rat anti-mouse Ly-6G
(clone 1A8), peridinin chlorophyll protein (PerCP)-conjugated rat anti-mouse CD4 (clone
RM4.5), allophycocyanin (APCy)-conjugated rat anti-mouse CD45 (clone 30-F11) and Rphycoerythrin (PE)-Cy7 conjugated hamster anti-mouse CD3e (clone 145-2C11) were from
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BD Biosciences. PE-conjugated rat anti-mouse CD11b (clone M1/70) was from BioLegend
(San Diego, CA, USA).
Enzymatic digestion of ears was performed as described (Rana et al., 2008). Briefly, dorsal
and ventral sides of ears were separated and incubated in 20 mM EDTA (Sigma-Aldrich) in
Tris-buffered saline (pH 7.3) for 2 hours at 37°C. Epidermal and dermal layers were
mechanically separated, cut into smaller fragments using a scalpel and homogenised in RPMI
1640 medium containing 1 mg/mL collagenase IV and 15 U/mL DNase I (both SigmaAldrich), and 5% heat-inactivated foetal bovine serum at room temperature for 90 min with
agitation. Enzymatic digestion was stopped by addition of 100 mM EDTA and suspensions
filtered through 70 μm cell strainers (Falcon, Franklin, NJ, USA). Cells were centrifuged
(300 x g for 5 min), resuspended in PBS and counted manually using a Boeco (Hamburg,
Germany) Neubauer Improved Bright Line haemocytometer. Cells were incubated with
CD16/32 Fc Block for 10 min and then with fluorochrome-conjugated monoclonal antibodies
in the dark for 10 min. Cells were washed twice with PBS (300 x g for 3 min), resuspended in
PBS and data was collected using a LSRFortessa X-20 flow cytometer (using band pass
filters 450/50 for BV421, 695/40-A for PerCP, 575/25-A for PE, 780/60 for PE-Cy7 and
670/30 for APCy) and FACSDiva software. The relative percentage of cells was analysed
using FlowJo software.
7.4.10. Statistical Analysis
Data is given as mean ± standard error of the mean (SEM). Statistical differences were
calculated using Student’s t test for single comparisons or one-way analysis of variance
(ANOVA) with Tukeys post-hoc test for multiple comparisons. Weight and ear
measurements were analysed using a repeated measures two-way ANOVA. All statistical
analyses and graphs were generated using Prism 5 for Windows software (GraphPad
Software, La Jolla, CA, USA).
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7.5. Results
7.5.1. IMQ Treatment Induces Greater Ear Swelling in BALB/c Mice
Compared to C57BL/6 Mice
To investigate the role of P2X7 in psoriasis, IMQ-induced psoriasis-like inflammation was
first compared over 6 days in BALB/c and C57BL/6 mice. C57BL/6 mice encode a loss-offunction mutation (P451L) in the P2RX7 gene, while BALB/c mice are wild-type at this
allele (Adriouch et al., 2002). IMQ induced ear swelling in ears relative to control
(contralateral untreated) ears from day 3 in both strains (Figure 7.1.a.). However, IMQinduced ear swelling was greater in BALB/c mice compared to C57BL/6 mice over 6 days (P
< 0.0001) (Figure 1a). Histological analysis of IMQ-treated ears from BALB/c and C57BL/6
mice demonstrated acanthosis (epidermal thickening) and leukocyte infiltration compared to
control ears; however, there was no difference between strains (Figure 7.1.b.). Image analysis
of histological sections revealed that epidermal thickness was significantly greater in IMQtreated ears compared to control ears from both BALB/c mice (P < 0.0001) and C57BL/6
mice (P < 0.0001). However, IMQ-induced epidermal thickening did not significantly differ
between the two strains (Figure 7.1.c.).
7.5.2. P2X7 mRNA is Up-Regulated in IMQ-Induced Psoriatic Lesions and
IMQ Induces ATP Release From Keratinocytes
Next, P2X7 mRNA expression in IMQ-treated and control ears was analysed by qPCR. P2X7
was significantly up-regulated almost three-fold and two-fold in IMQ-treated ears compared
to control ears from BALB/c mice (P = 0.0002) and C57BL/6 mice (P = 0.0343),
respectively (Figure 7.2.a.). To further determine a potential role for P2X7 activation in IMQinduced psoriasis-like inflammation, HaCaT keratinocytes were incubated in the presence of
1 μg/mL IMQ or DMSO (vehicle control) for 30 min and the amount of ATP released
measured using a bioluminescence assay. IMQ induced significantly greater amounts of ATP
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Figure 7.1. IMQ treatment induces greater ear swelling in BALB/c mice compared to C57BL/6
mice. (a-b) AldaraTM cream (containing 5% IMQ) was applied to one ear of BALB/c and C57BL/6
mice from day 0 to 5. Contralateral ears were left untreated (control). (a) Ear swelling was measured
over 6 days. Data represents group means ± SEM (n = 14 per strain). *** P < 0.0001 compared to
C57BL/6. (b) Ears from mice at end-point were stained with haematoxylin and eosin, and viewed by
microscopy. Each image is representative of 14 mice per group. Bars represent 200 μm. (c) Epidermal
thickness was measured on histological images using ImageJ. Data represents group means ± SEM (n
= 14 mice per group); symbols represent individual ears; *** P < 0.0001 compared to corresponding
control.

release compared to DMSO (P = 0.0425) (Figure 7.2.b.). To examine if this ATP release was
due to cytotoxicity by IMQ, the relative amount of LDH in the above supernatants was
determined using a spectrophotometric assay. Although the absorbance in the IMQ cells was
reduced the absorbance values were not significantly different between IMQ and control
groups (Figure 7.2.c.).
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Figure 7.2. P2X7 is up-regulated in IMQ-treated skin and IMQ can induce ATP release from
keratinocytes. (a) P2X7 expression in untreated (control) and IMQ-treated ears from BALB/c and
C57BL/6 mice at end-point (Figure 1) was assessed by qPCR. Data represents group means ± SEM (n
= 5 mice per strain); symbols represent individual ears; * P < 0.05, *** P < 0.0001 compared to
corresponding control. (b and c) Human HaCaT keratinocytes were incubated in DMSO or 1 µg/mL
IMQ for 30 min and (b) ATP release assessed using a bioluminescence assay, and (c) LDH release
was assessed using a spectrophotometric assay. Data represents group means ± SEM (n = 9 from three
individual experiments); * P < 0.05 compared to DMSO.

7.5.3. BBG Does Not Prevent IMQ-Induced Psoriasis-Like Inflammation
To investigate the role of P2X7 in IMQ-induced psoriasis-like inflammation, the P2X7
antagonist BBG (Jiang et al., 2000) was used in this model. First, to confirm that BBG can
impair murine P2X7 activation, J774 macrophages, which express functional P2X7
(Coutinho-Silva et al., 2005), were pre-incubated in the absence or presence of 10 μM BBG
and ATP-induced cation dye uptake was measured by flow cytometry. BBG significantly
reduced ATP-induced ethidium+ uptake by 87% (P < 0.0001) (Figure 7.3.a.). To determine if
BBG could prevent the development of IMQ-induced psoriasis-like inflammation BALB/c
mice were treated with IMQ as above and injected with BBG or saline (vehicle control) every
second day (days 0, 2 and 4). IMQ induced ear swelling in mice from day 3 regardless of
treatment. However, IMQ-induced ear swelling was partially reduced (by 21%) in BBGinjected mice compared to saline-injected mice over 6 days (P = 0.0068) (Figure 7.3.b.).
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Histological analysis of IMQ-treated ears from BBG- and saline-injected mice demonstrated
epidermal thickening and leukocyte infiltration compared to control ears; but there were no
differences between BBG and saline treatments (Figure 7.3.c.). Image analysis of histological
sections revealed that epidermal thickness was greater in IMQ-treated ears compared to
control ears from BBG-injected mice (P < 0.0001) and saline-injected mice (P < 0.0001).
Epidermal thickness in IMQ-treated and control ears was similar between BBG and saline
treatments (Figure 7.3.d.).
7.5.4. A-804598 Does Not Prevent IMQ-Induced Psoriasis-Like Inflammation
To further examine the potential effects of P2X7 blockade on psoriasis-like inflammation, the
P2X7 antagonist A-804598 (Donnelly-Roberts et al., 2009b) was used. Similar to BBG, A804598 near-completely abrogated ATP-induced ethidium+ uptake in J774 macrophages (P <
0.0001) (Figure 7.4.a.). BALB/c mice were treated with IMQ as above and injected with A804598 or DMSO (vehicle control) every second day (days 0 and 2). IMQ induced ear
swelling in mice from day 3 regardless of treatment. A-804598- and DMSO-injected mice
demonstrated similar ear swelling (Figure 7.4.b.). Histological analysis of IMQ-treated ears
from A-804598-injected and DMSO-injected mice demonstrated epidermal thickening and
leukocyte infiltration compared to control ears with no difference between A-804598 and
control treatments (Figure 7.4.c.). Image analysis of histological sections revealed that
epidermal thickness was greater in IMQ-treated ears compared to control ears from A804598-injected mice (P < 0.0001) and DMSO-injected mice (P < 0.0001). Epidermal
thickness in IMQ-treated and control ears was also similar between A-804598 and control
treatments (Figure 7.4.d.).
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Figure 7.3. BBG does not prevent IMQ-induced psoriasis-like inflammation. (a) Murine J774
macrophages were incubated for 15 min at 37°C in the absence or presence of 10 μM BBG, and then
with 25 μM ethidium bromide in the absence or presence of 1 mM ATP for 10 min at 37°C. Assays
were stopped by addition of MgCl2 medium, and ethidium+ uptake was then assessed by flow
cytometry. Data represents group means ± SEM (n = 3); * P < 0.05, *** P < 0.0001 compared to
corresponding basal. (b-d) AldaraTM cream (containing 5% IMQ) was applied to one ear of BALB/c
mice from day 0 to 5. Contralateral ears were left untreated (control). Mice were injected i.p. with
BBG or saline (control) on days 0, 2, and 4. (b) Ear swelling was measured over 6 days. Data
represents group means ± SEM (n = 5 mice per treatment); ** P < 0.005 compared to BBG. (c) Ears
from mice at end-point were stained with haematoxylin and eosin, and viewed by microscopy. Each
image is representative of 5 mice per treatment. Bars represent 200 μm. (d) Epidermal thickness was
measured on histological images using ImageJ. Data represents group means ± SEM (n = 5 mice per
treatment); symbols represent individual ears; *** P < 0.0001 compared to corresponding control.
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Murine
Figure 7.4. A-804598 does not prevent IMQ-induced psoriasis-like inflammation. (a)
J774 macrophages were incubated for 15 min at 37°C in the absence or presence of 1 μM A-804598,
and then with 25 μM ethidium bromide in the absence or presence of 1 mM ATP for 10 min at 37°C.
Assays were stopped by addition of MgCl2 medium, and ethidium+ uptake was then assessed by flow
cytometry. Data represents group means ± SEM (n = 3); *** P < 0.0001 compared to corresponding
basal. (b-d) AldaraTM cream (containing 5% IMQ) was applied to one ear of BALB/c mice from day 0
to 5. Contralateral ears were left untreated (control). Mice were injected i.p. with A-804598 or DMSO
(control) on days 0 and 2. (b) Ear swelling was measured over 6 days. Data represents group means ±
SEM (n = 5 mice per treatment). (c) Ears from mice at end-point were stained with haematoxylin and
eosin, and viewed by microscopy. Each image is representative of 5 mice per treatment. Bars
represent 200 μm. (d) Epidermal thickness was measured on histological images using ImageJ. Data
represents group means ± SEM (n = 5 mice per treatment); symbols represent individual ears; *** P <
0.0001 compared to corresponding control.
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7.5.5. Genetic Deletion of P2X7 Does Not Prevent IMQ-Induced Psoriasis-Like
Inflammation
Finally, to determine if genetic deficiency of P2X7 could alter IMQ-induced psoriasis-like
inflammation, C57BL/6 and P2X7 KO mice were treated with IMQ as above. Both C57BL/6
and P2X7 KO mice demonstrated ear swelling in IMQ-treated ears from day 3, but this was
not significantly different between the two strains over 6 days (Figure 7.5.a.). Histological
analysis of IMQ-treated ears from C57BL/6 and P2X7 KO mice demonstrated epidermal
thickening and leukocyte infiltration compared to control ears, with no difference between
strains (Figure 7.5.b.). Image analysis of histology revealed that epidermal thickness was
significantly greater in IMQ-treated ears compared to control ears from C57BL/6 mice (P <
0.0001) and P2X7 KO mice (P < 0.0001). Epidermal thickness in IMQ-treated and control
ears was also similar between C57BL/6 and P2X7 KO mice (Figure 7.5.c.).
7.5.6. IMQ-Induced Leukocyte Infiltration is Similar in C57BL/6 and P2X7 KO
Mice
The data above indicates that P2X7 deficiency does not prevent IMQ-induced psoriasis-like
inflammation in mice. However, the possibility remained that P2X7 deficiency may have
altered the number of leukocyte subsets infiltrating the skin in this disease model. Therefore,
whole ear cell suspensions of IMQ-treated and control ears from C57BL/6 and P2X7 KO
mice were examined by flow cytometry. IMQ induced a significant increase in total skin
leukocytes in both C57BL/6 (P = 0.0002) and P2X7 KO (P = 0.0029) mice, but there was no
significant difference between strains (Figure 7.6.a.). Subset analysis also revealed IMQ
induced a significant increase in neutrophils and macrophages in both C57BL/6 (P = 0.0027
and P < 0.0001, respectively) and P2X7 KO (P = 0.0020 and P = 0.0046, respectively) mice,
but there was no significant difference between strains (Figure 7.6.b-c.). IMQ induced a
significant increase in T cells in C57BL/6 (P = 0.0006) but not P2X7 KO mice; yet there was
no significant difference between strains (Figure 7.6.d.).
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Figure 7.5. Genetic deletion of P2X7 does not prevent IMQ-induced psoriasis-like inflammation.
(a-c) AldaraTM cream (containing 5% IMQ) was applied to ears of C57BL/6 and P2X7 KO mice from
day 0 to 5. Contralateral ears were left untreated (control). (a) Ear swelling was measured over 6 days.
Data represents group means ± SEM (n = 10 mice per strain). (b) Ears from mice at end-point were
stained with haematoxylin and eosin, and viewed by microscopy. Each image is representative of 10
mice per group. Bars represent 200 μm. (c) Epidermal thickness was measured on histological images
using ImageJ. Data represents group means ± SEM (n = 10 mice per strain); symbols represent
individual ears; *** P < 0.0001 compared to corresponding control.
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Figure 7.6. IMQ-induced leukocyte infiltration is similar in C57BL/6 and P2X7 KO mice.
(a-d) Single whole ear cell suspensions of ears from untreated (control) and IMQ-treated C57BL/6
and P2X7 KO mice at end-point (Figure 5) were labelled with fluorochrome-conjugated mAb and
analysed by four-colour flow cytometry. Data represents total numbers of group means ± SEM for (a)
leukocytes (CD45+), (b) neutrophils (CD45+ Ly6G+ CD11b+) (c) macrophages (CD45+ Ly6GCD11b+), and (d) T cells (CD45+ CD3+) in each cell suspension (n = 5 mice per group); symbols
represent individual ears; ** P < 0.005, *** P < 0.0001 compared to respective control ears.
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7.6. Discussion
This study demonstrated that P2X7 is not essential for the development of IMQ-induced
psoriasis-like inflammation in mice. With the exception of a partial effect on ear swelling by
BBG, pharmacological blockade or genetic deletion of P2X7 did not impact development of
IMQ-induced psoriasis-like inflammation. The general lack of effect of either P2X7
antagonist was not due to the preparations of BBG or A-804598, as both compounds blocked
ATP-induced dye uptake into murine macrophages in this study. Moreover, both compounds
were used in vivo at concentrations known to inhibit murine P2X7 (Bartlett et al., 2014). In
regards to IMQ-induced ear swelling, BBG may be blocking alternate molecules, such as
P2X1 (Seyffert et al., 2004), P2X5 (Bo et al., 2003), the ATP channel pannexin-1 (Qiu and
Dahl, 2009) or a voltage-gated sodium channel (Jo and Bean, 2011).
Genetic deficiency of P2X7 did not impact leukocyte infiltration in IMQ-induced psoriasislike inflammation. In contrast, a previous study reported that P2X7 KO mice had reduced
neutrophil infiltration into skin in a croton oil model of irritant contact dermatitis (Da Silva et
al., 2013). However, in line with our current study, ear swelling was similar between wildtype and P2X7 KO mice in croton oil-induced irritant contact dermatitis (Weber et al., 2010,
Da Silva et al., 2013). Conversely, P2X7 KO mice are protected from allergic contact
dermatitis, which was also assessed by ear swelling measurements (Weber et al., 2010). This
previous study demonstrated that P2X7-mediated IL-1β release, which requires NLRP3
inflammasome activation (Di Virgilio, 2007), was essential for allergic contact dermatitis
(Weber et al., 2010). In contrast, activation of the NLRP3 inflammasome is not required for
IMQ-induced psoriasis-like inflammation (Rabeony et al., 2015). Thus, this provides a
possible explanation as to why P2X7 is not essential in this model of psoriasis. Collectively,
this indicates P2X7 plays differing roles in various inflammatory skin disorders, but given
previous findings (Pastore et al., 2007, Killeen et al., 2013) further investigation of P2X7 in
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human psoriasis and other mouse models of this disease is warranted. Moreover, it should be
noted that C-terminal truncated P2X7 variants are present at low amounts in C57BL/6 and
Pfizer P2X7 KO mice (Masin et al., 2012), the same strains used in the current study.
Although P2X7-induced pore formation is absent in splenic T and B cells (Pupovac et al.,
2015), epidermal Langerhans cells and keratinocytes (Tran et al., 2010) from these P2X7 KO
mice, a role for these escape P2X7 variants in IMQ-induced psoriasis-like inflammation in
P2X7 KO mice cannot be excluded. P2X7 KO strains in which escape variants have not been
reported, such as those from Lexicon Pharmaceuticals (Basso et al., 2009) or conditional
humanised P2X7 KO mice (Metzger et al., 2016), provide alternatives to assess the potential
role of P2X7 in psoriasis.
Ear swelling, but not histological acanthosis or inflammation, differed between BALB/c and
C57BL/6 mice. Thus, this difference in ear swelling most likely reflects differences in
oedema. Coincidentally, this difference in ear swelling corresponds to P2RX7 genotype
(P451L mutation), but P2X7 deficiency in mice on a C57BL/6 background does not alter ear
swelling compared to wild-type C57BL/6 mice. This suggests that the difference between
BALB/c and C57BL/6 mice is not due to reduced P2X7 activity as a result of the P451L
mutation in C57BL/6 mice. In this regard, whilst some have reported that the P451L mutation
results in a loss of P2X7 activity (Adriouch et al., 2002, Young et al., 2006), others have
observed no differences in the activity or pharmacological profiles between recombinant
BALB/c and C57BL/6 P2X7 (Donnelly-Roberts et al., 2009a). Moreover, it remains to be
established if P2X7 variants differ between BALB/c and C57BL/6 mice, and if P2X7 activity
differs between these two mouse strains in vivo. BALB/c and C57BL/6 mice have a diverse
lineage and display phenotypic and genetic differences (Simpson et al., 1997, Beck et al.,
2000). Thus, differences in IMQ-induced ear swelling between these strains could be due to
any number of genotypic or phenotypic differences. Notably, IL-22 expression is increased in
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IMQ-induced psoriasis-like inflammation in BALB/c, but not C57BL/6, mice (van der Fits et
al., 2009). Conversely, IL-6 is detected in C57BL/6 mice, but not BALB/c mice (van der Fits
et al., 2009). Thus, a role for these cytokines in oedema during psoriasis warrants further
investigation.
Analysis by qPCR revealed P2X7 mRNA expression was up-regulated in IMQ-treated skin in
both BALB/c and C57BL/6 mice. Although, it was not determined if P2X7 protein is
increased in these mice, P2X7 protein is increased in lesional skin from psoriasis patients
(Pastore et al., 2007, Killeen et al., 2013). Notably, P2X7 is up-regulated on human
keratinocytes by IFN-γ (Pastore et al., 2007), a cytokine implicated in psoriasis pathogenesis
(Johnson-Huang et al., 2012) including IMQ-induced psoriasis-like inflammation (van der
Fits et al., 2009). Therefore, P2X7 may be up-regulated on keratinocytes due to IFN-γ present
in IMQ-treated skin. Alternatively, since P2X7 is also found on various skin immune cells
(Geraghty et al., 2016), increased P2X7 expression in IMQ-treated ears may simply reflect
increased numbers of infiltrating leukocytes in IMQ-induced skin as observed in the current
study.
Finally, this study demonstrated that HaCaT keratinocytes can constitutively release ATP, as
previously observed (Burrell et al., 2005), and that this release could be increased by IMQ.
The IMQ-induced ATP release was not due to cytotoxicity, as IMQ did not significantly alter
LDH release. Although genetic deletion or pharmacological blockade of P2X7 did not impact
IMQ-induced psoriasis-like inflammation in this study, extracellular ATP may be involved in
the development of this disease through activation of purinergic receptors other than P2X7. In
particular, P2Y1, P2Y2 and P2Y6 have been implicated in psoriasis or other inflammatory
skin conditions (Burnstock et al., 2012). Conversely, ATP can be degraded to adenosine by
ecto-nucleotidases such as CD39, present on Langerhans cells in the skin (Mizumoto et al.,
2002), and CD73, present on dendritic cells (Airas and Jalkanen, 1996), to promote anti202

inflammatory effects through activation of adenosine receptors (Gessi et al., 2014).
Therefore, CD39 or CD73 may also play a role in the development of psoriasis-like
inflammation in this model.
In conclusion, pharmacological blockade and genetic deletion of P2X7 could not prevent
IMQ-induced psoriasis-like inflammation. However, given the potential roles of P2X7 in
human psoriasis (Pastore et al., 2007, Killeen et al., 2013) and other skin diseases (Geraghty
et al., 2016), a role for this receptor in human psoriasis or other mouse models of this disease
cannot be excluded.
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Chapter 8: General Discussion
8.1.

Introduction

The purinergic signalling system is important in immunity, with P2X, P2Y and adenosine
(P1) receptors found on a number of immune cell subtypes (Burnstock and Boeynaems,
2014). Extracellular adenosine triphosphate (ATP) can act as a danger associated molecular
pattern (DAMP), and exert pro-inflammatory effects through P2X7 activation (Adinolfi et al.,
2017). ATP is broken down by ecto-nucleoside triphosphate diphosphohydrolase-1 (CD39) to
adenosine diphosphate (ADP) and adenosine monophosphate (AMP), and subsequently by
ecto-5’-nucleotidase (CD73) to adenosine, which can activate adenosine receptors to exert
anti-inflammatory effects (Antonioli et al., 2013). Purinergic signalling has been studied in
transplantation, including hematopoietic stem cell transplantation (HSCT) (Section 1.8.1).
Moreover, this signalling pathway has been implicated in graft-versus-host disease (GVHD),
a common complication of allogeneic HSCT. In particular, allogeneic mouse models of
GVHD have implicated a pro-inflammatory role for the P2X7 receptor in this disease
(Wilhelm et al., 2010). Conversely, allogeneic mouse models of GVHD have supported an
anti-inflammatory role of the CD73/A2A receptor pathway in this disease (Lappas et al., 2010,
Tsukamoto et al., 2012, Han et al., 2013, Wang et al., 2013). However, prior to this thesis the
role of purinergic signalling had not been investigated in a humanised mouse model of
GVHD.

8.2.

Establishment and Characterisation of a Humanised Mouse Model of
GVHD

In GVHD, humanised mouse models are valuable preclinical models to investigate cell
signalling pathways and to identify potential therapeutics (Hogenes et al., 2014). The most
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commonly used model is the humanised non-obese diabetic (NOD)-severe combined
immunodeficient (SCID)-interleukin (IL)-2 receptor γ common chain null (IL-2Rγnull) (NSG)
mouse model, due to the superior engraftment of human leukocytes after injection of human
(h) peripheral blood mononuclear cells (PBMCs) (King et al., 2008). Thus, this model was
chosen to investigate the role of purinergic signalling in GVHD (Chapters 3-6). However,
prior to these studies, the humanised NSG mouse model of GVHD was established at the
University of Wollongong (Wollongong, Australia) (Chapter 2). This initial study (Chapter 2)
described the successful establishment of this model, with 77% of mice injected with
hPBMCs (10 out of 13) developing clinical GVHD. All mice engrafted human leukocytes
(hCD45+), with the majority of engrafted leukocytes identified as T cells (hCD3+), similar to
previous studies (King et al., 2009, Ali et al., 2012). Furthermore, histological evidence of
GVHD was similar to previous studies including leukocyte infiltration and inflammatory
damage of target organs (King et al., 2009). The current study (Chapter 2) also reported that
23% of mice injected with hPBMCs (3 out of 13) developed subclinical GVHD but did not
progress to clinical GVHD. This afforded the opportunity to compare differences between
humanised NSG mice with clinical or subclinical GVHD. Humanised NSG mice that develop
clinical GVHD demonstrate increased splenic hCD4+:hCD8+ T cell ratios compared to mice
with subclinical GVHD. This finding is consistent with human studies, where higher
CD4+:CD8+ T cell ratios indicate greater disease severity (Huttunen et al., 2015, Budde et al.,
2017). Serum hIFN-γ was also increased in humanised NSG mice with clinical GVHD
compared to those with subclinical GVHD. Whilst reduced hIFN-γ correlates with reduced
disease severity in allogeneic (Wilhelm et al., 2010) and humanised mouse models (GregoireGauthier et al., 2012), this thesis is the first to highlight this cytokine as a potential biomarker
in this humanised mouse model of GVHD.
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Although histology of saline-injected and humanised NSG mice has been compared
previously (King et al., 2009, Choi et al., 2011), this study (Chapter 2) also provided a
comparison of histology of GVHD target organs between healthy (saline-injected) NSG mice,
mice with subclinical GVHD and mice with clinical GVHD. Mice with subclinical GVHD
demonstrated some human cell infiltration into spleens, liver, small intestines and skin.
Conversely, histological damage and leukocyte infiltration were more evident in mice with
clinical GVHD, with greater leukocyte infiltration and inflammatory damage to target organs,
similar to previous studies (King et al., 2008). The lesser amount of damage in mice with
subclinical GVHD compared to clinical GVHD is similar to that observed in the liver (Vlad
et al., 2009, Abraham et al., 2015, Ehx et al., 2017, Burlion et al., 2017), and small intestine
(Vlad et al., 2009, Nakauchi et al., 2015) of humanised mice following various treatments to
prevent GVHD.
Although our initial study (Chapter 2) provided insight into the humanised NSG mouse
model of GVHD, further studies could investigate engraftment of human antigen presenting
cells (APCs), including subtype analysis. Murine APC activation of human T cells has been
demonstrated, as genetic deficiency of MHC I or II molecules delays GVHD development
(King et al., 2009), and deficiency of both prevents GVHD almost completely (Brehm et al.,
2018) in humanised mice. Further, murine β7.2 on APCs interaction with CD28 on human T
cells can provide co-stimulation for human T cell activation (Freeman et al., 1993). Yet, later
mouse models (Chapters 5 and 6) highlighted engraftment of a hCD45+ hCD3- hCD19hCD83+ population, which are likely dendritic cells (DCs), as CD83 is a marker of DCs
(Zhou and Tedder, 1995), which could potentially be activating human T cells to promote
GVHD in this humanised NSG mouse model. Therefore, whilst murine MHC activation is
likely activating T cells in humanised NSG mice in these studies, the possibility of engrafted
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human APCs resulting in T cell activation remains to be elucidated, potentially using the
MHC I and II deficient NSG mouse model.
Future studies could also further explore leukocyte infiltration into target organs. Neutrophils
are recruited into the intestines early during GVHD (Hülsdünker et al., 2018) and are
important in disease pathogenesis in HSCT patients with GVHD (Schwab et al., 2014).
Whilst human T cells are the predominant human cell type responsible for mediating damage
in the humanised NSG mouse model used throughout this thesis, one study (Chapter 4)
highlighted that T cells were present in target organs but did not constitute all immune
infiltrates. The origin (human or murine) of neutrophils could also be explored, since NOD
mice, the background strain of NSG mice, demonstrate increased numbers of murine
neutrophils into target organs (Shultz et al., 1995), and it is unknown whether human
neutrophils will engraft after injection of hPBMCs.
Nevertheless, this thesis has demonstrated that the humanised NSG mouse model of GVHD
is reproducible, having been performed multiple times, with five different human donors.
Clinical and histological evidence (characterised in Chapter 2 and demonstrated in Chapters
3-6) highlights the efficacy of this humanised mouse model as a useful preclinical model of
GVHD.

8.3.

The Role of Purinergic Signalling in a Humanised Mouse Model of
GVHD

These studies (Chapters 3 and 4) investigated the previously unexplored role of P2X7 in a
humanised NSG mouse model of GVHD. In allogeneic mouse models of GVHD, ATP
released from damaged and dying cells accumulates at sites of damage (Wilhelm et al., 2010)
and P2X7 blockade using the antagonists pyridoxalphosphate-6-azophenyl-2',4'-disulfonic
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acid (PPADS), KN-62 (Wilhelm et al., 2010), stavudine (Fowler et al., 2014), and BBG
(Zhong et al., 2016) can reduce disease severity. The first of these studies (Chapter 3)
demonstrated that a short-term regime of BBG was able to reduce serum hIFN-γ and
histological GVHD in humanised mice, paralleling features of mice with subclinical GVHD
(Chapter 2). Moreover, this reduction in serum hIFN-γ and histological GVHD parallels
studies of P2X7 blockade or deficiency in allogeneic mouse models of GVHD (Wilhelm et
al., 2010). However, the short-term BBG regime did not impact clinical GVHD (Chapter 3),
suggesting that other mechanisms are involved in subclinical GVHD (Chapter 2) and in the
increased survival observed in allogeneic GVHD following P2X7 blockade or deficiency
(Wilhelm et al., 2010).
In contrast to the short-term BBG regimen (Chapter 3), a long-term regimen of BBG
(Chapter 4) only showed reduced leukocyte infiltration and histological damage in the liver
of humanised mice, and did not reduce serum IFN- γ. The greater reduction in serum hIFN-γ
concentrations and reduced histological damage, using the short-term BBG regimen,
compared to the long-term regimen may indicate the importance of P2X7 early in GVHD
induction, indicating more frequent P2X7 blockade early post-transplantation (days 0, 2, 4, 6,
8) may be more important than prolonged P2X7 blockade (3 times weekly). Alternatively,
comparison of humanised mice following short-term or long-term treatment regimens with
either BBG or saline suggest that long-term treatment with saline in humanised NSG mice
reduces serum hIFN-γ concentrations and negating any benefits of long-term BBG. This is
supported by the injection of saline as a means to rescue mice from weight loss in other
inflammatory disease models (van der Fits et al., 2009).
Potential limitations in these studies include the use of BBG as the P2X7 antagonist. BBG
was chosen as it is cheap, and has shown efficacy in over 40 studies of disease (Bartlett et al.,
2014). However, BBG has a relatively high half maximal inhibitory concentration (IC50)
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(Jiang, 2012), and has off-target effects (Qiu and Dahl, 2009). Thus, other more potent,
selective P2X7 antagonists, including A804598 (Chapter 7), could be used in future studies in
the humanised NSG mouse model of GVHD. Otherwise, the use of PPADS or KN-62, the
drugs shown to be efficacious in allogeneic mouse models of GVHD (Wilhelm et al., 2010)
could be used to further investigate the role of P2X7, and the therapeutic potential of P2X7
blockade to prevent disease in a humanised mouse model of GVHD. Alternatively, biologics
such as nanobodies could be tested in this model. Nanobodies against P2X7 can limit the
inflammation associated with experimental glomerulonephritis and allergic contact dermatitis
(Danquah et al., 2016) and thus represent a potential therapy for GVHD prevention.
Further, this thesis aimed to explore the role of the CD73/A2A signalling axis on the
development of GVHD in humanised NSG mice. However, during the course of this thesis
Covarrubias et al. (2016) revealed that the purported CD73 inhibitor αβ-methylene ADP
(APCP), could also inhibit CD39. Thus, data using APCP (Chapter 5) could not be solely
attributed to the prevention of adenosine production but also to the accumulation of ATP.
Administration of APCP or the broad-spectrum adenosine receptor antagonist caffeine
(Chapter 5) were hypothesised to worsen GVHD in humanised NSG mice based on previous
studies in allogeneic mouse models of GVHD (Tsukamoto et al., 2012, Wang et al., 2013). In
contrast to this hypothesis, APCP, but not caffeine, worsened GVHD in humanised NSG
mice. APCP worsened disease through increased weight loss, liver GVHD and serum hIL-2
concentrations. Collectively, this suggests that accumulation of ATP rather than adenosine
receptor blockade worsened GVHD in humanised NSG mice. Given that P2X7 is involved, in
part, in GVHD development in these mice (Chapters 3 and 4), the accumulation of ATP, as a
result of CD39 blockade by APCP, may be acting on P2X7 to promote GVHD in this model.
However, serum hIFN-γ concentrations from APCP-injected mice exceeded the scale using
the flow cytometric cytokine assay whilst subsequent analysis of this cytokine using an
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ELISA failed to detect any hIFN-γ, possibly due to freeze-thawing samples. Thus, this serum
cytokine could not be compared between BBG- and APCP-injected humanised NSG mice.
The inability of caffeine to alter GVHD in humanised NSG mice contrasts the worsening
effect of this compound in allogeneic mouse models of GVHD (Tsukamoto et al., 2012).
Notably, the same caffeine regime was used in these two studies suggesting that the observed
differences in GVHD progression relates to differences between the two models, and that the
CD73/A2A pathway may have a minor role in the humanised NSG mouse model of GVHD.
This may be attributed to species selective differences of caffeine on murine and human A2A
or other adenosine receptors and other targets (Fredholm et al., 2011a). However, due to
problems dissolving the more selective A2A antagonist SCH 52861 (Varani et al., 1996) and
that caffeine did not offer observable effects, A2A blockade was not explored further in
humanised NSG mice. Given the role of A2A in allogeneic GVHD (Lappas et al., 2010,
Tsukamoto et al., 2012, Han et al., 2013, Wang et al., 2013) investigation with other A2A
antagonists or agonists in humanised NSG mice remains warranted.
The A2A agonist CGS 21680 was hypothesised to reduce GVHD progression in humanised
NSG mice based on previous studies where another A2A agonist, ATL-146e, reduced disease
severity and mortality in allogeneic mouse models of GVHD (Lappas et al., 2010, Han et al.,
2013). This study (Chapter 6) demonstrated that activation of A2A with CGS 21680 had both
positive and negative effects on disease progression in humanised NSG mice. This was
unlikely due to the effectiveness of CGS 21680, as the same dose (0.1 mg/kg) has been
efficacious in preventing disease in mouse models of acute lung inflammation (Impellizzeri et
al., 2011), pleurisy (da Rocha Lapa et al., 2012) and arthritis (Mazzon et al., 2011). In the
allogeneic mouse models of GVHD, the anti-inflammatory effects of adenosine receptor
activation was shown to rely on the production of adenosine by regulatory T (Treg) cells
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(Han et al., 2013). Human (h) Treg cells were shown to be present in humanised NSG mice
(Chapters 5 and 6), but may not be present in sufficient numbers in this model to drive
adenosine production to protect GVHD target organs. Abraham et al. (2012) demonstrated
that functional hTreg cells can only be maintained in humanised NSG mice by providing
hIL-2. Thus, the lack of functional hTreg cells in humanised NSG mice may explain why
CGS 21680 did not have a significant impact on GVHD development. Although CGS 21680
had confounding effects, and caused weight loss in healthy NSG mice, it is worthwhile
investigating the effect of ATL-146e in this humanised mouse model of GVHD, due to the
beneficial effects of ATL-146e, and its analogues ATL-370 and ATL-1223, in allogeneic
mouse models of GVHD (Lappas et al., 2010, Han et al., 2013). These drugs could not be
investigated in the current study, as ATL-146e is currently being investigated in clinical trials
(Gao and Jacobson, 2011), and all three are no longer commercially available.
In summary, the above studies support a role for extracellular ATP and P2X7 activation in
GVHD progression in humanised NSG mice, whilst A2A activation has both beneficial and
detrimental effects on disease progression in this model. Short-term P2X7 blockade with
BBG (Chapter 3) led to reduced serum hIFN-γ concentrations, and reduced histological
damage in all organs, while a long-term regime (Chapter 4) reduced leukocyte infiltration and
damage to a greater extent. Conversely, CD39/CD73 blockade using APCP (Chapter 5) led to
increased leukocyte infiltration and histological damage, and an increase in the
pro-inflammatory cytokine hIL-2. However, A2A activation had conflicting results (Chapter
6). Therefore, theoretically in this humanised mouse model of GVHD the release and
accumulation of ATP leads to activation of P2X7, potentially on APCs such as DCs. This
leads to T cell activation and proliferation, and release of pro-inflammatory cytokines such as
IFN-γ and IL-2. T cells then migrate to target tissues, predominantly the liver, to promote
inflammation (Figure 8.1.).
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Figure 8.1. The potential role of purinergic signalling in the humanised NSG mouse model of
GVHD. 1. Early after transplantation of hPBMCs, ATP is released, and accumulation of ATP leads to
P2X7 activation on APCs, such as DCs. 2. APCs subsequently activate Th1 cells which release IL-2
and IFN-γ. 3. These cytokines propagate damage, potentially resulting in further ATP release and
P2X7 activation on APCs (1.), resulting in a feed-forward loop of inflammation. A2A activation cannot
prevent GVHD development in humanised NSG mice (not shown). 4. Degradation of ATP to ADP,
AMP and subsequently adenosine can potentially reduce GVHD. Abbreviations; ADP, adenosine
diphosphate, AMP, adenosine monophosphate, APC, antigen presenting cell, APCP, αβ-methyleneADP, ATP, adenosine triphosphate, DC, dendritic cell, IFN-γ, interferon gamma, IL-2, interleukin-2,
Th, T helper, Treg, regulatory T cell.

8.4.

The Role of P2X7 in a Psoriasis-Like Inflammatory Mouse Model of
Inflammation

A preliminary study was undertaken to assess the role of P2X7 in psoriasis (Chapter 7), as an
alternate inflammatory disease to GVHD. This involved the establishment of the imiquimod
(IMQ)-induced psoriasis-like inflammation model (van der Fits et al., 2009) at the University
of Wollongong. The landmark study by van der Fits et al. (2009) demonstrated IMQ induces
redness, scaling and thickening of skin due to altered differentiation and the
hyperproliferation of keratinocytes, as well as immune infiltrates consisting of neutrophils, T
cells and professional APCs resulting in psoriatic-like lesions. Our study confirmed that
BALB/c mice develop greater psoriasis (ear swelling and inflammation) compared to
C57BL/6 mice as previously described (van der Fits et al., 2009). IMQ also induced ATP
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release from keratinocytes in vitro and up-regulated P2X7 expression in the skin of these
mice. Nevertheless, pharmacological blockade of P2X7 with the antagonists BBG or
A804598 or P2X7 deficiency failed to alter disease progression in this model. During the
course of this PhD a study by Diaz-Perez et al. (2018) confirmed that P2X7 does not impact
IMQ-induced

psoriasis-like

inflammation.

Thus,

the

IMQ-induced

psoriasis-like

inflammation model was not explored further, with time and resources directed to exploring
the role of purinergic signalling in GVHD. Moreover, it was never intended to use the IMQinduced psoriasis-like inflammation mouse model of psoriasis to investigate the role of
adenosine receptor signalling as it is well known that IMQ can interact as an antagonist of
adenosine receptors (Schön et al., 2006).
Notably, Diaz-Perez et al. (2018) demonstrated a role for P2X7 in recombinant IL-23 (rIL23) induced psoriasis-like inflammation, a finding consistent with the up-regulation of P2X7
in human psoriatic skin (Pastore et al., 2007, Killeen et al., 2013). To reconcile these
differences in the role for P2X7 in IMQ- and recombinant IL-23-induced psoriasis-like
inflammation, Diaz-Perez et al. (2018) propose that IMQ bypasses the need to activate the
NLRP3 inflammasome/IL-1β to directly induce IL-17 production, which is a key cytokine in
psoriasis (Rizzo et al., 2011). This proposal was based on prior studies (Rabeony et al., 2015)
in which IMQ-induced psoriasis was found to be independent of the NLRP3 inflammasome.
Thus, although further studies of P2X7 in psoriasis were not continued in this model, future
studies could potentially utilise the recombinant IL-23 induced psoriasis-like inflammation
model to explore the role of P2X7 in this disease.
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8.5.

Conclusion

This thesis demonstrated that the purinergic signalling system plays a role in the development
of disease in a humanised mouse model of GVHD. Increased serum hIFN-γ was identified as
a marker of worsened disease severity in humanised mice. Similar to allogeneic mouse
models, short-term P2X7 blockade with BBG reduced GVHD severity through decreased
serum hIFN-γ and reduced histological damage, and long-term P2X7 blockade with BBG
reduced liver GVHD compared to control mice. Additionally, CD39/CD73 blockade using
APCP worsened GVHD in humanised mice, paralleling results in allogeneic mouse models.
However, in contrast to allogeneic mouse models, adenosine receptor blockade using the
broad spectrum antagonist caffeine did not worsen GVHD severity in humanised mice.
Further, adenosine receptor activation with the specific agonist CGS 21680 did not prevent
GVHD, but instead exaggerated both positive and negative aspects of GVHD. This suggests
that extracellular ATP and P2X7 activation is the main purinergic signalling pathway
involved in disease pathogenesis in a humanised mouse model of GVHD.
P2X7 was also investigated in the IMQ-induced psoriasis-like inflammation mouse model of
GVHD, where genetic deficiency or pharmacological blockade did not impact disease
development in this model. However, the role of this purinergic signalling pathway in
psoriasis cannot be excluded based on this one model, as it has been shown to be important in
other models of this disease.
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Figure S3.1. Flow cytometric gating of leukocytes in blood from humanized mice.
Blood cells from humanized mice were labelled with isotype control or CD-specific monoclonal
antibodies (mAb). Forward and side scatter was used to identify leukocytes, which were subsequently
used to identify human leukocytes (hCD45+ mCD45-), human T cells (hCD45+ mCD45- hCD3+
hCD19-) and human B cells (hCD45+ mCD45- hCD3- hCD19+).
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Figure S3.2. Flow cytometric gating of leukocytes in spleens from humanised mice.
Splenocytes from humanised mice were labelled with isotype control or CD-specific monoclonal
antibodies (mAb). Forward and side scatter was used to identify leukocytes, which were subsequently
used to identify human leukocytes (hCD45+ mCD45-), human T cells (hCD45+ mCD45- hCD3+
hCD19-) and human B cells (hCD45+ mCD45- hCD3- hCD19+). Forward and side scatter was used to
identify leukocytes, which were subsequently used to identify human CD4+ T cell (hCD3+ hCD4+
hCD8-), and human hCD8+ T cell (hCD3+ hCD4- hCD8+) subsets.
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Figure S3.3. Flow cytometric analysis of YO-PRO-12+ uptake into human hCD3+ T cells and
murine CD11c+ splenic dendritic cells. Human PBMCs and splenocytes from NOD-SCID-IL2Rγnull
mice were incubated with YO-PRO-12+ in the absence (basal) (grey histograms) or presence of
adenosine triphosphate (ATP) (black histograms), and subsequently labelled with anti-human (h) CD3
or anti-murine (m) CD11c monoclonal antibody. Forward and side scatter was used to identify
leukocytes, which were subsequently used to identify hCD3+ T cells or murine CD11c+ splenic DCs.
YO-PRO-12+ uptake into these cells was then quantified using geometric mean fluorescence of
histograms.
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Figure S3.4. Flow cytometric analysis of intracellular human IFN-γ and IL-17 in human CD4+
and CD8+ T cells. Splenocytes from humanised mice were incubated with phorbol 12-myristate 13acetate and ionomycin, and labelled with isotype control or specific monoclonal antibodies. Forward
and side scatter was used to identify leukocytes, which were subsequently used to identify human
CD4+ T cell (hCD3+ hCD4+ hCD8-), and human hCD8+ T cell (hCD3+ hCD4- hCD8+) subsets. The
percentage of hIFN-γ and hIL-17 was quantified as the difference between cytokine specific (black
histograms) and isotype control (grey histograms) mAb labelling (indicated by marker regions as
shown).
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Figure S4.1. Flow cytometric gating of leukocytes in blood and spleens from humanised mice
. (a-b) NOD-SCID-IL2Rγnull (NSG) mice were injected intra-peritoneally with 10 x 106 human (h)
peripheral blood mononuclear cells, and subsequently with saline or saline containing Brilliant Blue G
(BBG) (50 mg/kg) thrice weekly. (a) Blood cells and (b) splenocytes from humanised NSG mice were
labelled with isotype control or CD-specific monoclonal antibodies. (a, b) Leukocytes, initially gated
by forward scatter (FSC-A) and side scatter (SSC-A), were analysed to determine the percentages of
human leukocytes (hCD45+ mCD45-), human T cells (hCD45+ mCD45- hCD3+ hCD56-), human
NK cells (hCD45+ mCD45- hCD3- hCD56+), human NKT cells (hCD45+ mCD45- hCD3+
hCD56+), human non-T/NK/NKT cells (hCD45+ mCD45- hCD3- hCD56-), and (spleen only) human
CD4+ T cell (hCD3+ hCD4+ hCD8-), and human hCD8+ T cell (hCD3+ hCD4- hCD8+) subsets.
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Figure S4.2. Long-term BBG treatment does not affect intestinal or skin damage in a humanised
mouse model of GVHD. (a-b) NOD-SCID-IL2Rγnull (NSG) mice were injected intra-peritoneally
(i.p.) with 10 x 106 human (h) peripheral blood mononuclear cells (hPBMCs), and subsequently with
saline or saline containing Brilliant Blue G (BBG) (50 mg/kg) thrice weekly. (a) Small intestines and
(b) skin from hPBMC-injected mice injected with saline or BBG at end-point were stained with
haematoxylin and eosin. Images were captured by microscopy; representative images from one mouse
of seven saline- or 10 BBG-injected mice. (b) Image analysis was used to quantitate the mean
epidermal thickness from three different skin images per mouse. Data represents group means ± SD
(saline n = 6; BBG n = 7; P = 0.2174); symbols represent individual mice.

Figure S5.1. Flow cytometric gating of leukocytes in blood from humanised mice.
The percentage of human leukocytes in blood at 3 weeks post-hPBMC injection collected from all
humanised NSG mice were determined by flow cytometry. Forward scatter area (FSC-A) and forward
scatter height (FSC-H) were used to identify single cells (far left panel). Forward scatter (FSC-A) and
side scatter (SSC-A) (middle left panel) were used to identify and subsequently analyse the
percentages of human leukocytes (hCD45+mCD45-; middle right panel), which comprised T and nonB/T
cells
(hCD3+hCD19and
hCD3-hCD19respectively;
far
right
panel).
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Figure S5.2. Flow cytometric gating of leukocytes in spleens from humanised mice.
(a-b) The percentage of human leukocytes in spleens at end-point collected from all humanised NSG
mice were determined by flow cytometry. (a) Forward scatter (FSC-A, FSC-H) and side scatter (SSCA) were used to identify and subsequently analyse single leukocytes (top left and middle panels).
These leukocytes were analysed to determine the percentages of human leukocytes (hCD45+mCD45-;
top right panel), and subsequently used to identify T cells (hCD3+hCD19-; bottom left panel) and
iNKT cells (hCD3+hCD19-hVα24-Jα18+; bottom middle panel), or non-B/T cells (hCD3-hCD19-;
bottom left panel), which were subsequently used to identify monocytes and DCs (hCD14+CD83- and
hCD14-CD83+ respectively; bottom right panel). (b) Single leukocytes were gated as above. T cells
were identified (hCD3+; top left panel), and subsequently used to determine hCD4+ and hCD8+ T cell
subsets (top middle panel), and hCD39 and hCD73 expression on hCD4+ (top right panel) and hCD8+
(bottom left panel) T cells was analysed. hCD4+ T cells were also gated to identify Tregs
(hCD25+hCD127lo; bottom right panel).

286

